Conditions: Overweight Obesity
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 201
Healthy volunteers: no

Brief summary:
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - which treatment is decided by chance. The teenagers will take 1 injection every week, on the same day of the week for about 15 months. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The teenagers will have 17 clinic visits, will have blood samples taken and will have to complete questionnaires and keep a diary. All this will be explained before study start.

Detailed description:

Arms:
arm 1: 2.4 mg or maximum tolerated dose (MTD) injected subcutaneously (under the skin, s.c.) once weekly arm 2: Placebo injected s.c. once weekly .

Interventions: intervention 1: Semaglutide intervention 2: Placebo
Intervention descriptions: intervention 1: Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks intervention 2: Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks

Protocol document:
Prot_000.pdf: 
Cover Page for Protocol 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT04102189 
Sponsor trial ID: 
NN9536-4451 
Official title of study: 
Effect and safety of semaglutide 2.4 mg once weekly on 
weight management in adolescents with overweight or obesity 
Document date* 
03 February 2021 
*Document date refers to the date on which the document was most recently updated. Note: The date in the header of Page 2 is the
date of compilation of the documents and not of an update to content.


Link
Link
Link
Link
List of contents
Protocol ...............................................................................................................................................
Protocol attachment ...........................................................................................................................
IE local protocol amendment 1 .........................................................................................................
IE local protocol amendment 2 .........................................................................................................
CONFIDENTIAL
Date:
Novo Nordisk
Version:
Status:
Semaglutide
Trial ID: NN9536-4451
Clinical Trial Report
Appendix 16.1.1
10 March 2022
1.0
Final
16.1.1 Protocol and protocol amendments
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
1 of 118 
 
Protocol 
 
Protocol title:  
Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with 
overweight or obesity  
Substance: semaglutide 
Universal Trial Number: U1111-1215-7560  
EUdraCT Number: 2018-002431-18  
Trial phase: 3a 
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”. 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
1
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
2 of 118 
 
Protocol amendment summary of changes table  
DOCUMENT HISTORY 
Document version 
Date 
Applicable in country(-ies) and/or 
site(s)  
Protocol version 2.0 
06 January 2021 
Austria, Belgium, Croatia, Ireland, 
Mexico, Russia, United Kingdom, 
United States 
Original protocol version 1.0 
09 April 2019 
All countries 
 
Protocol version 2.0 (06 January 2021) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1 for the 
countries participating in the NN9536-4451 trial.  
Overall rationale for preparing protocol, version 2.0: 
Co-participation in other clinical trials is generally not allowed while participating in a Novo Nordisk 
trial. However, given the large societal impact of the COVID-19 pandemic, Novo Nordisk will allow for 
co-participation in trials with the primary objective of evaluating an approved or non-approved 
investigational medicinal product for prevention or treatment of COVID-19 disease or postinfectious 
conditions. For the current trial it has been evaluated that the safety profile of semaglutide is well 
established and based on current knowledge it is expected that co-participation in COVID-19 trials will 
not lead to unreasonable unforeseen risks for trial subjects. Discontinuation criterion 6 regarding 
simultaneous participation in other trials has thus been amended. A number of other changes were 
implemented for clarification of trial procedures; see below. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
2
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
3 of 118 
 
Section # and name 
Description of change 
Brief rationale 
Table of Contents 
Addition of the two attachments I 
and II to the Table of Contents. 
Correction of omission. 
Section 7.6 
Further details added for how to 
assess drug treatment compliance. 
Implementation of information 
previously sent out by memo to sites. 
Section 8.1 
Amending discontinuation criterion 
6, so that subjects are allowed to 
continue in the trial, while also 
participating in a COVID-19 trial. 
To allow for simultaneous 
participation in current trial and a 
COVID-19 trial.  
Section 9.1.1 
Waist circumference to be measured 
to the nearest 0.5 cm or 0.2 inch, 
instead of to the nearest cm or inch. 
To increase precision of 
measurement. 
Section 9.4 
Correction of the definition of 
concomitant illness. 
The previous definition of 
concomitant illness was faulty. 
Section 9.9 and Appendix 7 
Correction of the requirement for 
signing the separate ICF for 
biosamples. 
The requirement for signing of the 
separate ICF for biosamples depends 
on local legislation. 
Section 10 
Description of the ‘available on 
randomised treatment (AT)’ category 
updated in Table 10.1 “Taxonomy 
for subjects based on week 68 
assessments being available or 
missing” 
Clarification that subjects must have 
a week 68 assessment to be in scope 
for this category. 
Appendix 2 
Details added of how abnormal 
values identified by the central lab 
should be handled. 
Clarification in order to avoid 
misunderstandings of process. 
Appendix 5 
Detailed description of timing of 
pregnancy tests replaced with a 
cross-reference to Appendix 2 where 
the visits are listed. 
Alignment of directions for urine 
pregnancy testing given in Appendix 
2, Appendix 5 and section 9.4.7. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
3
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
4 of 118 
 
Throughout 
Minor updates to wording and 
references 
To correct errors and omissions, and 
to provide updated references 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
4
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
5 of 118 
 
Table of Contents    
 
Page 
Protocol amendment summary of changes table ........................................................................................... 2 
Table of Contents.............................................................................................................................................. 5 
1 
Synopsis ...................................................................................................................................................... 8 
2 
Flowchart ................................................................................................................................................. 11 
3 
Introduction ............................................................................................................................................. 13 
3.1 
Trial rationale ............................................................................................................................... 13 
3.2 
Background .................................................................................................................................. 14 
3.2.1 
Semaglutide ............................................................................................................... 14 
3.2.2 
Trial population .......................................................................................................... 14 
3.3 
Benefit-risk assessment ................................................................................................................ 15 
3.3.1 
Benefits ...................................................................................................................... 15 
3.3.2 
Risks and precautions ................................................................................................ 15 
3.3.3 
Conclusion on benefit-risk profile ............................................................................. 17 
4 
Objectives and endpoints ........................................................................................................................ 17 
4.1 
Primary, secondary and exploratory objective(s) ........................................................................ 17 
4.2 
Primary, secondary and exploratory endpoint(s) ......................................................................... 19 
4.2.1 
Primary endpoint ........................................................................................................ 19 
4.2.2 
Secondary endpoints .................................................................................................. 19 
4.2.2.1 
Confirmatory secondary endpoints ..................................................... 19 
4.2.2.2 
Supportive secondary endpoints .......................................................... 19 
4.2.3 
Exploratory endpoints ................................................................................................ 19 
5 
Trial design .............................................................................................................................................. 22 
5.1 
Overall design .............................................................................................................................. 22 
5.2 
Subject and trial completion ........................................................................................................ 23 
5.3 
End of trial definition ................................................................................................................... 23 
5.4 
Scientific rationale for trial design ............................................................................................... 23 
5.5 
Justification for dose .................................................................................................................... 24 
6 
Trial population ....................................................................................................................................... 26 
6.1 
Inclusion criteria .......................................................................................................................... 26 
6.2 
Exclusion criteria ......................................................................................................................... 26 
6.3 
Run-in criteria .............................................................................................................................. 28 
6.4 
Randomisation criteria ................................................................................................................. 28 
6.5 
Lifestyle restrictions .................................................................................................................... 29 
6.5.1 
Meals and dietary restrictions .................................................................................... 29 
6.5.2 
Caffeine and tobacco ................................................................................................. 29 
6.6 
Screen failures .............................................................................................................................. 29 
7 
Treatments ............................................................................................................................................... 30 
7.1 
Treatments administered .............................................................................................................. 30 
7.1.1 
Medical device ........................................................................................................... 32 
7.1.2 
Diet counselling ......................................................................................................... 32 
7.1.3 
Physical activity counselling...................................................................................... 33 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
5
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
6 of 118 
 
7.2 
Dose modification ........................................................................................................................ 33 
7.3 
Method of treatment assignment .................................................................................................. 33 
7.4 
Blinding ....................................................................................................................................... 33 
7.5 
Preparation/Handling/Storage/Accountability ............................................................................. 33 
7.6 
Treatment compliance .................................................................................................................. 34 
7.7 
Concomitant medication .............................................................................................................. 35 
7.8 
Treatment after the end of the trial .............................................................................................. 35 
8 
Discontinuation/Withdrawal criteria .................................................................................................... 36 
8.1 
Discontinuation of trial treatment ................................................................................................ 36 
8.1.1 
Temporary discontinuation of trial treatment ............................................................ 37 
8.2 
Withdrawal from the trial............................................................................................................. 37 
8.2.1 
Replacement of subjects ............................................................................................ 38 
8.3 
Lost to follow-up ......................................................................................................................... 38 
9 
Trial assessments and procedures ......................................................................................................... 39 
9.1 
Efficacy assessments .................................................................................................................... 40 
9.1.1 
Body measurements ................................................................................................... 40 
9.1.2 
Clinical outcome assessments .................................................................................... 41 
9.1.3 
Clinical efficacy laboratory assessments ................................................................... 41 
9.2 
Adverse events ............................................................................................................................. 41 
9.2.1 
Time period and frequency for collecting AE and SAE information ........................ 42 
9.2.2 
Method of detecting AEs and SAEs .......................................................................... 43 
9.2.3 
Follow-up on AEs and SAEs ..................................................................................... 44 
9.2.4 
Regulatory reporting requirements for SAEs............................................................. 44 
9.2.5 
Cardiovascular and death events ................................................................................ 44 
9.2.6 
Pregnancies and associated adverse events ................................................................ 44 
9.2.7 
Medical device incidents (including malfunctions) ................................................... 45 
9.2.8 
Technical complaints ................................................................................................. 45 
9.3 
Treatment of overdose ................................................................................................................. 46 
9.4 
Safety assessments ....................................................................................................................... 46 
9.4.1 
Clinical outcome assessments .................................................................................... 46 
9.4.2 
Physical examinations ................................................................................................ 47 
9.4.3 
Pubertal status ............................................................................................................ 47 
9.4.4 
Vital signs .................................................................................................................. 48 
9.4.5 
Bone age assessment (X-ray) ..................................................................................... 48 
9.4.6 
Electrocardiograms .................................................................................................... 48 
9.4.7 
Clinical safety laboratory assessments ....................................................................... 48 
9.4.8 
Immunogenicity assessments ..................................................................................... 48 
9.4.9 
Severe hypersensitivity .............................................................................................. 49 
9.5 
Pharmacokinetics ......................................................................................................................... 49 
9.6 
Pharmacodynamics ...................................................................................................................... 50 
9.7 
Genetics ....................................................................................................................................... 50 
9.8 
Biomarkers ................................................................................................................................... 50 
9.9 
Biosamples for future analysis ..................................................................................................... 50 
9.10 
Subject diaries .............................................................................................................................. 51 
9.10.1 
PK diary ..................................................................................................................... 51 
9.10.2 
Menstrual period diary ............................................................................................... 51 
9.10.3 
Diabetes diary ............................................................................................................ 51 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
6
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
7 of 118
10 Statistical considerations ........................................................................................................................52
10.1
Sample size determination...........................................................................................................52
10.2
Definition of analysis sets............................................................................................................54
10.3
Statistical analyses .......................................................................................................................55
10.3.1
Primary endpoint........................................................................................................55
10.3.2
Secondary endpoints..................................................................................................59
10.3.2.1
Confirmatory secondary endpoints .....................................................59
10.3.2.2
Supportive secondary endpoints..........................................................60
10.3.3
Exploratory endpoints................................................................................................62
10.3.4
Other analyses............................................................................................................64
10.4
Pharmacokinetic and/or pharmacodynamic modelling................................................................64
11 Appendices...............................................................................................................................................66
Abbreviations and Trademarks ..........................................................................................67
Clinical laboratory tests .......................................................................................................71
Trial governance considerations .........................................................................................74
Adverse events: definitions and procedures for recording, evaluation, follow-up 
and reporting...........................................................................................................................................83
Contraceptive guidance and collection of pregnancy information...................................88
Technical complaints: Definition and procedures for recording, evaluation, follow-
up and reporting......................................................................................................................................91
Retention of human biosamples ..........................................................................................93
Flowchart and assessments for subjects with T2D ............................................................95
Clinical Charts for Body Mass Index by gender and age................................................106
Monitoring of calcitonin.....................................................................................................109
Country-specific requirements..........................................................................................112
12 References..............................................................................................................................................114
Attachment I Global list of key staff and relevant departments and supplier
Attachment II Country list of key staff and relevant departments
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
7
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 
2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
8 of 118 
 
1 
Synopsis 
Rationale: 
Obesity is currently one of the most significant public health challenges. There has been a dramatic 
increase in the prevalence of obesity among adults, children and adolescents in recent years with 
increasing trends in both developed and developing countries causing an immense burden on health 
care systems2. 
Similarly to obesity in adults, children with obesity can have multiple immediate serious 
comorbidities. In studies conducted in children and adolescents with obesity, weight loss has been 
associated with improvements in cardiometabolic risk factors, including measures of glycaemic 
control, beta-cell function, insulin sensitivity/resistance, lipid profile, systolic/diastolic blood 
pressure and metabolic syndrome3-6. Thus, obesity in childhood can have profound long-term 
consequences as it tracks strongly into adulthood, especially in those with severe obesity, which 
also increase the severity of their future health risk7. 
Lifestyle intervention in the form of diet and exercise is first line treatment for obesity, but most 
people with obesity struggle to achieve and maintain their weight loss8-17. Pharmacotherapy may 
therefore serve as a valuable adjunct to lifestyle intervention for adolescents with obesity in order to 
achieve and sustain a clinically relevant weight loss, to improve or prevent comorbid conditions and 
to facilitate a healthier lifestyle. Currently, orlistat is the only pharmacotherapy with U.S. Food and 
Drug Administration approval for the management of obesity in the paediatric population and is 
indicated for those aged ≥12 years18.  
The NN9536–4451 trial is being conducted to assess the effect and safety of semaglutide in the 
paediatric population in order to potentially address the unmet need for treatment of adolescents 
ages 12 to <18 years with obesity.  
Objectives and endpoints 
Primary objective 
To compare the effect of semaglutide subcutaneous once-weekly versus semaglutide placebo as an 
adjunct to a reduced-calorie diet and increased physical activity on weight management in 
adolescents (ages 12 to <18 years) with overweight or obesity.  
Secondary objectives 
To compare the effect of semaglutide subcutaneous once weekly versus semaglutide placebo as an 
adjunct to a reduced-calorie diet and increased physical activity in adolescents (ages 12 to <18 
years) with overweight or obesity on: 
• Cardiovascular risk factors  
• Glucose metabolism 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
8
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 
2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
9 of 118 
 
To compare the safety and tolerability of semaglutide subcutaneous once weekly versus 
semaglutide placebo as an adjunct to a reduced-calorie diet and increased physical activity in 
adolescents with overweight or obesity 
Primary estimand 
The estimand will quantify the average treatment difference of semaglutide relative to semaglutide 
placebo after 68 weeks, as an adjunct to a reduced-calorie diet and increased physical activity, in all 
randomised subjects regardless of adherence to treatment or initiation of rescue interventions 
(weight management drugs or bariatric surgery) (“effectiveness”/“treatment policy” estimand). The 
estimand will cover all effect-related objectives. 
Primary endpoint 
Change in body mass index from baseline (week 0) to week 68 (%) 
Confirmatory secondary endpoint 
Subjects achieving ≥5% reduction of body weight from baseline (week 0) to week 68 (yes/no) 
Overall design: 
This is a 68-week double-blind, randomised, parallel group, placebo-controlled, multi-national 
clinical trial comparing semaglutide subcutaneous 2.4 mg once weekly with semaglutide placebo in 
pubertal adolescents, ages 12 to <18 years, with obesity or overweight with ≥1 weight-related 
comorbidity.  
Key inclusion criteria 
• Informed consent of parent(s) or legally acceptable representative of subject and child assent, as 
appropriate obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial 
• Male or female, ages 12 to <18 years at the time of signing informed consent 
• BMI ≥95th percentile* OR ≥85th percentile* with ≥1 weight related comorbidity (treated or 
untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes 
• History of at least one self-reported unsuccessful dietary effort to lose weight 
* on gender and age-specific growth charts (CDC.gov) 
For subjects with type 2 diabetes at screening the following inclusion criteria apply in addition: 
• HbA1c ≤10.0% (86 mmol/mol) as measured by central laboratory at screening 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
9
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 
2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
10 of 118 
 
Key exclusion criteria 
• Prepubertal subjects (Tanner stage 1) 
• History of type 1 diabetes 
• A self-reported (or by parent(s)/legally acceptable representative where applicable) change in 
body weight >5 kg (11 lbs) within 90 days before screening irrespective of medical records 
• Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine causes)  
• For subjects with type 2 diabetes only: Uncontrolled and potentially unstable diabetic 
retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 
days prior to screening (V1). Pharmacological pupil-dilation is a requirement unless using a 
digital fundus photography camera specified for non-dilated examination 
 
Number of subjects: 
Approximately 237 subjects will be screened to achieve 213 subjects to be included in the run-in 
period to reach the anticipated 192 subjects randomly assigned to trial product.  
Treatment groups and duration: 
The total duration for the individual subject will be approximately 89 weeks. The trial includes a 
screening period of approximately 2 weeks followed by 12 weeks run-in period before 
randomisation. Eligible subjects fulfilling all randomisation criteria will be randomised in a 2:1 
manner to receive either semaglutide 2.4 mg or placebo once weekly as an adjunct to lifestyle 
intervention. 
Randomisation will be stratified according to gender and Tanner stage (2-3 vs 4-5). 
Dose escalation of semaglutide/semaglutide placebo will take place every 4 weeks during the first 
16 weeks after randomisation. All subjects should aim at reaching 2.4 mg once weekly. The 
treatment continues with 52 weeks on maintenance dose until the ‘end of treatment’ visit followed 
by a 7 weeks follow-up period.  
The following trial products are supplied by Novo Nordisk A/S: 
• Semaglutide B 1.0 mg/mL PDS290 and Semaglutide placebo, solution for injection, 3 mL 
PDS290 pre-filled pen-injector 
• Semaglutide B 3.0 mg/mL PDS290 and Semaglutide placebo, solution for injection, 3 mL 
PDS290 pre-filled pen-injector 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
10
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
 
Date: 
06 January 2021 
Status: 
Final 
Novo Nordisk 
Trial ID: NN9536-4451 
 
Version: 
2.0 
Page: 
11 of 118 
 
2 
Flowchart 
 For subjects with type 2 diabetes (T2D) at screening or if diagnosed during the trial, refer to flowchart in Appendix 8. 
Screening 
Run-in 
Randomisation 
Dose escalation 
Maintenance 
End of 
treatment 
End of trial 
Visita 
V1 
V2 P3 V4 P5 V6 P7 
V8 
P9 V10 P11 V12 P13 V14 P15 V16 P17 V18 P19 V20 P21 V22 P23 V24 P25 V26 P27 V28 P29 V30 V31 
Timing of Visit (Weeks) 
-14 -12 -10 -8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
24 
28 
32 
36 
40 
44 
48 
52 
56 
60 
64 
68 
75 
Visit Window (Days) 
-7/0 ±3 
±7 ±3 ±7 
±3 ±7 
±0 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
0/7 
Attend visit fasting (6.5.1) 
  
X 
  
  
  
  
  
X 
  
  
  
 
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
X 
Informed consent, Informed assent and  
Demographyb (Appendix 3) 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
  
Inclusion and exclusion criteria (6.1, 6.2) 
X 
X 
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
  
Run-in criteria (6.3) 
 
 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomisation criteria and randomisation (6.4) 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history/ Concomitant illness and  
Tobacco Usec  (6.5.2, 9.4) 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
  
Concomitant medication (7.7) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Childbearing potentiald, Menstrual cyclee and  
Pregnancy testf   
(9.2.6, 9.4.7, 9.10.2, Appendix 5)    
X 
X 
  
X 
  
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pubertal Status (9.4.3) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
ECG (9.4.6) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
 
 
 
 
X 
  
Vital Signs (9.4.4) 
X 
  
  
  
  
  
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
X 
Laboratory assessments (Appendix 2) 
X 
X 
 
 
 
 
 
Xg 
 
 
 
Xh 
  
  
  
Xh 
  
 
  
Xh 
  
Xh  
  
  
  
Xh 
 
 
 
Xh 
X 
Biosamples for future analysisi (9.7,  9.9) 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
X 
  
Clinical Outcome Assessments (9.1.2, 9.4.1) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Physical examination (9.4.2) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Height (9.1.1) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
X 
  
  
  
  
  
X 
  
  
  
X 
  
X 
 
 
 
X 
X 
Body Weight (9.1.1) 
X 
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
X 
VV-TMF-4175483|1.0|NN9536 -4451
  Protocol  V 2.0|11 of 118
VV-CLIN-134191
1.0
.


Protocol 
 
Date: 
06 January 2021 
Status: 
Final 
Novo Nordisk 
Trial ID: NN9536-4451 
 
Version: 
2.0 
Page: 
12 of 118 
 
Screening 
Run-in 
Randomisation 
Dose escalation 
Maintenance 
End of 
treatment 
End of trial 
Visita 
V1 
V2 P3 V4 P5 V6 P7 
V8 
P9 V10 P11 V12 P13 V14 P15 V16 P17 V18 P19 V20 P21 V22 P23 V24 P25 V26 P27 V28 P29 V30 V31 
Timing of Visit (Weeks) 
-14 -12 -10 -8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
24 
28 
32 
36 
40 
44 
48 
52 
56 
60 
64 
68 
75 
Visit Window (Days) 
-7/0 ±3 
±7 ±3 ±7 
±3 ±7 
±0 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
0/7 
Waist Circumference (9.1.1) 
X  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Bone age measurement (x-ray) (9.4.5) 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
X 
  
Evaluation of glycaemic status (9) 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Adverse event (9.2, Appendix 4, Appendix 6) 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Diet and physical activity counsellingj  
(7.1.2, 7.1.3) 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hand out and instruct in Diary (9) 
Xk 
  
  
  
  
  
  
 
  
X 
  
 
  
X 
  
 
  
X 
  
X 
  
 
  
X 
  
 
 
X 
 
 
  
Collect, review and transcribe diary 
(9.10, 9.10.1, 9.10.2) 
  
  
  
  
  
  
  
Xk 
  
  
  
X 
  
 
  
X 
  
 
  
X 
  
X 
  
 
  
X 
 
 
 
X 
 
Connect to IWRS (7.3)       
X 
  
  
  
  
  
  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Training in trial product, pen-handling (7.1.1) 
  
  
  
  
  
  
  
X 
  
 
  
X 
  
 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
  
  
Drug handling (7.1, 7.3, 7.5) 
 
 
 
 
 
 
 
X 
  
  
  
X 
  
  
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
 
Trial product compliance (7.1, 7.6) 
  
  
  
  
  
  
  
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
a) Visits marked as phone visits can be replaced by site visits or video calls to ensure flexibility for the subjects  
b) Demography consists of date of birth, sex, ethnicity, and race (according to local regulation) 
c) Smoking is defined as smoking at least one daily cigarette or equivalent (e.g. cigar, hookah or e-cigarette) 
d) Only for females 
e) Only for females that have started their menstrual period (of childbearing potential) 
f) Only for females that have started their menstrual period (of childbearing potential): Urine pregnancy test should also be performed at any time during the trial if 
pregnancy is suspected, if a menstrual period is missed, and/or according to local regulations/law. If a female becomes of childbearing potential (has first menstrual 
period) during the trial a urine pregnancy test must be performed for that subject at the latest at the next site visit. For country specific requirements, see Appendix 11. 
g) Blood samples should be taken prior to product dosing 
h) Due to PK sampling, subjects must be instructed to withhold their trial product dose in the morning until blood sampling has been performed at the visit. This is not 
applicable for subjects that have discontinued trial product 
i) Only for subjects where the separate informed consent for future research has been signed 
j) The counselling can be done independent of the site visits within the visit window and flexibly as site visits or phone or video call 
k) Only for females (for menstrual period record in run-in period) 
VV-TMF-4175483|1.0|NN9536 -4451
  Protocol  V 2.0|12 of 118
VV-CLIN-134191
1.0
.


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
13 of 118 
 
 
3 
Introduction 
3.1 
Trial rationale 
Obesity is currently one of the most significant public health challenges. There has been a dramatic 
increase in the prevalence of obesity among adults, children and adolescents in recent years with 
increasing trends in both developed and developing countries causing an immense burden on health 
care systems. Around 2.1 billion people worldwide are currently estimated to be either overweight 
or obese2. 
Similarly to obesity in adults, children with obesity can have multiple immediate serious 
comorbidities. These include T2D, hypertension, non-alcoholic fatty liver disease, obstructive sleep 
apnoea (OSA), and dyslipidaemia as well as various psychosocial implications including reduced 
health related quality of life. Thus, obesity in childhood can have profound long-term consequences 
as it tracks strongly into adulthood, especially in those with severe obesity, which also increases the 
severity of their future health risks7. 
In studies conducted in children and adolescents with obesity, weight loss has been associated with 
improvements in cardiometabolic risk factors, including measures of glycaemic control, beta-cell 
function, insulin sensitivity/resistance, lipid profile, systolic/diastolic blood pressure and metabolic 
syndrome3-6. 
Lifestyle intervention in the form of diet and exercise is first line treatment for obesity, but most 
people with obesity struggle to achieve and maintain their weight loss8-17. Surgical treatments may 
offer an effective alternative for some adolescents with severe obesity19, 20, but surgery carries a risk 
in connection with the procedure and is not without complications. Furthermore, surgery requires 
long-term follow-up of the individual which can be cumbersome and costly8-13, 21, 22. 
Pharmacotherapy may therefore serve as a valuable adjunct to lifestyle intervention for adolescents 
with obesity in order to achieve and sustain a clinically relevant weight loss, to improve or prevent 
comorbid conditions and to facilitate a healthier lifestyle. No pharmacotherapy is currently 
approved for the treatment of obesity in individuals <18 years of age outside USA. Currently, 
orlistat is the only pharmacotherapy with U.S. Food and Drug Administration (FDA) approval for 
the management of obesity in the paediatric population and is indicated for those aged ≥12 years18. 
However, orlistat effects modest weight loss in adolescents and treatment compliance is low due to 
gastrointestinal (GI) adverse events (AEs)18, 23, 24, and there is a need for more safe and effective 
therapeutic options for treatment of obesity in children and adolescents, especially treatments that 
also target weight maintenance, prevention and treatment of comorbidities7-11, 25, 26.   
The NN9536–4451 trial is being conducted to assess the effect and safety of semaglutide in the 
paediatric population in order to address the unmet need for treatment of adolescents ages 12 to <18 
years with obesity. This clinical trial is also being conducted to fulfil the regulatory requirement for 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
13
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
14 of 118 
 
paediatric trials from the U.S. Food and Drug Administration and the European Paediatric 
Committee (PDCO) of the European Medicines Agency (EMA).  
3.2 
Background 
3.2.1 
Semaglutide 
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) currently under 
development by Novo Nordisk for the weight management indication (NN9536). Semaglutide has a 
half-life of approximately 160 hours, making it suitable for once-weekly dosing27. GLP-1 is a 
physiological regulator of appetite and GLP-1 receptors are present in several areas of the brain 
involved in appetite regulation28.  
Clinical27, 29-33 and non-clinical data34 indicate that the body weight-reducing effect of semaglutide 
may be mediated primarily by a reduced energy intake. No unexpected safety findings in adults 
have been identified and the tolerability and safety profile was overall consistent with previous 
findings in the adult semaglutide T2D development programme and the GLP-1 RA class in general.  
In a 52-week phase 2 dose-finding trial in adults, within weight management (NN9536-4153), the 
estimated weight loss at week 52 was 13.8 % at the highest dose tested (0.4 mg once-daily) 
compared to the weight loss of 2.3% achieved by diet, exercise and placebo alone35. 
A comprehensive review of results from the non-clinical and clinical studies of semaglutide can be 
found in the current edition of the investigator’s brochure (IB)36 and any updates hereof.  
3.2.2 
Trial population 
The trial population will consist of pubertal adolescents ages 12 to <18 years with obesity (BMI ≥ 
95th percentile on CDC’s gender and age-specific growth charts) or with overweight (BMI ≥ 85th 
percentile on CDC’s gender and age-specific growth charts) and at least 1 weight-related 
comorbidity. These adolescents represent a clinically relevant population for pharmacotherapeutic 
weight management as they are at significant risk for weight-related comorbidities and have 
increased long-term mortality37, and are likely to benefit from weight reduction. Information about 
weight-related comorbidities, including T2D, hypertension, dyslipidaemia or OSA, will be collected 
systematically at screening by the investigators as part of the medical history. 
First line treatment in weight management should always be lifestyle modification through a 
reduced-calorie diet and increased physical activity. Thus only adolescents who have tried but failed 
a dietary weight loss intervention will be included in accordance with regulatory guidelines38, 39. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
14
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
15 of 118 
 
3.3 
Benefit-risk assessment 
3.3.1 
Benefits 
The adolescents will be treated with a regimen anticipated to be better than or equal to the weight 
management they receive at the time of entry into the trial. Results from the adult phase 2 trial 
(NN9536-4153) demonstrated that semaglutide once-daily as an adjunct to a reduced calorie diet 
and increased physical activity was effective for weight loss in subjects with obesity, while 
displaying a satisfactory tolerability profile. Overall, a monotone dose-dependent weight loss was 
observed across all tested doses of semaglutide (0.05 to 0.4 mg once-daily). The weight loss was 
11.55 percentage points larger for the 0.4 mg group compared with placebo. Weight loss was 
accompanied by a consistent improvement in the weight-related comorbidities, indicated by 
cardiovascular risk factors, lipid profile and glycaemic factors, as well as improvements in clinical 
outcome assessments (COAs). Semaglutide exposure is expected to be the same as in adults (refer 
to Section 5.5 for more details). 
In addition, it is expected that the adolescents and their parent(s)/LAR will benefit from 
participation through close contact with the trial site medical staff and counselling by a dietician or 
a similarly qualified healthcare professional according to local standard, all of which may result in 
improved weight management. 
3.3.2 
Risks and precautions 
The sections below describe identified and potential risks associated with semaglutide treatment. 
For classification and further details of the risks, please refer to the current version of the IB40 or 
any updates hereof. The identified/potential risks are based on findings in non-clinical studies and 
clinical trials in adults with semaglutide as well as other GLP-1 RAs. For each of these risks, 
mitigating actions have been implemented to address the risks for subjects enrolled in this trial. 
• Gastrointestinal adverse events 
Consistent with findings with other GLP-1 RAs, the most frequently reported AEs in 
clinical trials with semaglutide were gastrointestinal (GI) AEs. A low starting dose and 
dose escalation steps will be implemented in the trial to mitigate the risk of GI AEs. 
• Cholelithiasis 
Events of cholelithiasis were the most frequently reported gallbladder events in the phase 2 
weight management trial (NN9536-4153) and were in a few instances co-reported with the 
event adjudication committee (EAC) confirmed acute pancreatitis. As a precaution, if 
cholelithiasis is suspected, appropriate clinical follow-up is to be initiated at the 
investigator’s discretion. 
• Hypoglycaemia (identified for T2D subjects) 
The risk of hypoglycaemic episodes is low, when semaglutide is used as monotherapy in 
adults. Adults treated with semaglutide in combination with a sulfonylurea or insulin may 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
15
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
16 of 118 
 
have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by 
reducing the dose of sulfonylurea or insulin when initiating treatment with semaglutide. 
• Diabetic retinopathy complication (identified for T2D subjects) 
The cardiovascular outcome trial in the adult semaglutide T2D development programme 
showed an increased risk of events related to diabetic retinopathy complications in subjects 
treated with semaglutide compared to placebo, albeit the proportion of subjects with an 
event of diabetic retinopathy complications was low. The imbalance was driven by subjects 
with a history of diabetic retinopathy at randomisation and subjects who were treated with 
insulin. As a precaution, adolescents with T2D and a history of uncontrolled and potentially 
unstable diabetic retinopathy or maculopathy will be excluded from the trial, and fundus 
photography or slit-lamp biomicroscopy examination with pharmacologically dilated pupils 
will be performed according to flowchart in Appendix 8. 
• Acute pancreatitis 
Acute pancreatitis has been observed with the use of GLP-1 RA drug class. As a 
precaution, subjects with a history of chronic or acute pancreatitis will not be enrolled in 
the trial. In addition, trial product should be discontinued in case of suspicion of acute 
pancreatitis in accordance to Section 8.1. 
• Medullary thyroid cancer (MTC) (based on non-clinical data) 
Expected proliferative thyroid C-cell changes were seen in the mouse and rat 
carcinogenicity studies after daily exposure to semaglutide for 2 years. No hyperplasia was 
observed in monkeys after 52 weeks exposure up to 13-fold above the clinical plasma 
exposure at 2.4 mg/week. In clinical trials with semaglutide, there have been no clinically 
relevant changes in calcitonin levels. The C-cell changes in rodents are mediated by the 
GLP-1 receptor, which is not expressed in the normal human thyroid. Accordingly, the risk 
of GLP-1 receptor-mediated C-cell changes in humans is considered to be low. As a 
precaution, exclusion and discontinuation criteria related to medical history of multiple 
endocrine neoplasia type 2 (MEN2) or MTC and elevated plasma levels of calcitonin 
(biomarker for MTC) have been implemented in the trial. 
• Pancreatic cancer 
There is currently no support from non-clinical studies, clinical trials or post-marketing data 
that GLP-1 RA-based therapies increase the risk of pancreatic cancer, but pancreatic cancer 
has been classified as a potential class risk of GLP-1 RAs by EMA. As a precaution, 
subjects with a history of malignant neoplasms within the past 5 years prior to screening 
will be excluded from the trial. 
• Allergic reactions 
As is the case with all protein-based pharmaceuticals, subjects treated with semaglutide are 
at risk of developing immunogenic and allergic reactions. As a precaution, subjects with 
known or suspected hypersensitivity to semaglutide or related products will not be enrolled 
in this trial. 
• Pregnancy and fertility (based on non-clinical data) 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
16
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
17 of 118 
 
Studies in animals have shown reproductive toxicity. There are limited data from the use of 
semaglutide in pregnant women. Therefore, semaglutide should not be used during 
pregnancy. Exclusion and discontinuation criteria related to pregnancy have been 
implemented in the trial. 
3.3.3 
Conclusion on benefit-risk profile 
Necessary precautions have been implemented in the design and planned conduct of the trial in 
order to mitigate the risks and inconveniences of participation in the trial. The safety profile for 
semaglutide generated from the clinical and non-clinical development programme has not revealed 
any safety issues that would prohibit administration of semaglutide s.c. 2.4 mg once-weekly in the 
adolescent population with obesity. The results of the adult phase 2 trial (NN9536-4153) indicate 
that semaglutide will provide a clinically meaningful weight loss. 
In conclusion, the potential risk to the subjects in this trial is considered to be low and to be 
outweighed by the anticipated benefits that semaglutide as well as dietitian counselling would 
provide subjects included in the trial.  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of semaglutide may be found in the current version of the IB40 and any updates 
hereof.  
4 
Objectives and endpoints 
4.1 
Primary, secondary and exploratory objective(s) 
Primary objective 
To compare the effect of semaglutide s.c. once-weekly versus semaglutide placebo as an adjunct to 
a reduced-calorie diet and increased physical activity on weight management in adolescents (ages 
12 to <18 years) with overweight or obesity.  
Secondary objectives 
To compare the effect of semaglutide s.c. once weekly versus semaglutide placebo as an adjunct to 
a reduced-calorie diet and increased physical activity in adolescents (ages 12 to <18 years) with 
overweight or obesity on: 
• Cardiovascular risk factors  
• Glucose metabolism 
To compare the safety and tolerability of semaglutide s.c. once weekly versus semaglutide placebo 
as an adjunct to a reduced-calorie diet and increased physical activity in adolescents with 
overweight or obesity. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
17
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
18 of 118 
 
Exploratory objectives 
To compare the effect of semaglutide s.c. once weekly versus semaglutide placebo as an adjunct to 
a reduced-calorie diet and increased physical activity in adolescents (ages 12 to <18 years) with 
overweight or obesity on: 
• Clinical Outcome Assessments (COAs) 
To compare additional safety and tolerability of semaglutide s.c. once weekly versus semaglutide 
placebo as an adjunct to a reduced-calorie diet and increased physical activity in adolescents with 
overweight or obesity. 
Estimands 
Primary estimand 
The estimand will quantify the average treatment difference of semaglutide relative to semaglutide 
placebo after 68 weeks, as an adjunct to a reduced-calorie diet and increased physical activity, in all 
randomised subjects regardless of adherence to treatment or initiation of rescue interventions 
(weight management drugs or bariatric surgery) (“effectiveness”/“treatment policy” estimand). The 
estimand will cover all effect-related objectives. 
The following expansion of the primary estimand will cover the exploratory endpoint “Change in 
body mass index from baseline (week 0) to week 52 (%)”. The estimand will quantify the average 
treatment effect of semaglutide relative to semaglutide placebo after 52 weeks, as an adjunct to a 
reduced-calorie diet and increased physical activity, in all randomised subjects regardless of 
adherence to treatment or initiation of rescue interventions. 
The following expansion of the primary estimand will cover the exploratory endpoint “Change in 
body mass index from baseline (week 0) to week 75 (%)”. The estimand will quantify the average 
treatment effect of semaglutide relative to semaglutide placebo after 75 weeks, as an adjunct to a 
reduced-calorie diet and increased physical activity, in all randomised subjects regardless of 
adherence to treatment or initiation of rescue interventions. 
Secondary estimand 
The estimand will quantify the average treatment difference of semaglutide relative to semaglutide 
placebo after 68 weeks, as an adjunct to a reduced-calorie diet and increased physical activity, in all 
randomised subjects had they remained on their randomised treatment for the entire planned 
duration of the trial and not started any rescue intervention (weight management drugs or bariatric 
surgery) (“efficacy”/”hypothetical” estimand). The estimand will cover the primary objective. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
18
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
19 of 118 
 
4.2 
Primary, secondary and exploratory endpoint(s) 
4.2.1 
Primary endpoint 
Change in BMI from baseline (week 0) to week 68 (%) 
4.2.2 
Secondary endpoints 
4.2.2.1 
Confirmatory secondary endpoints 
Subjects achieving ≥5% reduction of body weight from baseline (week 0) to week 68 (yes/no) 
4.2.2.2 
Supportive secondary endpoints 
Effect endpoints from baseline (week 0) to week 68: 
• Change in: 
• 
Body weight (kg) 
• 
Body weight (%) 
• 
BMI percentage of the 95th percentile on gender and age-specific growth charts (CDC.gov) 
(%) 
• 
BMI (standard deviation score) (WHO.int)41 
• 
Waist circumference (cm) 
• 
Systolic blood pressure (mmHg) 
• 
Diastolic blood pressure (mmHg) 
• 
HbA1c (% point) 
• Subjects achieving ≥5% reduction of BMI (yes/no) 
Safety endpoints from baseline (week 0) to week 75:  
• Number of treatment-emergent adverse events (TEAEs) 
• Number of treatment-emergent serious adverse events (SAEs) 
Safety endpoints from baseline (week 0) to week 68: 
Change in: 
• Pulse (bpm) 
• Amylase (U/L) 
• Lipase (U/L) 
• Calcitonin (ng/L) 
4.2.3 
Exploratory endpoints 
• Effect endpoints 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
19
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
20 of 118 
 
Change from baseline (week 0) to week 68 in:  
• BMI (kg/m2) 
• Fasting plasma glucose (mmol/L) 
• Fasting insulin (mU/L) 
• Lipids (mmol/L) 
• 
Total cholesterol 
• 
High density lipoprotein (HDL) cholesterol 
• 
Low density lipoprotein (LDL) cholesterol 
• 
Very low density lipoprotein (VLDL) cholesterol 
• 
Triglycerides 
• Homeostasis model assessment (HOMA-B and HOMA-IR) 
• Impact of Weight on Quality of Life Kids (IWQOL-Kids) 
o physical comfort domain score 
o body esteem domain score 
o social life domain score 
o family-relations score 
o total score 
 
• Subjects who after 68 weeks achieve (yes/no):  
• 
Body weight reduction ≥ 10% from baseline 
• Change in body mass index from baseline (week 0) to week 52 (%) 
• Change in body mass index from baseline (week 0) to week 75 (%) 
Safety 
Safety endpoints for adolescents with T2D from baseline (week 0) to week 75: 
• Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemia 
episodes  
• Number of treatment-emergent hypoglycaemic episodes: 
• 
According to ADA/ISPAD classification 
• 
According to Novo Nordisk classification  
Other Safety Assessments  
Change from baseline (week 0) to week 68 (unless otherwise stated): 
• Occurrence of anti-semaglutide antibodies (also to week 75) 
• Bone age assessment, x-ray (years) 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
20
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
21 of 118 
 
• Electrocardiogram (ECG) 
• Laboratory parameters  
• Pubertal status (Tanner staging) (stage 2-5 where 5 is full sexual maturity) 
• Height standard deviation score (SDS) 
• Mental health assessed by Columbia Suicidality Severity Rating Scale (C-SSRS) 
• Patient Reported Health Questionnaire 9 (PHQ-9) 
• For subjects with T2D: Ophthalmological evaluation 
PK analysis 
• Sparse PK sampling: Clearance (CL/F) including between-subject variability, area under the 
steady state concentration – time curve in the dosing interval (AUCτ) and average concentration 
(Cavg) 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
21
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
22 of 118 
 
5 
Trial design 
5.1 
Overall design 
This is a 68-week double-blind, randomised, parallel group, placebo-controlled, multi-national 
clinical trial comparing semaglutide s.c. 2.4 mg once weekly with semaglutide placebo in pubertal 
adolescents, ages 12 to <18 years, with obesity or overweight with ≥1 weight related comorbidity.  
The trial includes a screening visit to assess the subject’s eligibility. Subjects fulfilling the 
eligibility criteria commence with a 12-week non-pharmacological lifestyle intervention run-in 
period before randomisation. The run-in period is to ensure that lifestyle intervention which is first 
line treatment for children with obesity is insufficient. Lifestyle intervention consists of diet and 
physical activity counselling for weight loss and continues throughout the trial until ‘end of trial’ 
(week 75). 
Subjects who have fulfilled the randomisation criteria (see Section 6.4) will be randomised 2:1 to 
receive semaglutide s.c. once weekly or semaglutide placebo s.c. once weekly for a dose escalation 
period of 16 weeks and a maintenance period of 52 weeks.  
Site visits/phone calls will take place with an interval of maximum 4 weeks from run-in until ‘end 
of treatment’ (week 68) according to the flowchart.  
The follow-up period is 7 weeks after ‘end of treatment’ due to the long half-life of semaglutide.  
The trial design is outlined in Figure 5-1 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
22
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
23 of 118 
 
 
 
Figure 5-1 
A schematic diagram of the trial design  
5.2 
Subject and trial completion 
Approximately 237 subjects will be screened to achieve 213 subjects to be included in the run-in 
period to reach the anticipated 192 subjects randomly assigned to trial product. 
Trial period completion for a subject: 
Trial period completion is defined as when the randomised subject has completed the final 
scheduled visit ('end of trial' (V31) according to the flowchart). 
'Date of trial completion' is the date the subject completed the final scheduled visit.  
Treatment period completion for a subject:  
Treatment period completion is defined as when the randomised subject has attended the ‘end of 
treatment’ visit (V30) according to the flowchart.  
5.3 
End of trial definition 
The end of the trial is defined as the date of the last visit of the last subject in the trial.  
5.4 
Scientific rationale for trial design 
A randomised, double-blinded, placebo-controlled, multi-centre trial design is chosen to minimise 
bias in the assessment of the effect and safety of semaglutide 2.4 mg once-weekly versus 
semaglutide placebo, as an adjunct to a reduced-calorie diet and increased physical activity.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
23
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
24 of 118 
 
The treatment duration of the trial is 68 weeks comprising of 16 weeks of dose escalation and 52 
weeks of maintenance dose. This duration is considered sufficient to assess weight loss, safety and 
tolerability in the paediatric phase 3 weight management development programme in accordance 
with regulatory guidelines from EMA/PDCO and FDA. The off-drug follow-up period is 7 weeks 
and a follow-up visit (‘end of trial’ (V31)) for safety assessments is included to account for the long 
half-life of semaglutide and allowing for anti-semaglutide antibody measurement.  
The trial includes a 12-week non-pharmacological lifestyle intervention run-in period before 
randomisation. The run-in period is to ensure documentation of at least one failed lifestyle 
intervention attempt. All subjects will undergo diet and physical activity counselling for weight loss 
beginning at run-in (week -12) and continuing through the entire trial.  
After the run-in period, subjects who fulfil the randomisation criteria will enter the active double-
blind trial phase. 
Subjects will be randomised 2:1 to receive semaglutide s.c. once weekly or semaglutide placebo s.c. 
Randomisation will be stratified by gender and Tanner stage (2-3 vs 4-5) to ensure an even 
distribution of males vs. females, and early vs. late pubertal development.  
5.5 
Justification for dose 
Population pharmacokinetic (PK) analyses of semaglutide in adults with T2D show that the most 
important covariate for exposure is body weight42, and the same has been shown for adults with 
obesity (NN9536-4153). The range of baseline body weight observed in the PK/clinical 
pharmacology trial with liraglutide in an adolescent population of 12 to <18 years with obesity 
(NN8022-3967: 79 to 164 kg) was covered by the observed range in adults with obesity (SCALE, 
NN8022-1839: 63 to 244 kg). Thus, semaglutide exposure is expected to be the same in adults and 
adolescents. 
Results from the adult phase 2 dose-finding trial (NN9536-4153) showed that the semaglutide 0.4 
mg once-daily dose was most effective in terms of weight loss while displaying an acceptable 
tolerability profile. Using population pharmacokinetic modelling, it was estimated that a once-
weekly maintenance dose of 2.4 mg semaglutide will result in similar Cmax at steady-state as that 
obtained by the once-daily 0.4 mg semaglutide dose in trial NN9536- 4153. 
It is well known that to mitigate GI side effects with GLP-1 RA treatment, dose escalation to the 
target dose is required. Based on experience from the adult semaglutide T2D development 
programme, a similar fixed-dose escalation regimen was selected, with dose escalation every 4 
weeks until the target dose of 2.4 mg is reached after 16 weeks. 
A maintenance dose of 2.4 mg semaglutide once-weekly has been chosen for the phase 3 weight 
management development programme. The once-weekly dosing is anticipated to ease the burden of 
drug administration in clinical practice. Subjects will be initiated at a once-weekly dose of 0.25 mg 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
24
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
25 of 118 
 
and follow a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 
1.7 and 2.4 mg/week), until the target dose is reached after 16 weeks. In the trial specific setting, the 
maintenance dose may depend on tolerability. 
Please refer to Section 7.1 for more details on treatment doses.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
25
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
26 of 118 
 
6 
Trial population 
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
For country specific requirements on inclusion and exclusion criteria, refer to Appendix 11. 
6.1 
Inclusion criteria 
Subjects are eligible to be included in the trial only if all of the following criteria apply: 
1. Informed consent of parent(s) or legally acceptable representative (LAR) of subject and 
child assent, as appropriate obtained before any trial-related activities. Trial-related activities 
are any procedures that are carried out as part of the trial, including activities to determine 
suitability for the trial 
a) The parent(s) or LAR of the child must sign and date the Informed Consent Form 
(according to local requirements) 
b) The child must sign and date the Child Assent Form or provide oral assent (according to 
local requirements) 
2. Male or female, ages 12 to <18 years at the time of signing informed consent 
3. BMI ≥95th percentile* OR ≥85th percentile* with ≥1 weight related comorbidity (treated or 
untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or T2D 
4. History of at least one self-reported unsuccessful dietary effort to lose weight 
*On gender and age-specific growth charts (CDC.gov) (Appendix 9) 
For subjects with T2D at screening the following inclusion criteria apply in addition to criteria 1-4: 
5. Subject treated with either diet and exercise alone or stable treatment for at least 90 days 
prior to screening with metformin  
6. HbA1c ≤10.0% (86 mmol/mol) as measured by central laboratory at screening 
The criteria will be assessed at the investigator’s discretion unless otherwise stated. 
6.2 
Exclusion criteria  
Subjects are excluded from the trial if any of the following criteria apply: 
The following criteria apply to all subjects: 
Obesity related 
1. A self-reported (or by parent(s)/LAR where applicable) change in body weight >5 kg (11 
lbs) within 90 days before screening irrespective of medical records 
2. Treatment with any medication for the indication of obesity within the past 90 days before 
screening  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
26
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
27 of 118 
 
3. Previous surgical treatment for obesity (excluding liposuction if performed >1 year before 
screening)  
4. Uncontrolled thyroid disease at screening, in the opinion of the investigator 
5. Subjects with secondary causes of obesity (i.e., hypothalamic, monogenic or endocrine 
causes)  
Mental health 
6. History of major depressive disorder within 2 years before screening  
7. Diagnosis of other severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) 
8. A Patient Health Questionnaire-9 (PHQ-9) score of ≥15 at screening 
9. A lifetime history of suicidal attempt 
10. Suicidal behaviour within 30 days before screening  
11. Suicidal ideation corresponding to type 4 or 5 based on the Columbia-Suicide Severity 
Rating Scale (C-SSRS) within the past 30 days before screening  
12. Subjects with confirmed diagnosis of bulimia nervosa disorder  
General Safety 
13. Prepubertal subjects (Tanner stage 1) 
14. History or presence of pancreatitis (acute or chronic) 
15. Calcitonin ≥50 ng/L 
16. Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or 
medullary thyroid carcinoma 
17. History of type 1 diabetes 
18. Impaired renal function defined as serum-creatinine >upper normal range (UNR) for age in 
children unless renal function is proven normal by further assessments at the discretion of 
the investigator  
19. History of malignant neoplasms within the past 5 years prior to the day of screening 
20. Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the 
opinion of the investigator  
21. Known or suspected abuse of alcohol or recreational drugs 
22. Known or suspected hypersensitivity to trial product(s) or related products 
23. Previous participation in this trial. Participation is defined as signed informed consent 
24. Participation in any clinical trial of an approved or non-approved investigational medicinal 
product within 90 days before screening  
25. Other subject(s) from the same household participating in any semaglutide trial  
26. Known history of heart disease (including history of clinically significant arrhythmias or 
conduction delays on ECG) within 180 days before screening, new clinically significant 
arrhythmias or conduction delays on ECG identified at screening  
27. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using a highly effective contraceptive method  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
27
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
28 of 118 
 
28. Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria, 
which in the investigator’s opinion, might jeopardise the subject’s safety or compliance with 
the protocol 
Glycaemia-related for subjects without T2D 
29. Treatment with glucose-lowering agent(s) within 90 days before screening (except for 
metformin) 
30. Treatment with a GLP-1 receptor agonist within 180 days before screening 
Diabetes related for subjects with T2D  
31. Treatment with any medication for the indication of diabetes other than stated in the 
inclusion criteria within the past 90 days prior to the day of screening 
32. Treatment with a GLP-1 receptor agonist within 180 days before screening 
33. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a 
fundus examination performed within the past 90 days prior to screening (V1). 
Pharmacological pupil-dilation is a requirement unless using a digital fundus photography 
camera specified for non-dilated examination.  
The criteria will be assessed at the investigator’s discretion unless otherwise stated. 
6.3 
Run-in criteria 
Subjects will be considered screen failures, if any of the run-in criteria apply, see Section 6.6 
1. Included in the trial in violation of the inclusion and/or exclusion criteria. 
2. Pregnancy 
3. Intention of becoming pregnant 
4. Participation in another clinical trial during the run-in period 
5. Any safety concern judged at the investigators discretion  
6.4 
Randomisation criteria 
To be randomised, all randomisation criteria must be answered "yes". 
1. BMI corresponding to 
a) ≥95th percentile* OR  
b) ≥85th percentile* with ≥1 weight related comorbidity (treated or untreated): 
hypertension, dyslipidaemia, obstructive sleep apnoea or T2D 
2. Compliance with trial procedures and visit schedule as judged by the investigator 
3. A PHQ-9 score of <15 at randomisation 
4. No suicidal behaviour in the period between screening and randomisation 
5. No suicidal ideation corresponding to type 4 or 5 on the C-SSRS in the period between 
screening and randomisation  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
28
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
29 of 118 
 
6. Absence of uncontrolled and potentially unstable diabetic retinopathy or maculopathy. 
Verified by a fundus examination performed within the past 30 days prior to randomisation 
(V8)**. Pharmacological pupil-dilation is a requirement unless using a digital fundus 
photography camera specified for non-dilated examination.  
*On gender and age-specific growth charts (CDC.gov) (Appendix 9) 
**Diabetes related for subjects with T2D only (at screening or if diagnosed during the trial) 
Subjects not fulfilling the randomisation criteria will be considered screen failures.  
6.5 
Lifestyle restrictions 
To ensure alignment with regards to performance of assessments across subjects and trial sites, the 
below restrictions apply. 
6.5.1 
Meals and dietary restrictions 
• The subjects must attend several visits fasting according to the flowchart  
• Fasting is defined as at least 8 hours before the visit, without food or liquids, except for water. 
Trial product and any medication which should be taken with or after a meal should be withheld 
on the day of the visit until blood samples have been obtained  
• At the ‘end of trial’ visit only 2 hours of fasting is required prior to the anti-semaglutide 
antibody sampling 
• If the subject is not fasting as required, the subject should be called in for a new visit within the 
visit window to have the fasting procedures done  
6.5.2 
Caffeine and tobacco 
• Subject should avoid caffeine and smoking at least 30 minutes prior to measuring the blood 
pressure 
6.6 
Screen failures 
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible according to in/exclusion criteria, run-in criteria or randomisation criteria. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure subjects to 
meet requirements from regulatory authorities. Minimal information includes demography, screen 
failure details, eligibility criteria, and any serious adverse event (SAE). A screen failure session 
must be made in the interactive web response system (IWRS).  
Individuals who do not meet the criteria for participation in this trial may not be re-screened. Re-
sampling is not allowed if the subject has failed one of the inclusion criteria or fulfilled one of the 
exclusion criteria related to laboratory parameters. However, in case of technical issues (e.g. 
haemolysed or lost), re-sampling is allowed for the affected parameters.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
29
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
30 of 118 
 
7 
Treatments 
7.1 
Treatments administered 
• All trial products listed in Table 7-1 are considered investigational medicinal products (IMP) 
• Trial product must only be used, if it appears clear and colourless  
Table 7-1 
Trial products provided by Novo Nordisk A/S 
Trial product name: 
Semaglutide B 
1.0 mg/mL PDS290 or semaglutide placebo* 
Semaglutide B 
3.0 mg/mL PDS290 or semaglutide placebo 
Dosage form: 
 
Solution for injection 
Solution for injection 
Route of 
administration:  
Subcutaneous 
Subcutaneous 
Dosing instructions: 
 
Once weekly 
Once weekly 
Packaging: 
Delivery device 
3 mL PDS290 pre-filled pen-injector 
3 mL PDS290 pre-filled pen-injector 
* Semaglutide B 1.0 mg/mL PDS290/semaglutide placebo will only be dispensed at the first dispensing visit (V8) 
 
• Treatment will be initiated with 0.25 mg once-weekly dosing and will follow a dose-escalation 
regimen with 4-week dose escalation steps to 0.5, 1.0, 1.7 and 2.4 mg  
• The first dose of trial product must be taken at site on the day of randomisation and documented 
in the subject's medical record 
• Dose escalation of semaglutide/semaglutide placebo should take place during the first 16 weeks 
after randomisation. All subjects should aim at reaching the recommended target dose of 2.4 mg 
semaglutide once-weekly or the corresponding volume of placebo 
• If a subject does not tolerate the designated target dose (2.4 mg once-weekly), the subject may 
stay at a lower dose level. This should only be allowed if the subject would otherwise 
discontinue trial product completely and if considered safe to continue on trial product, as per 
the investigator’s discretion. It is recommended that the subject makes at least one attempt to re-
escalate to the designated target dose (2.4 mg once-weekly), as per the investigator’s discretion  
• In case the subject needs to be on a lower dose level than 1.0 mg after V12, the site must advise 
the subject how to administer the 0.25 or 0.50 mg dose using the 3 mg/mL pen.  
• It is recommended that the investigator consults Novo Nordisk in case the subject should be on 
a lower dose than 1.0 mg using the 3.0 mg/mL pen or in case of persistent deviation from the 
planned escalation regimen 
• A dose reminder card will be handed out to the subjects at each site visit during the escalation 
period. This is to remind the subjects of the dose to be taken until next site visit and provide a 
conversion of the dose to the value shown in the dose counter, see Table 7-2. Once the target 
dose has been reached, the dose reminder card is only handed out as needed 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
30
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
31 of 118 
 
• At V12 the investigator must ensure to instruct the subject that the dose/pen dose is dialled to 
adjust from 0.5 mg to 1.0 mg due to change in pen 
 
Table 7-2 
Dose escalation and maintenance of semaglutide 2.4 mg once 
weekly/semaglutide placebo 
Trial product name 
Dose 
Volume 
Value shown in 
dose counter* 
Duration 
Dose escalation period 
Semaglutide B 1.0 mg/mL PDS290/ 
semaglutide placebo 
0.25 mg 
0.25 mL 
25* 
4 weeks 
Semaglutide B 1.0 mg/mL PDS290/ 
semaglutide placebo 
0.5 mg 
0.50 mL 
50* 
4 weeks 
Semaglutide B 3.0 mg/mL PDS290/ 
semaglutide placebo 
1.0 mg 
0.34 mL 
34* 
4 weeks 
Semaglutide B 3.0 mg/mL PDS290/ 
semaglutide placebo 
1.7 mg 
0.57 mL 
57* 
4 weeks 
Maintenance period 
Semaglutide B 3.0 mg/mL PDS290/ 
semaglutide placebo 
2.4 mg 
0.80 mL 
80* 
52 weeks 
* Conversion to dose is calculated based on 0.01 mL/value for both strengths. 
 
• Subjects will be instructed to inject semaglutide/semaglutide placebo once-weekly at the same 
day of the week (to the extent possible) throughout the trial 
• Injections should be administered by subcutaneous injections either in the abdomen, thigh or 
upper arm at any time of day irrespective of meals 
• If a single dose of trial product is missed, it should be administered as soon as noticed, provided 
the time to the next scheduled dose is at least 2 days (48 hours). If a dose is missed and the next 
scheduled dose is less than 2 days (48 hours) away, the subject should not administer a dose 
until the next scheduled dose. A missed dose should not affect the scheduled dosing day of the 
week 
• If ≥2 consecutive doses of trial product are missed, the subject should be encouraged to re-
commence the treatment if considered safe as per the investigator’s discretion and if the subject 
does not meet any of the discontinuation criteria (Section 8.1). The trial product should be 
continued as early as the situation allows. The missed doses should not affect the scheduled 
dosing day of the week. The start dose for re-initiation of trial product is at the investigator’s 
discretion. In case of questions related to re-initiation of trial product, the investigator should 
consult Novo Nordisk global medical expert 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
31
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
32 of 118 
 
• 
For subject with T2D at screening or if diagnosed during the trial: If doses are missed, 
blood glucose (BG) should be more closely monitored if judged necessary by the 
investigator 
• Auxiliary supplies will be provided in accordance with the trial materials manual (TMM) please 
see Table 7-3 
 
Table 7-3 
Auxiliary supplies provided by Novo Nordisk A/S 
Auxiliary supply 
Details 
Needles 
Needles for pre-filled pen system. Detail provided in the TMM. 
Only needles provided and approved by Novo Nordisk must be used for administration 
of trial product.  
Direction for use (DFU) 
DFU for 3 mL PDS290 pre-filled pen-injector. 
Not included in the dispensing unit and to be handed out separately. 
BG meters  
For subjects with T2D at screening or if diagnosed during the trial.  
7.1.1 
Medical device 
Information about the PDS290 pre-filled pen-injector may be found in the IB40 and any updates 
hereof. 
Information about the use of the PDS290 pre-filled pen-injector for semaglutide 1.0 mg/mL, 
semaglutide 3.0 mg/mL, and semaglutide placebo can be found in the DFU. 
Training in the PDS290 pre-filled pen-injector 
The investigator must document that training in the DFU has been given to the subjects orally and 
in writing at the first dispensing visit. Training must be repeated during the trial at regular intervals 
in order to ensure correct use of the medical device. Training is the responsibility of the investigator 
or a delegate. 
7.1.2 
 Diet counselling 
All subjects (and parent(s)/LAR, as applicable) must receive individualised counselling in healthy 
nutrition with the goal of obtaining a weight loss. The counselling begins at run-in (week -12) and 
continues through the entire trial. The counselling must be done by a certified dietician or a 
similarly qualified health care professional according to local standard. The counselling can be done 
independently of the site visits within the visit window and flexibly as site visits, phone or video 
call.  
The focus of the counselling in healthy nutrition must be to educate on healthier food choices. If a 
BMI corresponding to <85th percentile on CDC’s growth charts is reached, subjects should be 
assigned a maintenance diet, at the discretion of the investigator. For details, refer to Appendix 9. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
32
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
33 of 118 
 
7.1.3 
Physical activity counselling 
At every site, there must be a qualified person (site staff trained in physical activity counselling) to 
provide instructions and advise on physical activity. The focus of the counselling in physical 
activity is to encourage and reinforce a goal of 60 minutes of moderate to high intensity physical 
activity per day43. The counselling can be done independently of the site visits within the visit 
window and flexibly as site visits, phone or video call. Activity trackers can be provided by Novo 
Nordisk in order to support the physical activity of the subjects. The use of these trackers is 
optional. 
7.2 
Dose modification 
Not applicable for this trial. Please refer to Section 7.1 for description of missed dose(s).  
7.3 
Method of treatment assignment 
All subjects will be centrally screened and randomised using an IWRS and assigned to the next 
available treatment according to randomisation schedule. Trial product will be dispensed at the trial 
visits summarised in the flowchart. An ‘end of treatment’ session should be made in IWRS, when 
the subject completes the treatment or permanently discontinues trial product. 
7.4 
Blinding 
The active drug and placebo drug are visually identical for the following trial products:  
• 
Semaglutide B 1.0 mg/mL PDS290/semaglutide placebo 
• 
Semaglutide B 3.0 mg/mL PDS290/semaglutide placebo 
The IWRS is used for blind-breaking. The blind may be broken in a medical emergency if knowing 
the actual treatment would influence the treatment of the subject. Novo Nordisk will be notified 
immediately after breaking the blind. The date when and reason why the blind was broken must be 
recorded in the source documentation. 
Whenever the blind is broken, the person breaking the blind must print the "code break 
confirmation" notification generated by the IWRS, record the reason and sign and date the 
document.  
When the blind is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of blind break, the 
IWRS helpdesk should be contacted. Contact details are listed in Attachment I.  
7.5 
Preparation/Handling/Storage/Accountability 
Only subjects enrolled in the trial may receive trial product and only authorised site staff may 
supply or administer trial product.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
33
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
34 of 118 
 
Trial Product storage, in-use conditions and in-use time will be available on the label and in the 
TMM. 
• Each trial site will be supplied with sufficient trial products for the trial on an on-going basis 
controlled by the IWRS. Trial product will be distributed to the trial sites according to screening 
and randomisation 
• The investigator must confirm that appropriate temperature conditions have been maintained 
during transit for all trial products received (see TMM) and any discrepancies are reported and 
resolved before use of the trial products 
• All trial products must be stored in a secure, controlled, and monitored (manual or automated) 
area in accordance with the labelled storage conditions with access limited to the investigator 
and authorised site staff 
• The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. Additional details regarding handling of temperature deviations 
can be found in the TMM  
• Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by Novo Nordisk 
• The investigator is responsible for drug accountability and record maintenance (i.e. receipt, 
accountability and final disposition records) 
• Drug accountability should be performed on a pen level and must be documented in the IWRS 
according to "Drug handling" in the flowchart 
• The subject must return all used, partly used and unused trial product including empty 
packaging materials during the trial as instructed by the investigator 
• Destruction of trial products can be performed on an ongoing basis and will be done according 
to local procedures after accountability is finalised by the site and reconciled by the monitor.  
• Destruction of trial products must be documented in the IWRS  
• All returned, expired or damaged trial products (for technical complaint samples see Appendix 
6) must be stored separately from non-allocated trial products. No temperature monitoring is 
required 
• Non-allocated trial products including expired or damaged products must be accounted as 
unused, at the latest at closure of the trial site  
7.6 
Treatment compliance 
Throughout the trial, the investigator will remind the subjects to follow the trial procedures and 
requirements to ensure subject compliance. 
Compliance with trial product administration will be assessed and the assessment documented in 
source documents at each visit where information is available. If any suspicion of non-compliance 
arises, the site must enter into a dialogue with the patient, re-emphasizing the importance of 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
34
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
35 of 118 
 
compliance and uncover barriers to compliance. This dialogue must be documented. Compliance 
will be assessed by cross checking the following sources and comparing these to the expected use: 
• 
Drug accountability information; counting returned trial product, visual inspection of pens, 
whether the used trial product Dispensing Unit Numbers (DUNs) have been administered 
by the subjects as expected at each visit (see 7.5) 
• 
Review of PK diaries 
• 
Questioning of subjects 
Information about compliance and missed doses should be described in the subject’s medical 
records and entered into the case report form (CRF). 
7.7 
Concomitant medication 
Any medication (including over-the-counter or prescription medicines) other than the trial product 
that the subject is receiving at the time of the first visit or receives during the trial must be recorded 
along with: 
• Trade name or generic name 
• Indication 
• Dates of administration including start and stop dates 
• Dose for weight-related co-morbidities (diabetes, hypertension and dyslipidaemia)  
During the trial, subjects should not initiate any anti-obesity treatment (e.g. medication) which is 
not part of the trial procedures. If such treatment is initiated, the subject should be instructed to stop 
the anti-obesity treatment. 
Changes in concomitant medication must be recorded at each visit. If a change is due to an AE, this 
must be reported according to Section 9.2.  
7.8 
Treatment after the end of the trial 
After the end of the trial the subject should be treated at the discretion of the investigator. 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
35
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
36 of 118 
 
8 
Discontinuation/Withdrawal criteria  
The subject may be discontinued at any time during the trial at the discretion of the investigator for 
safety, behavioural, compliance or administrative reasons.  
Efforts must be made to have subjects who discontinue trial product continue in the trial. Subjects 
must be educated about the continued scientific importance of their data, even if they discontinue 
trial product. Only subjects who withdraw consent will be considered as withdrawn from the trial.  
8.1 
Discontinuation of trial treatment 
• Discontinuation of trial product can be decided by either the investigator, the subject or 
parent(s)/LAR 
• Subjects who discontinue trial product should continue with the scheduled visits and 
assessments to ensure continued counselling and data collection 
• 
If the subject does not wish to attend the scheduled clinic visits, efforts should be made to 
have the visits converted to phone contacts or video calls. However all efforts should be 
made to have the subject attend at least the ‘end of treatment’ clinic visit (V30) containing 
the final data collection of primary and confirmatory secondary efficacy endpoints, and the 
‘end of trial’ visit (V31) according to schedule.  
• 
If the subject refuses to attend the ‘end of treatment’ visit (V30) and/or ‘end of trial’ visit 
(V31), information about the attempts to follow up with the subject must be documented in 
the subject’s medical record 
The subject must be discontinued from trial product, if the following applies: 
1. Safety concern as judged by the investigator 
2. Calcitonin ≥50 ng/L (see Appendix 10)  
3. Suspicion of pancreatitis 
4. Pregnancy 
5. Intention of becoming pregnant 
6. Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal producta 
7. Diagnosis of type 1 diabetes 
a Simultaneous participation in a trial with the primary objective of evaluating an approved or non-approved 
investigational medicinal product for prevention or treatment of COVID-19 disease or postinfectious conditions is 
allowed at the investigator’s discretion without discontinuing trial product. 
Ad. 3. If acute pancreatitis is suspected, appropriate actions should be initiated, including local 
measurement of amylase and lipase (see Appendix 4 for reporting). 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
36
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
37 of 118 
 
Subjects meeting discontinuation criterion no. 3 are allowed to resume the trial product, if the 
Atlanta criteria44 are not fulfilled and thus, the suspicion of pancreatitis is not confirmed. The trial 
product may be restarted for subjects with a gallstone-induced pancreatitis in case of 
cholecystectomy. 
Subjects meeting discontinuation of trial product criteria no. 1, 4 or 5 are allowed to resume the trial 
product, if the criteria are no longer met (see Section 8.1.1). 
Subjects who discontinue the trial product will be asked to follow the visit schedule and perform all 
assessments as planned. 
The primary reason for discontinuation of trial product must be specified in the source data at the 
time of discontinuation, and subject should continue to follow the visit and assessment schedule. A 
change in ‘treatment status’ must be made in IWRS to discontinue trial product. If subject is not 
allowed to resume trial product, then the reason for discontinuation will be recorded in the ‘end of 
treatment’ form in the CRF, and final drug accountability must be performed. An ‘end of treatment’ 
session must be made in the IWRS. 
8.1.1 
Temporary discontinuation of trial treatment 
If a subject has discontinued trial product and is allowed to resume, the subject should follow the 
guide for missed doses (Section 7.1).  
If a ‘treatment status’ session previously has been made in IWRS to indicate discontinuation of trial 
product, a new ‘treatment status’ session must be made to resume trial product. 
8.2 
Withdrawal from the trial 
A subject may withdraw consent at any time at his/her own request, or at the request of the subject's 
parent(s) or the subject's LAR. Only subjects who withdraw consent will be considered as 
withdrawn from the trial. 
If a subject withdraws consent, the investigator must ask the subject if he/she is willing, as soon as 
possible, to have assessment performed according to the ‘end of treatment’ visit. ‘End of treatment’ 
and ‘end of trial’ forms must be completed by the investigator and (as a minimum) BMI and safety 
assessments should be performed if the subject agrees. See the flowchart and Appendix 2 for data to 
be collected.  
Final drug accountability must be performed even if the subject is not able to come to the trial site. 
The investigator must make a ‘treatment status’ session in IWRS to discontinue trial product.  
If a subject withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
37
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
38 of 118 
 
If the subject withdraws consent, Novo Nordisk may retain and continue to use any data collected 
before such a withdrawal of consent. 
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for withdrawal must be specified in the ‘end of trial’ 
form in the CRF. 
For country specific requirements, refer to Appendix 11. 
8.2.1 
Replacement of subjects 
Subjects who discontinue trial product or withdraw from trial will not be replaced. 
8.3 
Lost to follow-up 
A subject will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the trial site.  
The following actions must be taken if a subject fails to return to the trial site for a required visit: 
• The site must attempt to contact the subject and reschedule the missed visit as soon as possible 
and counsel the subject on the importance of maintaining the assigned visit schedule and 
ascertain whether or not the subject wishes to and/or should continue in the trial 
• Before a subject is deemed lost to follow-up, the investigator must make every effort to regain 
contact with the subject (where possible, at least three telephone calls and, if necessary, a 
certified letter to the subject's last known mailing address or local equivalent methods). These 
contact attempts should be documented in the subject's source document 
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of 'lost to follow-up'  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
38
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
39 of 118 
 
9 
Trial assessments and procedures 
• Trial procedures and their timing are summarised in the flowchart (Section 2) and in Appendix 
2  
• Refer to Appendix 8 for any investigations concerning subjects with T2D at screening or if 
diagnosed during the trial 
• To ensure flexibility for the subjects, phone visits may be replaced by site visits or video calls 
• Informed consent and informed assent (per local requirements) must be obtained before any trial 
related activity, see Appendix 3 and Appendix 7 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria  
• The investigator will maintain a screening log to record details of all subjects screened and to 
confirm eligibility or record reason for screen failure, as applicable 
• At screening, subjects will be provided with a card stating that they are participating in a trial 
and giving contact details of relevant trial site staff  
• Adherence to the trial design requirements, including those specified in the flowchart, is 
essential and required for trial conduct 
• Assessments should be carried out according to the clinic’s standard of practice unless 
otherwise specified in the current section. Efforts should be made to limit the bias between 
assessments. The suggested order of the assessments:  
1. ECG and vital signs 
2. Blood samples 
3. COAs (see Sections 9.1.2 and 9.4.1) 
4. Other assessments 
• Source data of clinical assessments performed and recorded in the CRF must be available and 
will usually be the subject’s medical records. Additional recording to be considered source data 
includes, but is not limited to laboratory reports, ECG, diary recordings and COAs 
• Subjects and/or the parent(s)/LAR must receive training in how to collect dosing information 
prior to PK sampling in a designated paper diary 
• Only the subject and/or the parent(s)/LAR can make entries and corrections in the diaries, 
unless the section is specified for site staff 
• Review of completed diaries, COAs, ECG and laboratory reports must be documented either on 
the documents or in the subject's source documents. If clarification of entries or discrepancies is 
needed, the subject must be questioned and a conclusion made in the subject's source 
documents. Care must be taken not to bias the subject 
• Approximately 115 mL blood will be collected from each subject during the entire trial period. 
Blood collection should be performed in accordance with the guidelines in EU Directive 
2001/20/EC45 unless stricter local requirements apply. According to EU Directive 2001/20/EC it 
is recommended not to draw more than 3% of the total blood volume in a 4-week period and 1% 
of total blood volume at any single occasion. The total volume of blood is estimated at 80 to 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
39
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
40 of 118 
 
90 ml/kg body weight; 3% is 2.4 ml blood per kg body weight. If a subject weighs less than 
33 kg a prioritisation of blood samples will be made on a case-by-case basis 
• For subjects who have consented to have biosamples for future analysis collected, 
approximately additional 13 mL blood will be collected. If the subject's weight is lower than 
41 kg, the regular blood samples must be prioritised and biosamples for future analysis should 
not be taken 
• Repeat samples may be taken for technical issues and unscheduled samples or assessments may 
be taken for safety reasons. Please refer to Appendix 2 for further details on laboratory samples 
• According to the flowchart, the investigator will periodically evaluate the glycaemic status of 
subjects without T2D. This evaluation will be based on all available relevant information e.g. 
medical records, concomitant medication, BG parameters (HbA1c, Fasting plasma glucose 
(FPG)) and AEs. The subject’s glycaemic status will be categorised as normo-glycaemia, 
prediabetes or diagnosed with T2D according to the American Diabetes Association’s (ADA) 
definitions46 
9.1 
Efficacy assessments  
Planned time points for all efficacy assessments are provided in the flowchart. 
9.1.1 
Body measurements 
• Body weight should be measured at all site visits without shoes, with an empty bladder and only 
wearing light clothing. It should be measured on a digital scale and recorded in kilograms or 
pounds (one decimal) preferably using the same scale throughout the trial. The scale must be 
calibrated yearly as a minimum 
• Height should be measured (centimetres or inches, one decimal) without shoes as two individual 
measurements performed by a single observer using identical technique with a Harpenden or 
other wall mounted stadiometer. The subject should be repositioned between the two 
measurements 
• BMI will be calculated in the CRF every time the weight and height are measured. BMI SDS 
and height SDS will be calculated using the methods outlined in WHO 200747, 48 
• Waist circumference is defined as abdominal circumference located midway between the lower 
rib margin and the iliac crest. Measures must be obtained in standing position with a non-
stretchable measuring tape and to the nearest 0.5 cm or 0.2 inch. The tape should touch the skin 
but not compress soft tissue and twists in the tape should be avoided. The subject should be 
asked to breathe normally. The same measuring tape should be used throughout the trial. The 
measuring tape will be provided by Novo Nordisk to ensure standardisation. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
40
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
41 of 118 
 
9.1.2 
Clinical outcome assessments 
The Impact of Weight on Quality of Life-Kids (IWQOL-Kids) is a disease specific questionnaire 
which measures the impact of weight on quality of life in adolescents and is validated in youth ages 
11 years and older49. The four concepts captured are: 
• 
the impact of weight on an individual’s physical mobility and comfort (Physical Comfort) 
• 
how an individual feels about themselves and their body (Body Esteem) 
• 
how an individual is treated in their social environment (Social Life) 
• 
the individual’s perception of what family members may think and feel about them (Family 
Relations) 
The questionnaire has 27 items and a total, as well as domain specific score(s), can be derived. The 
scaled scores range from 1-5, with higher scores representing better health related quality of life. 
IWQOL-Kids will be completed at V8, V20 and V30. Subjects should be given the opportunity to 
complete the questionnaires by themselves without interruption. If the subject has difficulty reading 
the questionnaire, the site staff or the parent(s)/LAR can read the questions out loud, but should not 
help explaining the question or do anything else that might influence the subject's answer to the 
question. The questionnaire takes approximately 10 minutes to complete and should preferably be 
completed after fasting related activities (i.e. blood sampling) have been concluded. 
Only subjects can make changes in the questionnaire. 
After completion, the questionnaire must be reviewed by the investigator or delegated staff on the 
same day for potential AEs, including any overall change in health and concomitant medication. 
When reviewing the questionnaires, the investigator should not influence or question the subject on 
the content of the subject’s response to the questionnaire questions. Review of questionnaires must 
be documented in the subject’s medical record. Care must be taken not to bias the subject. 
9.1.3 
Clinical efficacy laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in 
accordance with the flowchart and the laboratory manual. 
9.2 
Adverse events 
The definitions of AEs and SAEs can be found in Appendix 4. 
The investigator is responsible for detecting, documenting, recording and following up on events 
that meet the definition of an AE or SAE. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
41
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
42 of 118 
 
9.2.1 
Time period and frequency for collecting AE and SAE information 
All AEs will be collected from the first trial-related activity after obtaining informed consent and 
assent and until the ‘end of trial’ visit (V31), at the time points specified in the flowchart.  
All SAEs will be recorded and reported to Novo Nordisk or designee within 24 hours, as indicated 
in Appendix 4. The investigator must submit any updated SAE data to Novo Nordisk within 24 
hours of it being available. 
Investigators are not obligated to actively seek for AE or SAE in former trial subjects. However, if 
the investigator learns of any SAE, including a death, at any time after a subject has been 
discontinued from/completed the trial, and the investigator considers the event to be 
possibly/probably related to the investigational trial product or trial participation, the investigator 
must promptly notify Novo Nordisk. 
The method of recording, evaluating and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 4. The trial will be monitored 
by an external and un-blinded Data Monitoring Committee (DMC). 
Timelines for reporting of AEs are listed in Figure 9-1. 
Some AEs require additional data collection via a specific event form. This includes medication 
errors, misuse and abuse observed during the trial. The relevant specific events are listed in 
Table 9-1 and the reporting timelines in Figure 9-1. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
42
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
     
Status:
Final
     
Page:
43 of 118
AE identified
AE form ≤  24 hours
SIF ≤5 calendar days
Sign off ≤ 7 calendar days
Is the AE serious or 
non-serious?
AE form
Is the AE listed as 
requiring a Specific Event 
Form to be completed?
Non-serious
Serious
No additional action
No
Specific event form
For SAE:
≤14 calendar days
Yes
Timelines are from the awareness of an AE.
Queries and follow-up requests to be resolved ≤14 calendar days.
AE: Adverse Events, SAE: Serious Adverse Events, SIF: Safety Information Form
Figure 9-1
Decision tree for determining the event type and the respective forms to 
complete with associated timelines
Table 9-1
AEs requiring additional data collection (via specific event form)
Event type  
AE via specific event form
Acute gallbladder disease
X
Acute pancreatitis
X
Malignant neoplasm
X
Hepatic event
X
Medication error
X
Misuse*
X
Abuse*
X
Diabetic retinopathy (T2D only)
X
* Additional data for misuse or abuse of trial product is reported on the medication error event form
For further information regarding AEs requiring additional data collection, refer to Appendix 4.
9.2.2
Method of detecting AEs and SAEs
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the subject is the preferred method to inquire about events.
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
43
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
44 of 118 
 
9.2.3 
Follow-up on AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, or if the event 
is otherwise explained (e.g. chronic condition) or the subject is lost to follow-up (as defined in 
Section 8.3). Further information on follow-up procedures is given in Appendix 4. 
9.2.4 
Regulatory reporting requirements for SAEs 
Prompt notification by the investigator to Novo Nordisk of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a trial 
product under clinical investigation are met.  
Novo Nordisk has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a trial product under clinical investigation. Novo Nordisk 
will comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional review board (IRB), Independent ethics committee (IEC), and 
investigators. 
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(SUSARs) according to local regulatory requirements and Novo Nordisk policy and forwarded to 
investigators as necessary. 
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (e.g. summary or listing of SAEs), from Novo Nordisk will review and then file 
it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
9.2.5 
Cardiovascular and death events 
Cardiovascular and death events will be handled and reported according to AE/SAEs description in 
Section 9.2.1. 
9.2.6 
Pregnancies and associated adverse events 
Details of pregnancies in female subjects will be collected after the first-trial-related activity after 
obtaining informed consent and until pregnancy outcome. 
If a pregnancy is reported in female subjects, the investigator should inform Novo Nordisk within 
14 calendar days of learning of the pregnancy and should follow the procedures outlined in 
Figure 9-2 and Appendix 5.  
Pregnancy outcome should be documented in the subject's medical record. Abnormal pregnancy 
outcome (e.g. spontaneous abortion, foetal death, stillbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
44
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
     
Status:
Final
     
Page:
45 of 118
Maternal form 1b
14 calendar days after birth
Maternal form 1a
14 calendar days
After birth/
termination 
of pregnancy
No additional 
action
Normal outcome 
Maternal form 2 
14 calendar days
Paternal form*1
14 calendar days
Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 9.1.
Prior to 
birth or 
pregnancy 
termination 
For female subjects
Figure 9-2
Decision tree for determining the forms to complete with associated timelines 
for pregnancy.
9.2.7
Medical device incidents (including malfunctions)
Section not applicable for this trial. Refer to technical complaints in Section 9.2.8.
9.2.8
Technical complaints
The investigator must assess whether a technical complaint is related to an AE.
The definitions and reporting process for technical complaints can be found in Appendix 6.
Timelines for reporting technical complaints are listed in Figure 9-3.
Technical complaint form: 
24 hours 
AE form: 
24 hours 
SIF: 
5 calendar days
Is it related to an SAE?
Technical complaint 
identified
Is it related to an 
AE?
Yes
No
Technical complaint form

5 calendar days
Technical complaint form: 

5 calendar days
AE form: 
5 calendar days
No
Yes
AE: Adverse Event, SAE: Serious Adverse Event,  SIF: Safety Information Form
Figure 9-3
Decision tree for determining the forms to complete with associated timelines 
for technical complaints. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
45
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
46 of 118 
 
9.3 
Treatment of overdose 
Overdoses of up to 4 mg in a single dose, and up to 4 mg in a week have been reported in clinical 
trials. The most commonly reported AE was nausea. All subjects recovered without complications. 
There is no specific antidote for overdose with semaglutide. In the event of an overdose, appropriate 
supportive treatment should be initiated according to subject’s clinical signs and symptoms. 
The overdose must be reported as a medication error. Intentional overdose must be reported as 
misuse or abuse (Appendix 4). For reporting timelines see Section 9.2.1 and Figure 9-1. 
In the event of an overdose, the investigator should closely monitor the subject for overdose-related 
AE/SAE and laboratory abnormalities. The long half-life of semaglutide of approximately one week 
should be taken into account. 
Decisions regarding dose interruptions or modifications will be made by the investigator based on 
the clinical evaluation of the subject. 
For more information on overdose, also consult the current version of the current IB40 and any 
updates hereof. 
9.4 
Safety assessments  
A concomitant illness is any illness that is present at the start of the trial (i.e. at the first visit) or 
found as a result of a screening procedure. 
Medical history is a medical event that the subject has experienced in the past. Any information of 
weight history, co-morbidities and history of psychiatric disorder must be recorded, otherwise only 
relevant and significant medical history should be recorded as judged by the investigator. 
In case of an abnormal and clinically significant finding, the investigator must record the finding on 
the Medical history/Concomitant illness form if it is present at screening. Any new finding fulfilling 
the AE definition (see Appendix 4) during the trial and any clinically significant worsening from 
baseline (screening, V1) must be reported as an AE (see Section 9.2). 
9.4.1 
Clinical outcome assessments 
The mental health assessment instruments PHQ-9 and C-SSRS will be completed at V1, V8, V20 
and V30. 
• PHQ-950 is a self-administered 9-item depression module of the patient health questionnaire 
used for assessment of mental disorders. The questionnaire will be available in a linguistically 
validated translated version 
• C-SSRS51 is a detailed questionnaire assessing both suicidal behaviour and suicidal ideation. 
The questionnaire will be administered as an interview by the investigator or a qualified 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
46
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
47 of 118 
 
delegate. The questionnaires (C-SSRS Baseline and C-SSRS Since Last Visit) will be available 
in a linguistically validated translated version. When answering the C-SSRS Since Last Visit 
questionnaire, the subjects should be instructed to answer the questions having the period since 
the last assessment in mind  
• Prior to administering the C-SSRS questionnaire, the investigator or qualified delegate must 
complete sufficient training 
A subject must be referred to a Mental Health Professional (MHP) if: 
• the subject has a PHQ-9 score ≥15 or 
• the subject has any suicidal behaviour or 
• the subject has any suicidal ideation of type 4 or type 5 on any C-SSRS assessment or 
• in the opinion of the investigator, it is necessary for the safety of the subject 
If one or more of the criteria are met, the investigator should explain to the subject why the referral 
and psychiatric evaluation by a MHP is needed. If the subject refuses it should be documented in 
the medical record and assessed if it is safe for the subject to continue on trial product and if the 
subject should continue in the trial.  
If a subject has a PHQ-9 score of 10-14 both inclusive the subject should be referred to a MHP if 
judged relevant by the investigator. If referral is not deemed relevant this and the reason why, must 
be documented in the subject’s medical records. 
If a subject’s psychiatric disorder can be adequately treated with psychotherapy and/or 
pharmacotherapeutic treatment, then the subject, at the discretion of the investigator (and in 
agreement with the MHP), may continue in the trial.  
9.4.2 
Physical examinations 
• A physical examination will include assessments of the general appearance, thyroid gland, 
abdomen, central and peripheral nervous systems as well as the cardiovascular and respiratory 
systems 
• Investigators should pay special attention to clinical signs related to previous serious illnesses. 
9.4.3 
Pubertal status  
• Pubertal development must be assessed by the Tanner staging in accordance with stages 1-552. 
The assessments must be conducted by site staff trained in pubertal assessments. For males, the 
assessment of testicular volume by orchidometer must be included 
• Evidence of accelerated pubertal development at screening, as judged by the investigator must 
be recorded as Medical history/Concomitant illness in the CRF and in the subject’s medical 
record  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
47
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
48 of 118 
 
• Acceleration of pubertal development after screening as judged by the investigator must be 
reported as AEs in accordance with Section 9.2 and Appendix 4 
• Tanner staging is not required once the subject reaches the Tanner stage 5, as judged by the 
investigator 
9.4.4 
Vital signs 
• Pulse rate as well as diastolic and systolic blood pressure will be assessed. 
• Blood pressure (diastolic and systolic) and pulse measurements should be preceded by at least 5 
minutes of rest for the subject in a quiet setting without distractions (e.g. television, cell phones) 
• Blood pressure and pulse measurements will be assessed in a sitting position with a completely 
automated device. Manual techniques will be used only if an automated device is not available 
9.4.5 
Bone age assessment (X-ray) 
• An x-ray of left hand and wrist will be performed at randomisation (V8) and at ‘end of 
treatment’ (V30) for all subjects for evaluation of bone age. An x-ray will not be performed at 
V30 for subjects for whom the bone age evaluation at randomisation indicates that the epiphyses 
are fused 
• The x-ray imaging data will be submitted to a supplier selected for central medical imaging 
services and will be analysed in a blinded manner by an independent paediatric radiology expert 
assigned by the supplier for bone age assessment  
A bone age x-ray performed within 2 weeks prior to the scheduled assessments is acceptable. 
9.4.6 
Electrocardiograms 
• 12-lead ECG will be obtained as outlined in the flowchart using a local ECG machine that 
automatically calculates the heart rate and measures PR, QRS, QT and QTc intervals. The 
investigator should make an overall interpretation of the ECG  
9.4.7 
Clinical safety laboratory assessments 
All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in 
accordance with the laboratory manual and the flowchart. 
• Urine pregnancy tests must be performed for women of childbearing potential (WOCBP) at all 
site visits. Urine pregnancy test must be repeated at any time during the trial whenever a 
menstrual period is missed or if pregnancy is suspected. Please refer to Appendix 5. Further 
instructions can be found in the laboratory manual 
9.4.8 
Immunogenicity assessments 
Blood samples for determination of serum antibodies against semaglutide, including cross reactivity 
to endogenous GLP-1, will be taken during the trial at visits specified in Appendix 2. Samples 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
48
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
49 of 118 
 
which are positive for anti-semaglutide antibodies will be further characterised for in vitro 
neutralising effect towards semaglutide. In addition, if samples are also positive for cross-reactivity 
against endogenous GLP-1, the samples will be analysed for in vitro neutralising effect towards 
endogenous GLP-1. Samples which are positive for anti-semaglutide antibodies will also be titrated. 
The results of the analysis will only be disclosed after completion of the clinical trial report (CTR) 
if required by local regulation. 
9.4.9 
Severe hypersensitivity 
In case of suspicion of an acute severe systemic hypersensitivity reaction to the trial product, the 
subject must be discontinued from trial product but should remain in the trial.  
In the event of an acute severe systemic hypersensitivity reaction possibly or probably related to 
trial product, the following sample should be taken 3-4 hours after the reaction, if possible:  
• Tryptase 
Furthermore, a blood sample should be taken as soon as possible and no later than 1-2 weeks after 
the reaction. A second sample should be taken 3-4 weeks after the reaction. 
For both samples, the following assessments will be performed: 
• Anti-semaglutide IgE antibodies  
• Anti-semaglutide antibodies  
• Tryptase 
If deemed relevant by Novo Nordisk other relevant exploratory tests may be performed, e.g. 
basophil activation, complement tests, prick tests and/or intra-dermal tests.  
The analyses will be performed by a laboratory assigned by Novo Nordisk. 
9.5 
Pharmacokinetics 
• Single blood samples for measuring plasma concentration of semaglutide will be drawn for all 
randomised subjects on visits specified in Appendix 2 
• Subject must be instructed to withhold their trial product dose in the morning of the clinic visit 
until blood sampling has been performed 
• The PK dosing information should be transcribed into the CRF for the last 2 doses of trial 
product prior to the PK assessment 
• The exact timing of obtaining the PK sample must be recorded on the laboratory form 
Samples will be used to evaluate the PK of semaglutide. Each plasma sample will be divided into 2 
aliquots (e.g. one for PK and a backup) and may also be used to evaluate safety or efficacy aspects 
that address concerns arising during or after the trial.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
49
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
50 of 118 
 
9.6 
Pharmacodynamics 
Not applicable for this trial 
9.7 
Genetics 
A blood sample for genetic analysis will be collected from subjects who have consented to 
participate in the optional biobank component of the trial. Refer to Section 9.9 and Appendix 7 for 
further details. 
9.8 
Biomarkers  
Collection of samples for biomarker research is part of this trial to support the safety objectives. 
The following samples must be taken in accordance with the laboratory manual and Appendix 2: 
Biomarkers: 
• Carcinoembryonic Antigen serum 
• Serum Insulin-like growth factor 1 
9.9 
Biosamples for future analysis  
Collection of biosamples for future analysis (stored in a biobank) is a component of this trial. The 
samples will allow for future analyses of biomarkers, both genetic and circulating when new 
knowledge or improved measurement technologies may have become available.  
Participation is optional, and parent(s)/LAR, and if required by local legislation also the subject, 
will be asked to sign a separate informed consent form in order to participate in the biobank 
component. Subjects who do not wish to participate in the biobank component may still participate 
in the trial. For the biobank, blood samples will be collected according to Appendix 2 and stored for 
future use.  
Genetic analyses may include analysis of candidate genes or genetic markers throughout the 
genome with the purpose of understanding and predicting response to semaglutide as well as to 
understand obesity or other related diseases. 
Analyses of circulating biomarkers will measure hormones, metabolites or other non-genetic serum 
entity with the purpose of understanding and predicting response to semaglutide as well as 
understanding obesity or other related diseases. 
These samples need to be frozen and should be sent in batches to the central laboratory. Results will 
not be part of the CTR. The biobank samples may be stored up to 15 years after end of trial at a 
central laboratory (see Appendix 7). 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
50
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
51 of 118 
 
9.10 
Subject diaries 
Subjects will be provided with a paper diary to be completed at home. Only the subjects and/or the 
parent(s)/LAR must enter data in the diary. Subjects and the parent(s)/LAR will be instructed by the 
investigator on when and how to complete the diary. It is important to explain to the subjects and/or 
the parent(s)/LAR the necessity of accurate diary recording.  
Review of diaries must be documented either on the document or in the subject’s medical record. If 
clarification of entries or discrepancies in the diary is needed, the subject must be questioned and a 
conclusion made in the subject’s medical record. Care must be taken not to bias the subject.  
All data from the diary must be transcribed into the CRF. 
9.10.1 
PK diary  
Trial product dosing diary pages should be completed by the subject before a visit including a blood 
sampling for semaglutide plasma concentration (see Section 9.5). 
The last 2 doses of trial product should be recorded in the diary before a visit with PK sampling 
stating: 
• 
Dose 
• 
Date 
• 
Exact time for dosing 
9.10.2 
Menstrual period diary  
For female subjects of childbearing potential the following should be recorded: 
• First date of recent menstrual period before the site visit of V8 (randomisation), V20, and V30 
(‘end of treatment’) 
If a subject experience a first menstrual period during the trial, the date for start of the period must 
be recorded.  
9.10.3 
 Diabetes diary  
Subjects with T2D at screening or if diagnosed during the trial will be provided with a diabetes 
diary on self-measured plasma glucose (SMPG) measurements and hypoglycaemic episodes. Refer 
to Appendix 8. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
51
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
52 of 118 
 
10 Statistical considerations  
Taxonomy of week 68 assessments being available or missing 
For each subject a given assessment at week 68 may be available or missing and Table 10-1 
describes the taxonomy for this. Note, this is done per assessment not per subject; subjects may be a 
different type for different assessments (a subject may have “available on treatment (AT)” for 
weight but “missing on treatment (MT)” for waist circumference). 
Table 10-1 
Taxonomy for subjects based on week 68 assessments being available or missing  
Assessment 
at week 68 
On 
randomised 
treatment 
at week 68 
Type description 
Type 
Abbreviation 
Available 
Yes 
Available on randomised treatment: 
Subjects who complete the trial on randomised treatment with an 
assessment at week 68: Includes those that stop and restart trial product. 
AT 
No 
Available but discontinued  
Subjects who discontinued randomised treatment prematurely but returned 
to have an assessment at week 68. These are also called retrieved subjects 
AD 
Missing 
Yes 
Missing on randomised treatment: 
Subjects who complete the trial on randomised treatment without an 
assessment at week 68: Includes those that stop and restart trial product. 
MT 
No 
Missing and discontinued: 
Subjects who discontinued randomised treatment prematurely and did not 
return to have an assessment at week 68. These are also called non-
retrieved subjects 
MD 
 
10.1 
Sample size determination  
The tests of superiority of s.c. semaglutide 2.4 mg to semaglutide placebo for the primary and 
confirmatory secondary endpoints are performed using the fixed-sequence statistical strategy. This 
strategy tests the endpoints using a predefined hierarchical order, all at the significance level of 5%, 
moving to test the next endpoint only after a significant superiority result (two-sided p-value < 5%) 
on the previous endpoint. The test hierarchy is given in Table 10-2 with underlying assumptions, 
marginal power and effective power. The effective power is calculated under the assumption of 
independence of endpoints by multiplying the respective marginal powers successively. 
In the analysis approach addressing the primary estimand, week 68 assessments from retrieved 
subjects (AD) are included. These data are also used to impute missing measurements at week 68 
for non-retrieved subjects (MD). The imputation is done separately within each treatment arm (see 
description below). However, for the sample size calculations, missing values (MT and MD), 
regardless of treatment arm, are assumed to be similar to semaglutide placebo subjects. These 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
52
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
53 of 118 
 
assumptions are likely conservative with respect to the power and correspond to the jump to 
reference sensitivity analysis described below. 
Assumptions 
The assumptions for the sample size calculations are: 
• The significance level is 5% 
• The randomisation ratio is 2:1 
• The t-test on the mean difference assuming equal variances is used 
• 35% of subjects discontinue permanently and ≥50% of these are retrieved (AD) at week 68  
• All subjects in the semaglutide placebo arm are assumed to have same effect as subjects who 
complete the trial on semaglutide placebo (AT) 
• Retrieved subjects (AD) in the semaglutide arm are assumed to have an effect corresponding to 
half the treatment difference (compared to semaglutide placebo) of subjects who complete the 
trial on semaglutide (AT) 
• In the semaglutide arm, non-retrieved subjects (MD) and subjects with data missing on 
randomised treatment (MT) are assumed to have an effect corresponding to the semaglutide 
placebo arm 
Further assumptions made to calculate the power for the primary and confirmatory secondary 
endpoints are conservatively based on findings from the s.c. semaglutide 0.1 mg and 0.2 mg once 
daily arms in trial NN9536-4153 and are presented in scenario 1 in Table 10-2. Alternate scenarios 
based on findings from the s.c. semaglutide 0.3 mg and 0.4 mg once daily arms (the latter expected 
to correspond to 2.4 mg once weekly) are presented in scenarios 2 and 3, respectively. 
Given these assumptions, the sample size of 192 subjects (128 in the semaglutide 2.4 mg and 64 in 
the semaglutide placebo arm), gives a power of at least 90% for the primary endpoint and an 
effective power (marginal powers multiplied) of at least 72% for both endpoints in the hierarchical 
testing procedure. Furthermore, this sample size is selected to ensure an adequate amount of subject 
exposure to s.c. semaglutide to support safety. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
53
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
54 of 118 
 
Table 10-2 
Assumptions and power for the primary and confirmatory secondary endpoints 
under various scenarios given an anticipated number of 192 randomised 
subjects   
Scenari
o 
Orde
r 
Endpoint 
Assumed mean (±SD) or 
proportion for completers 
Expected* 
mean (±SD) 
or 
proportion 
Expected* 
difference 
or 
proportio
n ratio 
Margina
l power 
(%) 
Effectiv
e power 
(%) 
Semaglutid
e 
2.4 mg 
Semaglutid
e placebo 
Semaglutid
e 
2.4 mg 
1 
1 
% change 
in BMI # 
10.5 (±10) 
3 (±10) 
8.5 (±11) 
5.5%-
points 
90 
90 
2 
≥5% 
responder
s in body 
weight 
71% 
42% 
63% 
1.5 
80 
72 
2 
1 
% change 
in BMI # 
12.5 (±10) 
3 (±10) 
10.0 (±11) 
7.0%-
points 
98 
98 
2 
≥5% 
responder
s in body 
weight 
77% 
42% 
68% 
1.6 
93 
92 
3 
1 
% change 
in BMI # 
14 (±10) 
3 (±10) 
11.1 (±11) 
8.1%-
points 
>99 
>99 
2 
≥5% 
responder
s in body 
weight 
82% 
42% 
72% 
1.7 
97 
97 
# shown as a positive number; *Accounting for reduced treatment effect among non-completers 
10.2 
Definition of analysis sets 
Two analysis sets are defined: 
The full analysis set (FAS) includes all randomised subjects according to the intention-to-treat 
principle. 
The safety analysis set (SAS) includes all randomised subjects exposed to at least one dose of 
randomised treatment. 
Any observation excluded from the analysis database will be documented before database lock with 
the reason for exclusion provided. 
Two observation periods are defined for each subject: 
• In-trial: The in-trial period is defined as the uninterrupted time interval from date of 
randomisation to date of last contact with trial site 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
54
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
55 of 118 
 
• On-treatment (with trial product): A time-point is considered as ‘on-treatment’ if any dose of 
trial product has been administered within the prior 2 weeks (14 days). The on-treatment period 
is defined as all times which are considered on-treatment 
• 
In general, the on-treatment period will therefore be from the date of first trial product 
administration to date of last trial product administration excluding potential off-treatment 
time intervals triggered by at least two consecutive missed doses 
• 
For the evaluation of AEs and hypoglycaemic episodes the lag time for each on-treatment 
time interval is 7 weeks (49 days) 
The in-trial and on-treatment periods define the patient years of observation (PYO) and patient 
years of exposure (PYE), respectively, as the total time duration in the periods. 
10.3 
Statistical analyses 
As a complete description of the statistical analyses are provided in this section of the protocol, a 
separate statistical analysis plan (SAP) has not been written for this trial. However, if it is later 
found to be necessary, a SAP may be written in addition to the protocol, including a more technical 
and detailed elaboration of the statistical analyses, in which case the SAP will be finalised before 
database lock. 
Effect endpoints will be analysed using the FAS; safety endpoints will be analysed using the SAS. 
Results from statistical analyses will generally be accompanied by two -sided 95% confidence 
intervals and corresponding p-values. 
Handling of missing baseline data 
The last available and eligible observation at or before randomisation is used as the baseline value. 
If no assessments are available, the mean value at randomisation across all subjects is used as the 
baseline value. 
10.3.1 
Primary endpoint 
Definition of primary endpoint: % change in BMI 
Change from baseline to week 68 in BMI (%) is defined as: 
% change in BMI= (BMI at week 68 – BMI at baseline)
BMI at baseline
 ×100. 
Analyses addressing the primary estimand 
The following statistical analyses and imputation methods are designed to address the primary 
estimand, i.e. to assess the effectiveness of semaglutide 2.4 mg. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
55
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
56 of 118 
 
The analysis model for % change in BMI is a linear regression (ANCOVA) of % change in BMI on 
randomised treatment and stratification group (gender *Tanner stage group) as factors, and baseline 
BMI (kg/m2) as covariate. The estimated treatment difference between s.c. semaglutide 2.4 mg and 
semaglutide placebo will be reported together with the associated two-sided 95% CI and 
corresponding p-value. 
The superiority tests of semaglutide 2.4 mg vs. semaglutide placebo will be carried out as follows. 
Let μsemaglutide and μsemaglutide placebo denote the true mean of % change in BMI for s.c. semaglutide 2.4 
mg and semaglutide placebo group, respectively. The null and alternative hypotheses tested are 
𝐻: 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒≥𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒 𝑝𝑙𝑎𝑐𝑒𝑏𝑜 𝑣𝑠
𝐻𝐴: 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒< 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒 𝑝𝑙𝑎𝑐𝑒𝑏𝑜.  
The hypothesis will be rejected and superiority claimed, if the upper limit of the estimated two-
sided 95% CI is below 0. 
Handling of missing week 68 values for the primary estimand 
All available data at week 68 (AT and AD) are used and missing values (MT and MD) at week 68 
will be imputed. Several approaches for imputation will be applied. First, a description of the 
primary imputation approach to address the primary estimand for the primary endpoints is given 
followed by a description of the sensitivity analyses used to assess the robustness of the primary 
analysis results. The sensitivity analyses investigate how assumptions on BMI development after 
discontinuation of randomised treatment impact the estimated treatment contrasts between s.c. 
semaglutide 2.4 mg and semaglutide placebo. An illustration of all imputation approaches for the 
effectiveness estimand is given in Figure 10-1. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
56
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
57 of 118 
 
 
Figure 10-1 Illustration of imputation approaches for the effectiveness estimand 
Primary imputation approach for the primary estimand 
Multiple imputation approach using retrieved subjects (RD-MI): The primary imputation approach 
for the primary estimand is a multiple imputation similar to the one described by McEvoy53. 
Missing BMI measurements at week 68 for non-retrieved subjects (MD) are imputed using 
assessments from retrieved subjects (AD) in each randomised treatment arm. This will be done 
according to the timing (month) of last available observation during the on-treatment period (LAO-
OT) of BMI. Missing BMI measurements at week 68 for subjects on randomised treatment (MT) 
are imputed by sampling from available measurements at week 68 from subjects on randomised 
treatment (AT) in the relevant randomised treatment arm. The multiple imputation approach is done 
in three steps: 
1. Imputation: Defines an imputation model using retrieved subjects (AD) from FAS and 
done within groups defined by randomized treatment and the timing (month) of the LAO-
OT of BMI (kg/m2). The model will be a linear regression of BMI (kg/m2) at week 68 on 
stratification group (gender *Tanner stage group) as a factor and baseline BMI (kg/m2) and 
LAO-OT of BMI (kg/m2) as covariates. No interactions will be included. If timing by month 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
57
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
58 of 118 
 
is too restrictive, quarters, half-years, or excluding timing will be used. If any subjects are 
MT, an imputation model for missing BMI measurements at week 68 for MT subjects will 
also be defined using AT subjects in a similar way. The estimated posterior distribution for 
the parameters (regression coefficients and variances) in the imputation models are then 
used to impute missing week 68 BMI values for each randomised treatment arm. This will 
be done 1000 times and result in 1000 complete data sets 
2. Analysis: Analysis of each of the 1000 complete data sets, using the analysis model 
(ANCOVA), resulting in 1000 estimations 
3. Pooling: Integrate the 1000 estimation results into a final result using Rubin’s formula 
Based on NN9536-4153 phase 2 results 1,000 copies should be sufficient to establish stable results. 
If 1,000 copies are insufficient, 10,000 copies will be used. The multiple imputations will be 
generated using Novo Nordisk trial number 95364451 as seed number. 
Sensitivity analyses 
Jump to reference multiple imputation approach (J2R-MI): Missing values of BMI at week 68 (MT 
and MD) for both the semaglutide 2.4 mg and semaglutide placebo group is by sampling among all 
available assessments at week 68 in the semaglutide placebo group (AT and AD). This approach 
makes the assumption that subjects instantly after discontinuation lose any effect of randomised 
treatment beyond what can be expected from semaglutide placebo treatment as adjunct to diet and 
physical activity54.The multiple imputation approach is done as above with the first step replaced 
by: 
1. Imputation: Defines an imputation model using semaglutide placebo subjects from FAS with a 
week 68 measurement (AT and AD). The model will be a linear regression of BMI (kg/m2) at week 
68 on stratification group (gender *Tanner stage group) as a factor and baseline BMI (kg/m2) as 
covariate. No interactions will be included. The estimated posterior distribution for the parameters 
(regression coefficients and variances) in the imputation models are then used to impute missing 
week 68 BMI values for each randomised treatment arms. This will be done 1000 times and result 
in 1000 complete data sets. 
The jump to reference approach is the basis for the sample size calculations.  
Tipping-point multiple imputation analysis (TP-MI): This analysis will be performed only if 
superiority is concluded with respect to the primary endpoint. First, missing data are imputed 
according to the primary multiple imputation approach. Second, for the semaglutide 2.4 mg 
treatment arm a penalty will be added to the imputed values at week 68. The approach is to 
gradually increase this penalty until the conclusion from the primary analysis is reversed. The 
specific value of the penalty that reverses the conclusion will be used to evaluate the robustness of 
the primary analysis results. This sensitivity analysis evaluates the robustness of the superiority 
conclusion. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
58
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
59 of 118 
 
Mixed model for repeated measurements (MMRM): This ‘MMRM for effectiveness’ will use all 
assessments regardless of adherence to randomised treatment, including assessments at week 68 for 
retrieved drop-outs (AD). The MMRM for effectiveness will be fitted using the same factor and 
covariate as for the primary analyses all nested within visit. An unstructured covariance matrix for 
measurements within the same subject will be employed, assuming that measurements for different 
subjects are independent. 
Analysis addressing the secondary estimand 
The secondary estimand for % change in BMI addresses the efficacy of semaglutide 2.4 mg and 
will be assessed using a ‘MMRM for efficacy’. Week 68 assessments for retrieved subjects (AD) 
are not used in this analysis. The MMRM for efficacy will use assessments only from subjects who 
are taking the randomised treatment until end of trial or at first discontinuation of randomised 
treatment. The derived date of the second consecutive missed dose will be used as the latest date for 
assessments included in this MMRM. The assessment closest in time and before the derived date of 
the second consecutive missed dose will be used as last assessment on randomised treatment. For 
subjects who initiate rescue interventions (weight management drugs or bariatric surgery) before 
completion or first discontinuation of randomised treatment, the date of starting weight 
management drugs or undergoing bariatric surgery will be used as last assessment on randomised 
treatment. The MMRM for efficacy will be fitted using % change in BMI and the same factor and 
covariate as for the primary analysis all nested within visit. An unstructured covariance matrix for 
measurements within the same subject will be employed, assuming that measurements for different 
subjects are independent. 
10.3.2 
Secondary endpoints 
10.3.2.1 
Confirmatory secondary endpoints 
The confirmatory secondary endpoint is weight loss ≥ 5% at week 68 (Y/N) (≥5% body weight 
responder endpoint), and is included in the fixed-sequence statistical strategy described above.  
Analysis addressing the primary estimand 
The ≥5% body weight responder endpoint will be analysed using the same imputation approach as 
used for the primary endpoint and to address the primary estimand. The imputation model is the 
same as for the primary endpoint, with BMI replaced by body weight, and the resulting imputed 
values will then be dichotomized to derive the responder endpoint. The statistical model for the 
≥5% body weight responder endpoint is a logistic regression using randomised treatment and 
stratification group (gender *Tanner stage group) as factors, and baseline body weight (kg) as a 
covariate. The estimated odds ratio (OR) between semaglutide 2.4 mg and semaglutide placebo will 
be reported together with the associated two-sided 95% CI and corresponding p-value. 
The superiority tests of semaglutide 2.4 mg vs. semaglutide placebo will be carried out as follows 
for the two analysis models. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
59
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
60 of 118 
 
Let ORsemaglutide/placebo denote the true odds ratio between semaglutide 2.4 mg and semaglutide 
placebo. The null and alternative hypotheses tested are 
𝐻: 𝑂𝑅𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒/𝑝𝑙𝑎𝑐𝑒𝑏𝑜≤1 𝑣𝑠
𝐻𝐴: 𝑂𝑅𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒/𝑝𝑙𝑎𝑐𝑒𝑏𝑜> 1.  
The hypothesis will be rejected and superiority claimed, if the lower limit of the estimated two-
sided 95% CI is above 1. 
Sensitivity analysis for the confirmatory secondary endpoint 
A sensitivity analysis considering non-retrieved subjects as non-responders will be carried out. 
Analyses addressing the secondary estimand 
The secondary estimand for the ≥5% body weight responder endpoint will be assessed using the 
same MMRM as for the primary endpoint. Subjects who are missing week 68 body weight will be 
replaced by predicted values for % weight change at week 68 from the MMRM, and these predicted 
values will then be dichotomized to derive the responder endpoint. A logistic regression model with 
randomised treatment as a factor and baseline body weight (kg) as a covariate will then be used to 
analyse the 5% responder endpoint. 
An overview of all analysis and imputation methods to address the effectiveness and efficacy 
estimands for the primary endpoints is given in Table 10-3. 
Table 10-3 
Analysis and imputation methods to address the effectiveness and efficacy 
estimands for the primary and confirmatory secondary endpoints in the 
statistical testing hierarchy 
Objective 
Endpoint 
Test 
order 
Endpoint 
type 
Estimand 
Analysis 
set 
Statistical 
model 
Imputation 
approach 
Sensitivity 
analyses 
Primary endpoint 
Primary 
% change in BMI 
1 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
J2R-MI 
TP-MI 
MMRM 
Secondary 
FAS 
MMRM 
- 
- 
Confirmatory secondary endpoint 
Primary 
≥5% body weight 
responders 
2 
Binary 
Primary 
FAS 
LR 
RD-MI 
Non-
responders 
Secondary 
FAS 
LR 
MMRM 
- 
FAS = full analysis set; ANCOVA = analysis of covariance; RD-MI = multiple imputation using retrieved subjects; J2R-MI = jump 
to reference multiple imputation; TP-MI = tipping point multiple imputation; MMRM = mixed model for repeated measurements; LR 
= logistic regression 
Test order refers to the order of the endpoint in the statistical test hierarchy outlined in Table 10-2. 
10.3.2.2 
Supportive secondary endpoints 
Supportive secondary endpoints are listed in Section 4. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
60
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
61 of 118 
 
Analyses addressing the primary estimand 
The effect-related supportive secondary endpoints will be analysed using the same imputation 
approach as used for the primary endpoint and to address the primary estimand. The imputation 
model is the same as for the primary endpoint with BMI replaced by assessments of the endpoint to 
be analysed. The statistical model for continuous endpoints will be ANCOVA with factor and 
covariate as for the primary endpoint % change in BMI with baseline BMI replaced by the baseline 
assessment of the endpoint to be analysed. 
The statistical model for the responder endpoint relating to BMI will be logistic regression with 
randomised treatment as a factor and the baseline assessment of the endpoint to be analysed as 
covariate.  
Analyses addressing the secondary estimand 
The supportive secondary endpoints which relate to the primary objective will be analysed to 
address the secondary estimand using the same MMRM for efficacy described for the primary 
endpoint. 
Analysis of safety endpoints 
The safety endpoint pulse will be analysed using an MMRM for efficacy as described in Section 
10.3.2.1. For amylase, lipase and calcitonin descriptive statistics will be provided. The analysis of 
calcitonin will be stratified by gender. 
AEs will be defined as “treatment-emergent” (TEAE), if the onset of the event occurs in the on-
treatment period (see definition in Section 10.2). TEAEs and SAEs will be summarised by 
descriptive statistics, such as frequencies and rates. No formal statistical inference will be carried 
out based on the number of TEAEs and SAEs. AEs in the run-in period (prior to randomisation) 
will be presented in listings. 
An overview of all analysis and imputation methods to address the effectiveness and efficacy 
estimands for supportive secondary endpoints is given in Table 10-4. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
61
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
62 of 118 
 
Table 10-4 
Analysis and imputation methods to address the effectiveness and efficacy 
estimands for supportive secondary endpoints 
Objective 
Endpoint 
Endpoint 
type 
Estimand 
Analysis 
set 
Statistical 
model 
Imputation 
approach 
Supportive secondary endpoints (effect related) 
Primary 
Weight change (kg) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FAS 
MMRM 
- 
Primary 
Weight change (%) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FAS 
MMRM 
- 
Primary 
BMI percentage of the 95th 
percentile (%) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FAS 
MMRM 
- 
Primary 
BMI (standard deviation score) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FAS 
MMRM 
- 
Primary 
Waist circumference change (cm) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FAS 
MMRM 
- 
Primary 
≥5% BMI responders 
Binary 
Primary 
FAS 
LR 
RD-MI 
Secondary 
FAS 
LR 
MMRM 
Secondary 
Systolic BP change (mmHg) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
Diastolic BP change (mmHg) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
HbA1c change (%, mmol/mol) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Supportive secondary endpoints (safety related) 
Secondary 
Number of TEAEs 
Continuous 
- 
SAS 
- 
- 
Secondary 
Number of SAEs 
Continuous 
- 
SAS 
- 
- 
Secondary 
Pulse change (bpm) 
Continuous 
- 
SAS 
MMRM 
- 
Secondary 
Amylase change (U/L) 
Continuous 
- 
SAS 
Descriptive 
statistics 
- 
Secondary 
Lipase change (U/L) 
Continuous 
- 
SAS 
Descriptive 
statistics 
- 
Secondary 
Calcitonin change (ng/L) 
Continuous 
- 
SAS 
Descriptive 
statistics 
- 
FAS = full analysis set; ANCOVA = analysis of covariance; RD-MI = multiple imputation using retrieved subjects; 
MMRM = mixed model for repeated measurements; BMI = body mass index; HbA1c = Hemoglobin A1c; BP = blood 
pressure; TEAEs = treatment-emergent adverse events; SAEs = serious adverse events 
10.3.3 
Exploratory endpoints 
Exploratory endpoints are listed in Section 4. 
Analyses addressing the primary estimand 
The effect-related exploratory endpoints will be analysed using the same imputation approach as 
used for the primary endpoint and to address the primary estimand. The imputation model is the 
same as for the primary endpoint with BMI replaced by assessments of the endpoint to be analysed. 
The statistical model for continuous endpoints will be ANCOVA with factor and covariate as for 
the primary endpoint % change in BMI with baseline BMI replaced by the baseline assessment of 
the endpoint to be analysed. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
62
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
63 of 118 
 
The statistical model for responder endpoints relating to body weight and COAs will be logistic 
regression with randomised treatment as a factor and the baseline assessment of the endpoint to be 
analysed as covariate.  
For fasting insulin, lipids, as well as for HOMA-B and HOMA-IR, a multiplicative model will be 
used, i.e. the ratio between post randomisation measurements and baseline will be calculated instead 
of differences, and both the dependent variable and covariate will be log-transformed. 
Analyses addressing the secondary estimand 
The exploratory endpoints measured at week 68 which relate to the primary objective will be 
analysed to address the secondary estimand using the same MMRM for efficacy described for the 
primary endpoint. 
An overview of all analysis and imputation methods to address the effectiveness and efficacy 
estimands for effect-related exploratory endpoints is given in Table 10-5. 
Analysis of safety endpoints 
Observed data for exploratory safety endpoints and other safety assessments will be summarised by 
descriptive statistics. 
Hypoglycaemic episodes will be summarised by descriptive statistics, such as frequencies and rates. 
No formal statistical inference will be carried out based on the number of hypoglycaemic episodes.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
63
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
64 of 118 
 
Table 10-5 
Analysis and imputation methods to address the effectiveness and efficacy 
estimands for exploratory endpoints 
Objective 
Endpoint 
Endpoint type 
Estimand 
Analysis 
set 
Statistical 
model 
Imputation 
approach 
Exploratory endpoints (effect related) 
Primary 
BMI change (kg/m2) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FAS 
MMRM 
- 
Primary 
≥10% body weight responders 
Binary 
Primary 
FAS 
LR 
RD-MI 
Secondary 
FAS 
LR 
MMRM 
Primary 
BMI change to week 52 (%) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Primary 
BMI change to week 75 (%) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
FPG change (mg/dL) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
Fasting insulin change (mIU/L) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
Total cholesterol change 
(mg/dL) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
HDL change (mg/dL) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
LDL change (mg/dL) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
VLDL change (mg/dL) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
Triglycerides change (mg/dL) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
HOMA-B change (%) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
HOMA-IR change (score) 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
IWQoL-Kids PCD score  
Continuous 
Primary 
FAS 
 ANCOVA 
RD-MI 
Secondary 
IWQoL-Kids BED score 
change 
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
IWQoL-Kids SLD score 
change  
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
IWQoL-Kids FRD score 
change  
Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
Secondary 
IWQoL-Kids total score change  Continuous 
Primary 
FAS 
ANCOVA 
RD-MI 
FAS = full analysis set; ANCOVA = analysis of covariance; RD-MI = multiple imputation using retrieved subjects; 
MMRM = mixed model for repeated measurements; BMI = body mass index; FPG = fasting plasma glucose; HDL = 
high density lipoprotein; LDL = low density lipoprotein; VLDL = very low density lipoprotein; LR = logistic 
regression; IWQoL-Kids = Impact of Weight on Quality of Life-Kids for Clinical Trials; PCD = physical comfort 
domain; BED = body esteem domain; SLD = social life domain; FRD = family relations domain;  
10.3.4 
Other analyses 
All collected data that were not defined as endpoints will be summarised by descriptive statistics. 
10.4 
Pharmacokinetic and/or pharmacodynamic modelling 
The population PK analysis will be performed by Quantitative Clinical Pharmacology, Novo 
Nordisk A/S. A more technical and detailed elaboration of the population PK analysis will be done 
in the modelling analysis plan, which will be finalised before database lock. 
The population PK analysis will be reported in a separate modelling analysis report included as an 
appendix to the CTR. Selected results will be summarised in the CTR.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
64
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
65 of 118 
 
The objective of this modelling analysis is to study the semaglutide exposure in adolescents with 
obesity and to investigate the effects of pre-specified covariates on the semaglutide plasma 
concentration. Semaglutide concentrations based on sparse PK samples drawn at site visits will be 
included in the analysis together with dosing information, as well as relevant demographic data and 
other covariates. Data from pre-specified historical trials in relevant adult populations will be 
included in the analysis to allow for the comparison between populations. 
A previously developed population PK model for semaglutide will be used in an analysis of data 
from the current paediatric trial including data and results from pre-specified historical trials with 
relevant adult patient populations. The pre-specified analysis will explore the effects of covariates 
on semaglutide exposure. The covariates of interest, such as body weight, gender and age group 
(paediatric subjects/adults) will be tested on CL/F. 
Exposure-response analysis 
The PK and PD data will be included in exploratory analyses of PK and exposure-response 
relationships, which may also include data from other trials. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
65
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
66 of 118 
 
11 Appendices 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
66
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
67 of 118
Abbreviations and Trademarks
AD
available but discontinued
ADA
American Diabetes Association
AE
adverse event
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
AST
aspartate aminotransferase
AT
available on randomised treatment
BG
blood glucose
BMI
body mass index
BUN
blood urea nitrogen
Cmax
maximum concentration
CI
confidence interval
CLAE
clinical laboratory adverse event
CL/F
Apparent clearance                                                                                                             
COA
clinical outcome assessment
CRF
case report form
C-SSRS
Columbia Suicidality Severity Rating Scale
CTR
clinical trial report
CTX1
type 1 C-telopeptide
DFU
direction for use
DHEAS
dehydroepiandrosterone sulfate
DMC
Data Monitoring Committee
DRE
disease-related event
DUN
dispensing unit number
EAC
event adjudication committee
ECG
electrocardiogram
EMA
European Medicines Agency
FAS
full analysis set
FDA
U.S. Food and Drug Administration
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
67
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
68 of 118 
 
FDAAA 
FDA Amendments Act 
FPG 
fasting plasma glucose 
FSH 
follicle-stimulating hormone  
GCP 
Good Clinical Practice 
GGT 
gamma-glutamyltransferase 
GI 
gastrointestinal 
GLP-1 
glucagon-like peptide-1 
HbA1c 
glycated haemoglobin 
hCG 
human chorionic gonadotropin 
HDL 
high density lipoprotein 
HOMA-B 
homeostasis model assessment of beta-cell function 
HOMA-IR 
homeostasis model assessment of insulin resistance 
IB 
investigator’s brochure 
ICH 
International Council for Harmonisation 
IEC 
independent ethics committee 
IMP 
investigational medicinal product 
IRB 
institutional review board 
ISPAD 
International Society for Paediatric and Adolescent Diabetes 
IUD 
intrauterine device 
IUS 
intrauterine hormone-releasing system  
IWQOL-Kids 
Impact of Weight on Quality of Life-Kids 
IWRS 
interactive web response system 
J2R-MI 
jump to reference multiple imputation  
LAO-OT 
last available observation on-treatment 
LAR 
legally acceptable representative 
LDL 
low-density lipoprotein 
LH 
luteinising hormone 
LR 
logistic regression 
MD 
missing and discontinued  
MEN2 
multiple endocrine neoplasia type 2 
MHP 
mental health professional 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
68
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
69 of 118 
 
MMRM 
mixed model for repeated measurements 
MT 
missing on randomised treatment 
MTC 
medullary thyroid cancer 
MTD 
maximum tolerated dose 
NTX1 
type 1 collagen N-telopeptide 
OAD 
oral antidiabetic drug 
OR 
odds ratio 
OSA 
obstructive sleep apnoea 
P1NP 
procollagen 1 N-terminal propeptide 
PCD 
primary completion date 
PD 
pharmacodynamic 
PDCO 
European Paediatric Committee 
PG 
plasma glucose 
PHQ-9 
Patient Health Questionnaire 9 
PK 
pharmacokinetic 
PYE 
patient years of exposure 
PYO 
patient years of observation  
RA 
receptor agonist 
RD-MI 
multiple imputation using retrieved subjects 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SAS 
safety analysis set 
s.c. 
subcutaneous 
SD 
standard deviation 
SDS 
standard deviation score 
SMPG 
self-measured plasma glucose 
SUSAR 
suspected unexpected serious adverse reaction 
T2D 
type 2 diabetes 
T4 
thyroxine 
TEAE 
treatment-emergent adverse event 
TMM 
trial materials manual 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
69
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
70 of 118 
 
TP-MI 
tipping-point multiple imputation 
TSH 
thyroid stimulating hormone 
UNL 
upper normal limit 
UNR 
upper normal range 
VLDL 
very low-density lipoprotein 
WOCBP 
woman of child bearing potential 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
70
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
71 of 118
Clinical laboratory tests
•
Laboratory samples specified in the protocol should be sent to the central laboratory for analysis
•
The tests detailed in Table 11-1 and Table 11-2 will be performed by the central laboratory
•
The tests detailed in Table 11-3 will be performed by a special laboratory
•
Additional tests may be performed at any time during the trial as determined necessary by the 
investigator or required by local regulations. Only laboratory samples specified in the protocol 
should be sent to the central laboratory for analysis; if additional laboratory sampling is needed, 
e.g. to follow up on AEs, this must be done at a local laboratory
•
The central lab will communicate to the investigator abnormal values of parameters not 
requested in the protocol, but identified by the laboratory equipment and/or their processes 
according to their lab SOPs. These data will not be transferred to the trial database. The 
investigator should review such values for AEs and report these according to this protocol.
•
The investigator must review all laboratory results for concomitant illnesses and AEs
•
Laboratory samples will be destroyed no later than at finalisation of the CTR except antibody 
samples which will be stored until marketing authorisation or destroyed at the latest 15 years 
from end of trial
•
Human biosamples for future analysis will be stored as described in Appendix 7
•
For haematology samples (differential count) where the test result is not normal, a part of the 
sample may be kept for up to two years or according to local regulations 
Table 11-1
Protocol-required efficacy laboratory assessments
Laboratory assessments
Parameters
Glucose metabolism 
(V2, V8, V20, V30)
• FPG1 (also taken at V12 and V26 for subjects with T2D at screening or if 
diagnosed during the trial)
• HbA1c (to be taken at V1, not V2. Also taken at V12, V16 and V26 for subjects 
with T2D at screening or if diagnosed during the trial)
• Fasting serum insulin
• Homeostasis model assessment (HOMA-B and HOMA-IR)
Lipids
(V8,V20, V30)
• Total cholesterol
• High density lipoprotein (HDL) cholesterol
• Low density lipoprotein (LDL) cholesterol
• Very low density lipoprotein cholesterol (VLDL)
• Triglycerides
NOTES :
1A FPG result ≤3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be reported as a 
hypoglycaemic episode but as a clinical laboratory adverse event (CLAE) at the discretion of the investigator 
(Appendix 4).
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
71
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
72 of 118 
 
Table 11-2 
Protocol-required safety laboratory assessments 
Laboratory assessments 
Parameters 
Haematology 
(V1,V8,V20, V30) 
• Haemoglobin 
• Haematocrit 
• Thrombocytes 
• Erythrocytes 
• Leucocytes 
• Eosinophils 
• Neutrophils 
• Basophils 
• Lymphocytes 
• Monocytes 
Biochemistry1 
• Creatinine 
• Creatine kinase 
• Urea (BUN)  
• Albumin 
• Bilirubin (total) 
• Alanine aminotransferase (ALT)2 
• Aspartate aminotransferase (AST)2 
• Alkaline phosphatase (ALP) 
• Sodium 
• Potassium 
• Calcium total 
• Calcium (albumin corrected) 
• Gamma-glutamyltransferase (GGT) 
• Calcitonin 
• Amylase 
• Lipase 
(V1,V8,V20, V30) 
Hormones 
(V8,V20, V30) 
• Thyroid stimulating hormone (TSH) (also taken at V1) 
• Free thyroxine (free T4) (also taken at V1) 
• Dehydroepiandrosterone sulfate (DHEAS) 
• Luteinising hormone (LH) 
• Follicle stimulating hormone (FSH) 
• Estradiol (females) 
• Testosterone (males) 
• Prolactin 
Bone metabolism 
(V8, V30) 
• Type 1 collagen N-telopeptide (NTX1) 
• Type 1 C-telopeptide (CTX1) 
• Procollagen 1 N-terminal propeptide (P1NP) 
• Alkaline phosphatase (bone) 
Pregnancy Testing 
(V1, V2, V4, V6, V8, 
V10, V12, V14, V16, 
V18, V20, V22, V24, 
V26, V28, V30, V31) 
• Urine human chorionic gonadotropin (hCG) pregnancy test (as needed for WOCBP), 
see Appendix 5 for further information. 
Biomarkers  
• Carcinoembryonic Antigen serum 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
72
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
73 of 118 
 
(V8,V20, V30) 
• Serum Insulin-like growth factor 1 
Other tests 
• Tryptase in case of acute severe systemic hypersensitivity, see Section 9.4.9. 
• Biosamples for future analysis (V8, V30) 
Notes : 
1Details of required actions and follow-up assessments for increased liver parameters including any discontinuation 
criteria are given in Appendix 4 (Hy’s Law) and Section 8.1. 
2If ALT or AST >3 upper normal limit (UNL) additional relevant blood samples should be taken by local laboratory 
(except at screening visit). Repeat testing of the abnormal lab assessments should be performed for the subject until 
abnormalities return to normal or baseline state. 
 
Table 11-3 
Protocol-required special laboratory parameters 
Laboratory assessments 
Parameters 
Antibodies 
(V8, V12, V16, V20, V26, 
V30, V31) 
• Anti-semaglutide antibodies  
• Antibodies cross-reacting native GLP-1 
• Semaglutide AB (Neutralising effect) 
• Antibodies neutralising native GLP-1 
• Semaglutide anti bodies (Titer) 
Antibodies (unscheduled)1 
• Anti-semaglutide antibodies  
• Anti-semaglutide IgE antibodies  
PK (V12, V16, V20, V22, 
V26, V30, V31) 
• Semaglutide PK 
NOTES : 
1 Anti-semaglutide IgE antibodies and anti-semaglutide antibodies are analysed in case of suspicion of trial drug 
induced acute severe systemic hypersensitivity, see 9.4.9 and Appendix 4.   
 
Laboratory results that could unblind the trial (e.g. antibodies) will not be reported to the trial sites 
until the trial has been unblinded. 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
73
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
74 of 118
Trial governance considerations
1) Regulatory and ethical considerations
•
This trial will be conducted in accordance with the protocol and with the following:
•
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki55 and applicable International Council for Harmonisation (ICH) 
Good Clinical Practice (GCP) Guideline56
•
Applicable laws and regulations
•
The protocol, informed consent form, IB (as applicable) and other relevant documents (e.g. 
advertisements), must be submitted to an IRB/IEC and reviewed and approved by the IRB/IEC 
before the trial is initiated
•
Regulatory authorities will receive the clinical trial application, protocol amendments, reports 
on SAEs, and the CTR according to national requirements
•
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate safety 
hazard to trial subjects
•
Before a trial site is allowed to start screening subjects, written notification from Novo Nordisk 
must be received
•
The investigator will be responsible for:
•
providing written summaries of the status of the trial annually or more frequently in 
accordance with the requirements, policies, and procedures established by the IRB/IEC 
and/or regulatory authorities
•
notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures
•
providing oversight of the conduct of the trial at the site and adherence to requirements of  
ICH guidelines, the IRB/IEC, and all other applicable local regulations
•
ensuring submission of the CTR synopsis to the IRB/IEC
For country specific requirements, see Appendix 11.
2) Financial disclosure
Investigators and sub-investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest.
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
74
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
75 of 118 
 
3) Informed consent process 
• The investigator or his/her representative will explain the nature of the trial to the subject and 
the parent(s)/LAR and answer all questions regarding the trial 
• The investigator must give the subject and the parent(s)/LAR verbal and written information 
according to his/her capacity to understand, always taking into consideration the subject’s 
presumed willingness to participate in the trial  
• The investigator must ensure the subject and their parent(s)/LAR ample time to come to a 
decision whether or not to participate in the trial  
• Subjects and their parent(s)/LAR must be informed that their participation is voluntary 
• Subjects or their parent(s)/LAR will be required to sign and date a statement of informed 
consent that meets the requirements of local regulations, ICH guidelines56, Declaration of 
Helsinki55 and the IRB/IEC or trial site 
• The medical record must include a statement that written informed consent was obtained before 
any trial related activity and the date when the written consent was obtained. The authorised 
person obtaining the informed consent must also sign and date the informed consent form before 
any trial related activity 
• The responsibility of seeking informed consent and assent must remain with the investigator, 
but the investigator may delegate the task of informing to a medically qualified person, in 
accordance with local requirements 
• Subjects and/or their parent(s)/LAR must be re-consented to the most current version of the 
informed consent form(s) during their participation in the trial 
• A copy of the informed consent form(s) must be provided to the subject or the subject’s LAR 
• If the minor reaches legal age while participating in the trial and has only signed an age specific 
informed consent/assent form, the subject has to re-consent to the informed consent form signed 
by the subject’s LAR 
4) Information to subjects during trial 
The site will be offered a communication package for the subject and the parent(s)/LAR during the 
conduct of the trial. The package content is issued by Novo Nordisk. The communication package 
will contain written information intended for distribution to the subjects or the parent(s)/LAR. The 
written information will be translated and adjusted to local requirements and distributed to the 
subject and the parent(s)/LAR at the discretion of the investigator.  
The subject and the parent(s)/LAR may receive a “welcome to the trial letter” and a “thank you for 
your participation letter” after completion of the trial. Further the subject and the parent(s)/LAR 
may receive other written information during the trial.  
All written information to subjects and the parent(s)/LAR must be sent to IRB/IEC for 
approval/favourable opinion and to regulatory authorities for approval or notification according to 
local regulations. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
75
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
76 of 118 
 
Different initiatives for subject retention will be implemented throughout this trial. Site retention 
activities may include cooking classes, group meetings and others. Materials and items will be 
supplied if locally acceptable. The retention items will be relevant for the subjects’ participation in 
the trial and/or their obesity and will not exceed local fair market value. 
The initiatives for subject retention must be sent to IRB/IEC for approval/favourable opinion and to 
regulatory authorities for approval or notification according to local regulations. 
5) Data protection 
• Subjects will be assigned a 6-digit unique identifier, a subject number. Any subject records or 
datasets that are transferred to Novo Nordisk will contain the identifier only; subject names or 
any information which would make the subject identifiable will not be transferred 
• The subject and any biological material obtained from the subject will be identified by subject 
number, visit number and trial ID. Appropriate measures such as encryption or leaving out 
certain identifiers will be enforced to protect the identity of subjects as required by local, 
regional and national requirements  
• The subject and the parent(s)/LAR must be informed that his/her personal trial related data will 
be used by Novo Nordisk in accordance with local data protection law. The disclosure of the 
data must also be explained to the subject  
• The subject and the parent(s)/LAR must be informed that his/her medical records may be 
examined by auditors or other authorised personnel appointed by Novo Nordisk, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities 
For country specific requirements, refer to Appendix 11. 
6) Committee structure 
Novo Nordisk safety committee 
Novo Nordisk will constitute an internal semaglutide s.c. safety committee to perform ongoing 
safety surveillance. The semaglutide s.c. safety committee may recommend unblinding of any data 
for further analysis, and in this case an independent ad hoc group will be established in order to 
maintain the blinding of the trial personnel. 
Data monitoring committee 
The DMC is an independent, external committee composed of members whose expertise covers 
relevant specialties including statistics. The DMC is established to review and evaluate accumulated 
data from the trial at predefined time points as well as ad hoc. This is done in order to protect the 
safety of the subjects and to evaluate the benefit-risk balance. The DMC will have access to 
unblinded data, and will provide recommendations on trial continuation, modification or 
termination. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
76
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
77 of 118 
 
Information regarding responsibilities, procedures and workflow to be used by the DMC are 
specified in the DMC charter. 
7) Publication policy 
The information obtained during the conduct of this trial is considered confidential, and may be 
used by or on behalf of Novo Nordisk for regulatory purposes as well as for the general 
development of the trial product. All information supplied by Novo Nordisk in connection with this 
trial shall remain the sole property of Novo Nordisk and is to be considered confidential 
information. 
No confidential information shall be disclosed to others without prior written consent from Novo 
Nordisk. Such information shall not be used except in the performance of this trial. 
The information obtained during this trial may be made available to other investigators who are 
conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial. 
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial. 
One (or two) investigator(s) will be appointed by Novo Nordisk to review and sign the CTR 
(signatory investigator) on behalf of all participating investigators. The signatory investigator(s) 
will be appointed based upon the criteria defined by the International Committee of Medical Journal 
Editors for research publications57. 
Communication of results 
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publication of a manuscript in a peer-reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by other means.  
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the CTR is available. This includes the 
right not to release the results of interim analyses, because the release of such information may 
influence the results of the entire trial. 
At the end of the trial, one or more scientific publications may be prepared collaboratively by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 days to protect intellectual property. 
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
77
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
78 of 118 
 
content of any publication, both the investigators’ and Novo Nordisk opinions will be fairly and 
sufficiently represented in the publication. 
Authorship 
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in one 
or more publications. 
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by the International 
Committee of Medical Journal Editors57. 
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication.  
Where required by the journal, the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by the journal.  
Site-specific publication(s) by investigator(s) 
For a multicentre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by Novo Nordisk. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscript of the trial. 
Investigator access to data and review of results 
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. 
Individual investigators will have their own research subjects' data, and will be provided with the 
randomisation code after results are available. 
8) Dissemination of clinical trial data 
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. It will also 
be disclosed according to other applicable requirements such as those of the International 
Committee of Medical Journal Editors (ICMJE)58, the Food and Drug Administration Amendment 
Act (FDAAA)59, European Commission Requirements60-62 and other relevant recommendations or 
regulations. If a subject requests to be included in the trial via the Novo Nordisk e-mail contact at 
these web sites, Novo Nordisk may disclose the investigator’s contact details to the subject. As a 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
78
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
79 of 118 
 
The Primary Completion Date (PCD) is the last assessment of the primary endpoint, and is for this 
trial Last Subject First Treatment (LSFT) + 68 weeks corresponding to ‘end of treatment’ visit 
(V30). If the last subject is withdrawn early, the PCD is considered the date when the last subject 
would have completed ‘end of treatment’ visit (V30). The PCD determines the deadline for results 
disclosure at clinicaltrials.gov according to FDAAA. 
9) Data quality assurance 
Case Report Forms (CRFs) 
• Novo Nordisk or designee is responsible for the data management of this trial including quality 
checking of the data 
• All subject data relating to the trial will be recorded on electronic CRFs unless transmitted 
electronically to Novo Nordisk or designee (e.g. laboratory data). The investigator is responsible 
for verifying that data entries are accurate and correct by physically or electronically signing the 
CRF  
• The following will be provided as paper CRFs to be used when access to the electronic CRF is 
revoked or the electronic CRF is temporarily unavailable: 
• 
AE forms  
• 
Safety information forms  
• 
Technical complaint forms (also to be used to report complaints that are not subject related, 
e.g. discovered at trial site before allocation) 
• Corrections to the CRF data may be made by the investigator or the investigator’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the old 
and the new data, identification of the person entering the data, date and time of the entry and 
reason for the correction. If corrections are made by the investigator’s delegated staff after the 
date when the investigator signed the CRF, the CRF must be signed and dated again by the 
investigator 
• The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to Novo 
Nordisk for data verification and validation purposes  
Monitoring 
• The investigator must permit trial-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents (original documents, 
data and records). Direct access includes permission to examine, analyse, verify and reproduce 
any record(s) and report(s) that are important to the evaluation of the trial. If the electronic 
medical record does not have a visible audit trail, the investigator must provide the monitor with 
signed and dated printouts. In addition the relevant trial site staff should be available for 
discussions at monitoring visits and between monitoring visits (e.g. by telephone)  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
79
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
80 of 118 
 
• Trial monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by authorised site personnel are accurate, complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is being 
conducted in accordance with the currently approved protocol and any other trial agreements, 
ICH GCP, and all applicable regulatory requirements 
• Monitoring will be conducted using a risk based approach including risk assessment, monitoring 
plans, centralised monitoring (remote assessment of data by Novo Nordisk) and visits to trial 
sites  
• Monitors will review the subject’s medical records and other source data e.g. the diaries and 
PROs, to ensure consistency and/or identify omissions compared to the CRF  
Protocol compliance 
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor and the implications of the deviation must be reviewed and discussed. 
Deviations must be documented and explained in a protocol deviation by stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the CRF or via listings from the trial database.  
10) Source documents 
• All data entered in the CRF must be verifiable in source documentation other than the CRF 
• The original of the completed diaries must not be removed from the trial site, unless they form 
part of the CRF and a copy is kept at the site 
• Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the trial site 
• Data reported on the paper CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer records. 
Also, current medical records must be available  
• It must be possible to verify subject’s medical history in source documents such as subject’s 
medical record 
• The investigator must document any attempt to obtain external medical information by noting 
the date(s) when information was requested and who was contacted 
• Definition of what constitutes source data can be found in a source document agreement at each 
trial site. There will only be one source document defined at any time for any data element 
11) Retention of clinical trial documentation 
• Records and documents, including signed informed consent forms, pertaining to the conduct of 
this trial must be retained by the investigator for 15 years after end of trial unless local 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
80
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
81 of 118 
 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No records 
may be transferred to another location or party without written notification to Novo Nordisk  
• The investigator must be able to access his/her trial documents without involving Novo Nordisk 
in any way. If applicable, electronic CRF and other subject data will be provided in an 
electronic readable format to the investigator before access is revoked to the systems and/or 
electronic devices supplied by Novo Nordisk. Site-specific CRFs and other subject data (in an 
electronic readable format or as paper copies or prints) must be retained by the trial site. If the 
provided electronic data (e.g. the CD-ROM) is not readable during the entire storage period, the 
investigator can request a new copy. A copy of all data will be stored by Novo Nordisk 
• Subject’s medical records must be kept for the maximum period permitted by the hospital, 
institution or private practice 
12) Trial and site closure 
Novo Nordisk reserves the right to close the trial site or terminate the trial at any time for any 
reason at the sole discretion of Novo Nordisk. If the trial is suspended or terminated, the 
investigator must inform the subjects promptly and ensure appropriate therapy and follow-up. The 
investigator and/or Novo Nordisk must also promptly inform the regulatory authorities and 
IRBs/IECs and provide a detailed written explanation. 
Trial sites will be closed upon trial completion. A trial site is considered closed when all required 
documents and trial supplies have been collected and a trial site closure visit has been performed. 
The investigator may initiate trial site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a trial site by Novo Nordisk or investigator may include but are not 
limited to: 
• failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines 
• inadequate recruitment of subjects by the investigator 
• discontinuation of further trial product development 
13) Responsibilities 
The investigator is accountable for the conduct of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well-being of the subjects.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
81
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
82 of 118 
 
A qualified physician, who is an investigator or a subinvestigator for the trial, must be responsible 
for all trial-related medical decisions.  
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data.  
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken. 
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time. 
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires) a 
new investigator will be appointed in consultation with Novo Nordisk.  
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s). 
14) Indemnity statement  
Novo Nordisk carries product liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.  
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by persons for whom the said site or investigator are 
responsible.  
Novo Nordisk may pay additional costs incurred in relation to assessments relevant for following 
the safety of the subject. Investigator must contact Novo Nordisk on a case by case basis for 
whether the costs will be covered. 
Novo Nordisk accepts liability in accordance with: Please refer to Appendix 11. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
82
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
83 of 118
Adverse events: definitions and procedures for 
recording, evaluation, follow-up and reporting
AE definition
• An AE is any untoward medical occurrence in a clinical trial subject that is temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product.
• An AE can be any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or 
disease (new or exacerbated) temporally associated with the use of a medicinal product.
Events meeting the AE definition
• Any abnormal laboratory test results or safety assessments, including those that worsen from baseline, considered 
clinically significant in the medical and scientific judgment of the investigator.
• A CLAE: a clinical abnormal laboratory finding which is clinically significant, i.e. an abnormality that suggests a 
disease and/or organ toxicity and is of a severity that requires active management. Active management includes 
active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to 
the abnormality.
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or 
intensity of the condition.
• Signs, symptoms or the clinical sequelae of a suspected drug-drug interaction.
• Signs, symptoms or the clinical sequelae of a suspected overdose of trial product regardless of intent.
• A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. 
Such instances will be captured in the efficacy assessments. However, the signs, symptoms and/or clinical 
sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition.
Events NOT meeting the AE definition 
• Pre-existing conditions, anticipated day-to-day fluctuations of pre-existing conditions, including those identified 
during screening or other trial procedures performed before exposure to trial product. 
Note: pre-existing conditions should be recorded as Medical history/Concomitant illness.
• Pre-planned procedures, unless the condition for which the procedure was planned has worsened from the first 
trial related activity after the subject has signed the informed consent.
Definition of an SAE
An SAE is an AE that fulfils at least one of the following criteria:
• Results in death
• Is life-threatening
The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death 
at the time of the event. It does not refer to an event which hypothetically might have caused death, if it were more 
severe.
• Requires inpatient hospitalisation or prolongation of existing hospitalisation
• Hospitalisation signifies that the subject has been detained at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. 
Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils 
any other serious criteria, the event is serious. When in doubt as to whether “hospitalisation” occurred or was 
necessary, the AE should be considered serious.
• Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not 
considered an AE.
Note:
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
83
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
84 of 118 
 
▪ Hospitalisations for administrative, trial related and social purposes do not constitute AEs and should 
therefore not be reported as AEs or SAEs.  
▪ Hospital admissions for surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.  
• Results in persistent disability/incapacity 
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions. 
• This definition is not intended to include experience of relatively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g. sprained ankle), 
which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
• Is a congenital anomaly/birth defect 
• Important medical event: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other 
situations. This includes important medical events that may not be immediately life-threatening or result in 
death or hospitalisation, but may jeopardise the subject or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events should usually be considered 
serious and reported as SAEs using the important medical event criterion. 
• The following AEs must always be reported as SAEs using the important medical event criterion, if no other 
seriousness criteria are applicable: 
▪ suspicion of transmission of infectious agents via the trial product.  
▪ risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where no alternative 
aetiology exists (Hy's law). 
 
Description of AEs requiring additional data collection (via specific event form) .  
AEs requiring additional data collection are AEs where the additional data will benefit the evaluation of the safety of 
the trial product (see Table 9-1). The selection of these events is based on the non-clinical and clinical data with 
semaglutide, knowledge from the GLP-1 RA drug class as well as regulatory requirements.  
Event type 
Description 
Acute gallbladder disease 
Events of symptomatic acute gallbladder disease (including 
gallstones and cholecystitis) 
Acute pancreatitis 
The diagnosis of acute pancreatitis requires two of the following 
three features: 
1. abdominal pain consistent with acute pancreatitis (acute 
onset of a persistent, severe, epigastric pain often 
radiating to the back) 
2. serum lipase activity (and/or amylase activity) at least 
three times greater than the upper limit of normal 
3. characteristic findings of acute pancreatitis on imaging 
Malignant neoplasm 
Malignant neoplasm by histopathology or other substantial 
clinical evidence 
Hepatic event 
Hepatic event defined as: 
- 
Disorders of the liver including cholestatic conditions 
and liver related signs and symptoms 
- 
ALT or AST > 3x UNL and total bilirubin > 2x UNL* 
- 
ALT or AST > 3x UNL with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
84
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
85 of 118 
 
*Please note that in case of a hepatic event defined as ALT or 
AST > 3x UNL and total bilirubin > 2x UNL, where no 
alternative aetiology exists (Hy's law), this must be reported as 
an SAE using the important medical event criterion if no other 
seriousness criteria are applicable. 
Medication error 
A medication error is an unintended failure in the trial drug 
treatment process that leads to, or has the potential to lead to, 
harm to the subject, such as: 
• 
Administration of wrong drug.  
• 
Note: Use of wrong dispensing unit number (DUN) is 
not considered a medication error unless it results in 
administration of wrong drug.  
• 
Wrong route of administration, such as intramuscular instead 
of subcutaneous.  
• 
Accidental administration of more than 2.4 mg/week or a 
higher dose than intended during dose escalation, however, 
the administered dose must deviate from the intended dose 
to an extent where clinical consequences for the trial subject 
were likely to happen as judged by the investigator, although 
they did not necessarily occur. 
Misuse 
 
Misuse is when the trial product is intentionally and 
inappropriately used not in accordance with the protocol.  
Abuse 
Abuse of trial product is persistent or sporadic, intentional 
excessive use, which is accompanied by harmful physical or 
psychological effects (e.g. overdose with the intention to cause 
harm) 
Diabetic retinopathy (T2D only) 
New onset or worsening of diabetic retinopathy 
 
AE and SAE recording 
• The investigator will record all relevant AE/SAE information in the CRF. 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical 
information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE. 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital 
progress notes, laboratory and diagnostics reports) related to the event. 
• There may be instances when copies of source documents (e.g. medical records) for certain cases are requested by 
Novo Nordisk. In such cases, all subject identifiers, with the exception of the subject number, will be redacted on 
the copies of the source documents before submission to Novo Nordisk. 
• For all non-serious AEs the applicable forms should be signed when the event is resolved or at the end of the trial 
at the latest. For sign-off of SAE related forms refer to “SAE reporting via paper CRF” later in this section. 
• Novo Nordisk products used as concomitant medication: If an AE is considered to have a causal relationship with 
a Novo Nordisk marketed product used as concomitant medication in the trial, it is important that the suspected 
relationship is reported to Novo Nordisk, e.g. in the alternative aetiology section on the safety information form. 
Novo Nordisk may need to report this adverse event to relevant regulatory authorities. 
 
Assessment of severity 
The investigator will assess intensity for each event reported during the trial and assign it to one of the following 
categories:  
• Mild: An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with 
everyday activities. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
85
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
86 of 118 
 
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities. 
• Severe: An event that prevents normal everyday activities.  
Note: Severe is a category used for rating the intensity of an event; and both an AE and SAE can be assessed as 
severe. An event is defined as ‘serious’ when it meets at least one of the outcomes described in the definition of an 
SAE and not when it is rated as severe. 
 
Assessment of causality 
The investigator is obligated to assess the relationship between trial product and the occurrence of each AE/SAE. 
Relationship between an AE/SAE and the relevant trial product should be assessed as:  
• Probable - Good reason and sufficient documentation to assume a causal relationship. 
• Possible - A causal relationship is conceivable and cannot be dismissed. 
• Unlikely - The event is most likely related to aetiology other than the trial product. 
Alternative aetiology, such as underlying disease(s), concomitant medication, and other risk factors, as well as the 
temporal relationship of the event to trial product administration will be considered and investigated. 
The investigator should use the IB for the assessment. For each AE/SAE, the investigator must document in the 
medical records that he/she has reviewed the AE/SAE and has provided an assessment of causality. 
There may be situations in which an SAE has occurred and the investigator has minimal information to include in the 
initial report. However, it is important that the investigator always makes an assessment of causality for every 
event before the initial transmission of the SAE data. 
The investigator may change his/her opinion of causality in light of follow-up information and send a follow-up 
report with the updated causality assessment. 
The causality assessment is one of the criteria used when determining regulatory reporting requirements. 
 
Final outcome 
The investigator will select the most appropriate outcome: 
• Recovered/resolved: The subject has fully recovered, or by medical or surgical treatment the condition has 
returned to the level observed at the first trial-related activity after the subject signed the informed consent. 
• Recovering/resolving: The condition is improving and the subject is expected to recover from the event. This 
term is only applicable if the subject has completed the trial or has died from another AE. 
• Recovered/resolved with sequelae: The subject has recovered from the condition, but with lasting effect due to a 
disease, injury, treatment or procedure. If the sequelae meet an SAE criterion, the AE must be reported as an SAE. 
• Not recovered/not resolved: The condition of the subject has not improved and the symptoms are unchanged or 
the outcome is not known. 
• Fatal: This term is only applicable if the subject died from a condition related to the reported AE. Outcomes of 
other reported AEs in a subject before he/she died should be assessed as “recovered/resolved”, 
“recovering/resolving”, “recovered/resolved with sequelae” or “not recovered/not resolved”. An AE with a fatal 
outcome must be reported as an SAE. 
• Unknown: This term is only applicable if the subject is lost to follow-up. 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
86
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
87 of 118 
 
Follow-up of AE and SAE 
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations 
as medically indicated or as requested by Novo Nordisk to elucidate the nature and/or causality of the AE or SAE as 
fully as possible (e.g. severe hypersensitivity reactions). This may include additional laboratory tests (e.g. skin prick 
test) or investigations, histopathological examinations, or consultation with other health care professionals. 
If a subject dies during participation in the trial or during a recognised follow-up period, the investigator should 
provide Novo Nordisk with a copy of autopsy report including histopathology. 
New or updated information will be recorded in the CRF. 
 
SAE reporting via electronic CRF 
• Relevant forms (AE form, safety information form and specific event form) must be completed in the CRF.  
• For reporting and sign-off timelines, see box below.  
• If the CRF is unavailable for more than 24 hours, then the site will use the paper AE form and if the CRF is 
unavailable for more than 5 calendar days then the site will use the paper safety information form (see box below). 
• The site will enter the SAE data into the CRF as soon as it becomes available, see Section 9.2.1. 
• After the trial is completed at a given site, the CRF will be decommissioned to prevent the entry of new data or 
changes to existing data. If a site receives a report of a new SAE from a subject or receives updated data on a 
previously reported SAE after CRF decommission, then the site can report this information on a paper AE and 
safety information form (see box below) or to Novo Nordisk by telephone. 
 
SAE reporting via paper CRF 
• Relevant CRF forms (AE and safety information form) must be forwarded to Novo Nordisk either by fax, e-mail 
or courier. 
• Initial notification via telephone is acceptable, although it does not replace the need for the investigator to 
complete the AE and safety information form within the designated reporting time frames (as illustrated in 
Figure 9-1): 
• AE form within 24 hours. 
• Safety information form within 5 calendar days.  
• Both forms must be signed within 7 calendar days. 
Contact details for SAE reporting can be found in the investigator trial master file. 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
87
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
88 of 118
Contraceptive guidance and collection of pregnancy 
information
It must be recorded in the CRF whether female subjects are of childbearing potential (have had first 
menstrual period). 
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. 
The childbearing potential of female subjects must be evaluated at every visit until the female 
subject becomes of childbearing potential. 
Contraception guidance
Male subjects 
No contraception measures are required for male subjects as the risk of teratogenicity/fetotoxicity 
caused by transfer of semaglutide in seminal fluid is unlikely.
Female subjects
Female subjects of childbearing potential are eligible to participate if they agree to use methods of 
contraception consistently and correctly as described in Table 11-4 below:
Table 11-4
Highly effective contraceptive methods (failure rate of <1% per year when used 
consistently and correctly)
Highly effective contraceptive methods that are user dependent a and b
Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation b
• oral 
• intravaginal 
• transdermal 
Progestogen only hormonal contraception associated with inhibition of ovulation
• oral 
• injectable 
Highly effective methods that are user independent b
• Implantable progestogen only hormonal contraception associated with inhibition of ovulation
• Intrauterine Device (IUD)
• Intrauterine hormone-releasing System (IUS)
• Bilateral tubal occlusion
Vasectomised partner
A vasectomised partner is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used.
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
88
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
89 of 118 
 
Sexual abstinenceb  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the trial product. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject.  
Notes: 
a Failure rates may differ from <1% per year, if not used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects participating in clinical trials.  
b Contraception should be utilised during the treatment period and for at least 49 days after the last dose of trial 
product. 
 
In certain cases, it is accepted to use double barrier methods (a condom combined with an occlusive 
cap (e.g. diaphragm) with/without the use of spermicide). This should only be allowed in females 
with: 
1. known intolerance to the highly effective methods mentioned in Table 11-4 or where the use 
of any of the listed highly effective contraceptive measures are contraindicated in the 
individual subject, and/or  
2. if the risk of initiating treatment with a specific highly effective method outweighs the 
benefit for the female 
Justification for accepting double barrier method should be at the discretion of the investigator 
taking into consideration his/hers knowledge about the female’s obesity history, concomitant 
illness, concomitant medication and observed AEs. The justification must be stated in the medical 
records. 
For country specific requirements, see Appendix 11.  
Pregnancy testing 
• WOCBP must only be included after a negative highly sensitive urine pregnancy test at 
screening (V1) and randomisation (V8) 
• Urine pregnancy testing must be performed according to Appendix 2. 
• If a girl becomes of childbearing potential (has first menstrual period) during the trial a urine 
pregnancy test must be performed as soon as possible or at the latest at the next site visit 
• Pregnancy testing must be performed whenever a menstrual period is missed or when pregnancy 
is otherwise suspected 
• Additional urine pregnancy testing must be performed at monthly intervals during the treatment 
period, if required locally (Appendix 11). Highly sensitive serum testing (sensitivity of 5-25 
mIU/mL) is mandatory if required by local regulations or ethics committees, or to resolve an 
indeterminate test or to confirm a positive urine test 
For country specific requirements, see Appendix 11. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
89
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
90 of 118 
 
Collection of pregnancy information  
Female subjects who become pregnant  
• Investigator will collect pregnancy information on any female subject, who becomes pregnant 
while participating in this trial 
• Information will be recorded on the appropriate form and submitted to Novo Nordisk within 14 
calendar days of learning of a subject's pregnancy 
• Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow-up information on subject and neonate, which will be forwarded to Novo 
Nordisk. Generally, follow-up will not be required for longer than 1 month beyond the delivery 
date 
• Any termination of pregnancy will be reported, regardless of foetal status (presence or absence 
of anomalies) or indication for procedure 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE  
• A spontaneous abortion is always considered to be an SAE and will be reported as such 
• Any SAE occurring as a result of a post-trial pregnancy which is considered possibly/probably 
related to the trial product by the investigator will be reported to Novo Nordisk as described in 
Appendix 4. While the investigator is not obligated to actively seek this information in former 
subjects, he or she may learn of an SAE through spontaneous reporting  
Any female subject who becomes pregnant while participating in the trial will discontinue trial 
product.  
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
90
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
91 of 118
Technical complaints: Definition and procedures for 
recording, evaluation, follow-up and reporting
Technical complaint definition
• A technical complaint is any written, electronic or oral communication that alleges product (medicine or device) 
defects. The technical complaint may be associated with an AE, but does not concern the AE itself.
Examples of technical complaints:
•
Problems with the physical or chemical appearance of trial products (e.g. discoloration, particles 
or contamination)
•
Problems with packaging material including labelling
•
Problems related to medical devices (e.g. to the injection mechanism, dose setting mechanism, 
push button or interface between the pen-injector and the needle)
Time period for detecting technical complaints 
All technical complaints, which occur from the time of receipt of the product at trial site until the time of the last 
usage of the product, must be collected for products predefined on the technical complaint form. 
Reporting of technical complaints to Novo Nordisk
Contact details (fax, e-mail and address) for Customer Complaint Center – refer to Attachment I
Technical complaints must be reported on a separate technical complaint form:
1.
One technical complaint form must be completed for each affected DUN
2.
If DUN is not available, a technical complaint form for each batch, code or lot number must be completed
Timelines for reporting of technical complaints to Novo Nordisk
The investigator must complete the technical complaint form in the CRF within the timelines specified in 
Figure 9-3.
If the CRF is unavailable or when reporting a technical complaint that is not subject related, the information must be 
provided on a paper form by fax, e-mail or courier to Customer Complaint Center, Novo Nordisk, within the same 
timelines as stated above. When the CRF becomes available again, the investigator must enter the information on the 
technical complaint form in the CRF.
Follow-up of technical complaints 
The investigator is responsible for ensuring that new or updated information will be recorded on the originally 
completed form.
Collection, storage and shipment of technical complaint samples
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
91
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
92 of 118 
 
The investigator must collect the technical complaint sample and all associated parts that were packed in the same 
DUN and notify the monitor within 5 calendar days of obtaining the sample at trial site. The sample and all 
associated parts must be sent as soon as possible to Customer Complaint Center, Novo Nordisk, together with a copy 
of the completed technical complaint form. The technical complaint sample should contain the batch, code or lot 
number and, if available, the DUN. If the technical complaint sample is unobtainable, the reason must be stated on 
the technical complaint form. If several samples are shipped in one shipment, the sample and the corresponding 
technical complaint form should be kept together. 
Storage of the technical complaint sample must be done in accordance with the conditions prescribed for the product. 
 
Reporting of technical complaints for Novo Nordisk products not included in technical complaint form 
Technical complaints on Novo Nordisk products not included in the technical complaint form should be reported to 
local Novo Nordisk affiliate with a reference to trial ID. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
92
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
93 of 118
Retention of human biosamples
Antibody samples
•
Antibody samples will be retained for potential later analysis for further characterisation of 
antibody responses towards drug, if required by health authorities or for safety reasons
•
Only Novo Nordisk staff and personnel from the specialised laboratory will have access to the 
stored specimens 
•
The samples will be stored at the specialised laboratory or Novo Nordisk after end of trial and 
until marketing authorisation approval or until the research project terminates, but no longer 
than 15 years from end of trial after which they will be destroyed 
•
Samples might be transferred to other countries, if not prohibited by local regulations 
•
The subject’s identity will remain confidential and the samples will be identified only by subject 
number, visit number and trial identification number. No direct identification of the subject will 
be stored together with the samples. The analyses will not have any medical consequences for 
the subjects or their relatives 
•
Subjects and the parent(s)/LAR can contact the investigator if they wish to be informed about 
results derived from stored biosamples obtained from their own body
Biosamples for future analysis
•
In countries where applicable, the trial will involve collection of human biosamples to be stored 
in a central archive for future use
•
The parent(s)/LAR, and if required by local legislation also the subject, must sign and date a 
separate informed consent form before biosamples are collected to be stored for future analysis
•
The material to be collected at randomisation (V8) and ‘end of treatment’(V30) is:
•
Whole blood (for genetic analysis)
•
Serum (for analysis of circulating biomarkers)
•
As new biomarkers related to the disease and/or safety, efficacy or mechanism of action of 
semaglutide may evolve during the conduct of the trial, the analyses of the stored biosamples 
may also include biomarkers that are unknown at present or have not been included in the 
scientific hypotheses at initiation of the trial
•
The biosamples will be stored at a central laboratory for 6 months and at a central storage 
facility contracted by Novo Nordisk for up to 15 years after end of trial. Only Novo Nordisk and 
storage facility employees will be able to access the stored biosamples. The biosamples may be 
transferred to other countries for analysis and will be destroyed at the latest 15 years after end of 
trial
The subject or the parent(s)/LAR may request the stored biosamples to be destroyed by 
withdrawing the designated informed consent. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
93
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
94 of 118 
 
In case the subject or the parent(s)/LAR withdraws his/her informed consent for biosamples for 
future analysis and genetics, the monitor must contact the trial manager at Novo Nordisk as soon as 
possible in order to have the samples withdrawn from storage. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
94
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
95 of 118
Flowchart and assessments for subjects with T2D 
Assessments relevant for subjects with T2D at screening or if diagnosed during the trial are 
described in this appendix. For these subjects, the flowchart in this appendix replaces the one in 
Section 2. 
Medical history of the subjects with T2D must include diabetes history and complications. If the 
subject is diagnosed with T2D during the trial this must be recorded as an AE. 
If the subject is on metformin the dose must be recorded in concomitant medication form. 
Furthermore, evaluation of oral anti diabetes medication must be done according to the flowchart. 
The evaluation should be based on whether an overall change from randomisation until the time of 
the evaluation has occurred (i.e., either increase, decrease or no change) after reviewing all 
available relevant information e.g., changes in drug dose, drug class, number of drugs or a 
combination of these.
A diary on SMPG measurements and hypoglycaemic episodes will be handed out at randomisation 
(V8) or when diagnosed with T2D.
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
95
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
      
Date: 
06 January 2021 
Status: 
Final 
Novo Nordisk 
Trial ID: NN9536-4451 
      
Version: 
2.0 
Page: 
96 of 118 
 
 
Flowchart for subjects with T2D at screening or if diagnosed during the trial. 
 
Screening 
Run-in 
Randomisation 
Dose escalation 
Maintenance 
End of 
treatment 
End of trial 
Visita 
V1 
V2 P3 V4 P5 V6 P7 V8 
P9 V10 P11 V12 P13 V14 P15 V16 P17 V18 P19 V20 P21 V22 P23 V24 P25 V26 P27 V28 P29 V30 V31 
Timing of Visit (Weeks) 
-14 -12 -10 -8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
24 
28 
32 
36 
40 
44 
48 
52 
56 
60 
64 
68 
75 
Visit Window (Days) 
-7/0 ±3 ±7 ±3 ±7 ±3 ±7 
±0 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
0/7 
Attend visit fasting (6.5.1) 
  
X 
  
  
  
  
  
X 
  
  
  
X 
  
  
  
  
  
  
  
X 
  
  
  
  
  
X 
 
 
 
X 
X 
Informed consent, Informed assent  
and Demographyb (Appendix 3) 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
  
Inclusion and exclusion criteria (6.1, 6.2) 
X 
X 
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
  
Run-in criteria (6.3) 
 
 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomisation criteria and randomisation (6.4) 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history/ Concomitant illness and  
Tobacco Usec (6.5.2, 9.4, Appendix 8) 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
  
  
Eye examination (Appendix 8) 
Xl 
 
 
 
 
 
 
Xm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Concomitant medication (7.7) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Evaluation Oral Anti Diabetes Medication  
(Appendix 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
 
Childbearing potentiald, Menstrual cyclee  and  
Pregnancy testf (9.2.6, 9.4.7, 9.10.2, Appendix 5) 
X 
X 
  
X 
  
X 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pubertal Status (9.4.3) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
ECG (9.4.6) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
 
 
 
 
X 
  
Vital Signs (9.4.4) 
X 
  
  
  
  
  
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
X 
Laboratory assessments (Appendix 2) 
X 
X 
 
 
 
 
 
Xg 
 
 
 
Xh 
  
  
  
Xh 
  
 
  
Xh 
  
Xh  
  
  
  
Xh 
 
 
 
Xh 
X 
Biosamples for future analysisi (9.7, 9.9) 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
X 
  
Clinical Outcome Assessments (9.1.2, 9.4.1) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Physical examination (9.4.2) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Height (9.1.1) 
X 
  
  
  
  
  
  
X 
  
  
  
  
  
X 
  
  
  
  
  
X 
  
  
  
X 
  
X 
 
 
 
X 
X 
VV-TMF-4175483|1.0|NN9536 -4451
  Protocol  V 2.0|96 of 118
VV-CLIN-134191
1.0
.


Protocol 
      
Date: 
06 January 2021 
Status: 
Final 
Novo Nordisk 
Trial ID: NN9536-4451 
      
Version: 
2.0 
Page: 
97 of 118 
 
Screening 
Run-in 
Randomisation 
Dose escalation 
Maintenance 
End of 
treatment 
End of trial 
Visita 
V1 
V2 P3 V4 P5 V6 P7 V8 
P9 V10 P11 V12 P13 V14 P15 V16 P17 V18 P19 V20 P21 V22 P23 V24 P25 V26 P27 V28 P29 V30 V31 
Timing of Visit (Weeks) 
-14 -12 -10 -8 
-6 
-4 
-2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
24 
28 
32 
36 
40 
44 
48 
52 
56 
60 
64 
68 
75 
Visit Window (Days) 
-7/0 ±3 ±7 ±3 ±7 ±3 ±7 
±0 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
0/7 
Body Weight (9.1.1) 
X 
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
X 
Waist Circumference (9.1.1) 
 X 
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
 
 
 
 
X 
  
Bone age measurement (x-ray) (9.4.5) 
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
X 
  
Adverse event (9.2, Appendix 4, Appendix 6) 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Diet and physical activity counsellingj  
(7.1.2, 7.1.3) 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hand out and instruct in diary 9, Appendix 8) 
Xk  
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Collect, review and transcribe diary  
(9.10, 9.10.1, 9.10.2, 9.10.3) 
  
  
  
  
  
  
  
Xk 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
X 
Connect to IWRS (7.3)      
X 
  
  
  
  
  
  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Training in trial product, pen-handling (7.1.1) 
  
  
  
  
  
  
  
X 
  
 
  
X 
  
 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
  
  
Drug handling (7.1, 7.3, 7.5) 
 
 
 
 
 
 
 
X 
  
  
  
X 
  
  
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
 
X 
 
X 
 
Trial product compliance (7.1, 7.6) 
  
  
  
  
  
  
  
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
Self-measured plasma glucose (SMPG)  
(Appendix 8) 
 
 
 
 
 
 
 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
Hand out and instruct in BG-meter  
(Appendix 8) 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypoglycaemic episodes (Appendix 8) 
 
 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
a) Visits marked as phone visits can be replaced by site visits or video calls to ensure flexibility for the subjects  
b) Demography consists of date of birth, sex, ethnicity, and race (according to local regulation) 
c) Smoking is defined as smoking at least one daily cigarette or equivalent (e.g. cigar, hookah or e-cigarette) 
d) Only for females 
e) Only for females that have started their menstrual period (of childbearing potential) 
f) Only for females that have started their menstrual period (of childbearing potential): Urine pregnancy test should also be performed at any time during the trial if 
pregnancy is suspected, if a menstrual period is missed, and/or according to local regulations/law. If a female becomes of childbearing potential (has first menstrual 
period) during the trial a urine pregnancy test must be performed for that subject at the latest at the next site visit. For country specific requirements, see Appendix 11. 
VV-TMF-4175483|1.0|NN9536 -4451
  Protocol  V 2.0|97 of 118
VV-CLIN-134191
1.0
.


Protocol 
      
Date: 
06 January 2021 
Status: 
Final 
Novo Nordisk 
Trial ID: NN9536-4451 
      
Version: 
2.0 
Page: 
98 of 118 
 
g) Blood samples should be taken prior to product dosing 
h) Due to PK sampling, subjects must be instructed to withhold their trial product dose in the morning until blood sampling has been performed at the visit. This is not 
applicable for subjects that have discontinued trial product 
i) Only for subjects where the separate informed consent for future research has been signed 
j) The counselling can be done independent of the site visits within the visit window and flexibly as site visits or phone or video call 
k) Only for females (for menstrual period record in run-in period) 
l) Fundus examination can be performed up to 90 days prior to and until screening (V1) 
m) Fundus examination can be performed up to 30 days prior to and until randomisation (V8) 
 
 
 
VV-TMF-4175483|1.0|NN9536 -4451
  Protocol  V 2.0|98 of 118
VV-CLIN-134191
1.0
.


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
99 of 118 
 
Eye examination 
Subjects with uncontrolled and potentially unstable diabetic retinopathy or maculopathy are not 
eligible as this indicates retinopathy that has recently progressed to a level that requires intervention 
or is approaching intervention, but has yet to be brought under control.  
Results of an eye examination performed by an ophthalmologist or another suitably qualified health 
care provider must be available and evaluated by the investigator at screening and before 
randomisation to assess eligibility. If T2D is diagnosed during the trial, an eye examination should 
be performed as soon as possible.  
The eye examination should be performed as a fundus photography (e.g. 2-field 60 degree or better, 
colour or red-free) or by slit-lamp biomicroscopy examination (e.g. using a pre-corneal or corneal 
contact lens examination) and performed with pharmacologically dilated pupils. 
If the subject had such an eye examination performed within 90 days prior to screening, the 
investigator may base his/her evaluation upon the results of that examination. The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination. If the applicable eye examination was performed before the subject signed the 
informed consent form, it must be documented that the reason for performing the examination was 
not related to this trial. A second examination must be repeated within 30 days prior to 
randomisation (V8). 
After randomisation an eye examination performed according to above must be performed as per 
the flowchart in this appendix. The investigator should indicate the outcome of each eye 
examination. Relevant findings prior to randomisation must be recorded as concomitant 
illness/medical history. While relevant findings occurring after randomisation should be reported as 
an AE, if applicable according to Appendix 4. 
Self-measured plasma glucose (SMPG) 
Subjects will be provided with a BG meter including auxiliaries as well as instructions for use at 
randomisation or if diagnosed with T2D during the trial. The subjects will be instructed in how to 
use the device. Investigator should ensure throughout the trial that the subject is able to correctly 
measure BG at any time. 
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capillary blood are automatically calibrated to plasma equivalent glucose values, which will be 
shown on the display.  
The BG meter provided by Novo Nordisk should be used for the measurements required in the 
protocol.  
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
99
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
100 of 118 
 
SMPG measurements should be taken fasting (at least 8 hours overnight before the visit), and prior 
to taking any diabetes medication. SMPG should be taken either on the day of the clinic visit or on 
the day before, according to the flowchart. In case of suspicion of a hypoglycaemic event a SMPG 
should also be taken. Subjects should be instructed in how to record the results of the SMPG values 
in the diaries. The record of each SMPG value should include date, time and value. All data from 
the diary must be transcribed into the CRF during or following the contact. If obtained via phone 
and a discrepancy is later detected, the values in the CRF must be corrected. 
Rescue criteria 
If the confirmatory HbA1c exceeds the values described below then the subject should be offered 
treatment intensification (rescue medication) at the discretion of the investigator and according to 
the recommendations below. To allow for observation of the expected effect of trial product, rescue 
criteria will be applied from week 8 (V12) to week 68 (V30). Below rescue criteria applies to all 
subjects regardless if on active treatment or placebo. 
• subjects with a central HbA1c value above 8.5% (69 mmol/mol), who have experienced 
deterioration in glycaemic control, as expressed by an increase in HbA1c equal to or above 1% 
from randomisation (or lowest level post-randomisation) that is confirmed within 30 days by the 
central laboratory*  
• subjects with persistent poor glycaemic control, as expressed by a stable HbA1c value above 
8.5% (69 mmol/mol) that is confirmed at the next planned visit and by the central laboratory 
and considered unacceptably high according to investigator’s assessment*  
* with no intercurrent illness or explanation including non-compliance according to investigator’s 
assessment. 
Rescue medication 
Glycaemic rescue medication, i.e. intensification of background oral antidiabetic drug (OAD) 
treatment or addition of new background OADs, should be implemented at the discretion of the 
investigator in case of persistent hyperglycaemia. 
The following guidelines should be used: 
Rescue medication according to ADA/International Society for Pediatric and Adolescent Diabetes 
(ISPAD) guidelines63, 64 (excluding GLP-1 RAs, DPP-4 inhibitors and amylin analogues). Rescue 
medication should preferably be weight-neutral. 
If deemed necessary at the discretion of the investigator, insulin rescue therapy can be initiated, if 
so it should be according to ADA/ISPAD guidelines63, 64 and as short duration as possible. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
100
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
101 of 118 
 
Subjects that are started on rescue medication should continue to follow the protocol-specified visit 
schedule and stay on randomised treatment unless the investigator judge that it jeopardise safety. 
Rescue medication should be documented in medical records and reported as concomitant 
medication. 
Rescue medication will not be supplied by Novo Nordisk, but reimbursed as long as subject is 
participating in the trial, if required according to local regulations Appendix 11. 
Disease-related events and/or disease-related outcomes not qualifying as an AE or SAE  
The following Disease-Related Event (DRE) is common in subjects with T2D and can be 
serious/life threatening: 
• Hypoglycaemic episodes 
Non-serious hypoglycaemia must be reported on a hypoglycaemic episode form only. 
If the hypoglycaemic episode fulfils the criteria for an SAE then in addition to the above, an AE 
form and a safety information form must also be filled in. One AE form and safety information 
form can cover several hypoglycaemic episode forms, if the subject has not recovered between the 
episodes. 
Hypoglycaemic episodes 
Novo Nordisk classification of hypoglycaemia in paediatrics 
Hypoglycaemic episodes are classified according to ISPAD’s definition of severe hypoglycaemia65, 
as well as the Novo Nordisk classification of hypoglycaemia and the ADA classification of 
hypoglycaemia (Figure 11-1). 
In normal physiology, symptoms of hypoglycaemia occur below a Plasma Glucose (PG) level of 3.1 
mmol/L (56 mg/dL)66. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below 
this cut-off point in the definition of BG confirmed hypoglycaemia. 
Novo Nordisk uses the following classification in addition to the ADA/ISPAD classification: 
1. Severe hypoglycaemia according to the ISPAD classification65: Was the hypoglycaemic 
episode associated with severe neuroglycopenia, usually resulting in coma or seizure and 
requiring parenteral therapy (glucagon or intravenous glucose)? 
2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value 
<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia 
3. Severe or BG confirmed symptomatic hypoglycaemia: The union of 1. and 2 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
101
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
102 of 118 
 
ADA/ISPAD classification of hypoglycaemia in paediatrics65, 66 
• Severe hypoglycaemia according to the ISPAD classification65: Was the hypoglycaemic episode 
associated with severe neuroglycopenia, usually resulting in coma or seizure and requiring 
parenteral therapy (glucagon or intravenous glucose)? 
• Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of 
hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL) 
• Documented symptomatic hypoglycaemia: An episode during which typical symptoms of 
hypoglycaemia are accompanied by a measured PG concentration ≤3.9 mmol/L (70 mg/dL) 
• Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the 
typical symptoms of hypoglycaemia with a measured PG concentration >3.9 mmol/L (70 
mg/dL) but approaching that level 
• Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia 
are not accompanied by a PG determination but that was presumably caused by a PG 
concentration ≤3.9 mmol/L (70 mg/dL) 
For hypoglycaemic episodes reported with missing information related to the classification, the 
following applies when classifying the episode according to the ADA/ISPAD classification: 
• A hypoglycaemic episode with missing information on severe neuroglycopenia will be 
classified as no severe neuroglycopenia 
• A hypoglycaemic episode with missing information on symptoms will be classified as without 
symptoms 
Episodes that cannot be classified according to the above, are included in the following category: 
• ‘ADA/ISPAD unclassifiable’ includes episodes where subjects did not have severe 
neuroglycopenia with PG>3.9 mmol/L (70 mg/dL) or missing PG, and with missing information 
on symptoms 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
102
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
     
Status:
Final
     
Page:
103 of 118
Hypo-
glycaemic 
episode 
SMPG
measurement
Asymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo- 
hypoglycaemia
Probable 
symptomatic 
hypoglycaemia
Yes
No
No measurement 
with symptoms
PG > 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG 
 3.9 mmol/L 
(70 mg/dL)
with symptoms
PG 
 3.9 mmol/L 
(70 mg/dL)
without symptoms
No
Yes
Note: Glucose measurements are performed with capillary blood calibrated to plasma equivalent glucose values
PG: plasma glucose  SMPG: Self-measured plasma glucose
Was the 
hypoglycaemic 
episode 
associated with 
severe 
neuroglyco-
penia, usually 
resulting in 
coma or seizure 
and requiring 
parenteral 
therapy 
(glucagon or 
intravenous 
glucose)?
Severe 
hypoglycaemia 
(ISPAD 2014)
Figure 11-1
ADA/ISPAD classification of hypoglycaemia in paediatrics65, 66
Treatment-emergent: hypoglycaemic episodes will be defined as treatment-emergent, if the onset of 
the episode occurs in the on-treatment period (see definition in Section10.2).
Nocturnal hypoglycaemic episodes: episodes occurring between 23:00 and 07:00 both inclusive.
Hypoglycaemic episodes are classified according to ISPAD’s definition of severe hypoglycaemia65, 
as well as the Novo Nordisk classification of hypoglycaemia and the ADA classification of 
hypoglycaemia (Figure 11-1).
Reporting of hypoglycaemic episodes:
PG should always be measured and recorded when a hypoglycaemic episode is suspected. 
All PG values:
≤3.9 mmol/L (70 mg/dL) or 
>3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms should be 
reported as a hypoglycaemic episode according to the flowchart and instructions below. When a 
subject experiences a hypoglycaemic episode, subject or the parent(s)/LAR should record the 
general information in relation to the hypoglycaemia (timing, PG measurements, symptoms etc. as 
described in the diary). In case a subject is not able to fill in the diary (e.g. in case of hospitalisation 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
103
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
104 of 118 
 
or at the ‘follow-up phone contact’), then investigator should report the hypoglycaemic episode 
directly in the CRF.  
The hypoglycaemic episode diary pages should be completed if the subject recognises a 
hypoglycaemic episode in between visits.  
Upon onset of a hypoglycaemic episode the subject is recommended to measure PG every 15 
minutes until the SMPG value is >3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance with current guidelines66. 
Repeated SMPG measurements and/or symptoms will by default be considered as one 
hypoglycaemic episode until a succeeding SMPG value is >3.9 mmol/L (70 mg/dL) and/or 
symptoms have been resolved. One hypoglycaemic episode form is to cover these measurements 
and/or symptoms.  
In case of several low SMPG values within the hypoglycaemic episode, the lowest value is the one 
that will be reported as the SMPG value for the hypoglycaemic episode but the start time of the 
episode will remain as the time for the first low SMPG value and/or symptom. 
The lowest value measured during the hypoglycaemic episode will be reported as the PG value for 
the episode. The remaining values will be kept as source data in the diary. 
A hypoglycaemic episode starting without symptoms should be updated to symptomatic if the 
subject experiences symptoms later during the episode. 
If the severity of a hypoglycaemic episode worsens, only one hypoglycaemic episode should be 
reported, reflecting the most severe degree of hypoglycaemia. 
If the question "Was the hypoglycaemic episode associated with severe neuroglycopenia, usually 
resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose)?" is 
answered "YES", the hypoglycaemic episode is classified as “severe65”. The subject or the 
parent(s)/LAR should be instructed to contact the investigator as soon as possible after recovery for 
further guidance. 
Additional information (e.g. description of symptoms, alleviation of symptoms, seizure, coma, 
fatal) in relation to these severe hypoglycaemic episodes must be recorded. 
Oral carbohydrates must not be given if the subject is unconscious.  
The investigator must review the diary for low SMPG values not reported as hypoglycaemic 
episodes. The subject must be questioned whether any of the low values were severe, i.e. whether 
the subject was able to self-treat or not. If the subject was not able to self-treat, it has to be reported 
as a severe hypoglycaemic episode. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
104
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
105 of 118 
 
For low SMPG values for hypoglycaemic episodes where the subject was able to self-treat: If a 
hypoglycaemic episode form is not completed within 7 calendar days of the SMPG measurement, 
the episode should be reported on a hypoglycaemic episode form with as much information as 
possible. Novo Nordisk will not query for additional data except for the start date, SMPG value and 
whether the subject was able to self-treat due to decreased validity of such data67, 68. 
The subject must be re-trained in how to report hypoglycaemic episodes if the investigator identifies 
low SMPG values not reported as hypoglycaemic episodes. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
105
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
106 of 118
Clinical Charts for Body Mass Index by gender and age
Age calculated from CDC.gov: https://www.cdc.gov/growthcharts/percentile_data_files.htm  
In Table 11-5 BMI cut-off points are listed for the entire month; for example, 17:1 (age:months) 
represent 17 years and 1 month up to but not including 17 years and 2 months of age.
According to the protocol inclusion criterion (Section 6.1) and the protocol randomisation criterion 
(Section 6.4), subjects must have a BMI corresponding to ≥95th percentile OR ≥85th percentile  with 
≥1 weight related comorbidity, on gender and age-specific growth charts (CDC.gov). Table 11-5
must be used to determine subjects’ eligibility. 
If a BMI corresponding to <85th percentile on gender and age-specific growth charts (CDC.gov)
(Table 11-5) is reached during the trial, subjects should be assigned a maintenance diet, at the 
discretion of the investigator (see Section 7.1.2). 
If subjects becomes 18 years of age during the trial (after signing the Informed Consent Form), the 
definition for obesity is BMI ≥30 kg/m2 and the definition for overweight is BMI ≥27 kg/m2, while 
if a BMI corresponding to <25 kg/m2 is reached during the trial, subjects should be assigned a 
maintenance diet, at the discretion of the investigator (see Section 7.1.2).
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
106
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
107 of 118 
 
Table 11-5 
Cut-off points for BMI (Weight in kg/Height in m2) for obesity (≥95th percentile) 
and for overweight (≥85th percentile) and for diet maintenance  (<85th 
percentile) by gender for children from 12 and <18 years of age 
Age 
(Year: Month) 
Obesity (95th percentile) 
Overweight (85th percentile) 
BMI for Males 
BMI for Females 
BMI for Males 
BMI for Females 
12:0 
24.23 
25.26 
21.02 
21.74 
12:1 
24.31 
25.35 
21.09 
21.81 
12:2 
24.39 
25.43 
21.16 
21.88 
12:3 
24.47 
25.52 
21.23 
21.96 
12:4 
24.55 
25.61 
21.30 
22.03 
12:5 
24.63 
25.70 
21.37 
22.10 
12:6 
24.71 
25.79 
21.44 
22.17 
12:7 
24.79 
25.87 
21.51 
22.23 
12:8 
24.87 
25.96 
21.58 
22.30 
12:9 
24.95 
26.05 
21.65 
22.37 
12:10 
25.03 
26.13 
21.71 
22.44 
12:11 
25.10 
26.22 
21.78 
22.51 
13:0 
25.18 
26.30 
21.85 
22.58 
13:1 
25.25 
26.38 
21.92 
22.64 
13:2 
25.33 
26.46 
21.99 
22.71 
13:3 
25.40 
26.55 
22.06 
22.77 
13:4 
25.48 
26.63 
22.12 
22.84 
13:5 
25.55 
26.71 
22.19 
22.90 
13:6 
25.62 
26.79 
22.26 
22.97 
13:7 
25.69 
26.87 
22.33 
23.03 
13:8 
25.77 
26.95 
22.39 
23.10 
13:9 
25.84 
27.03 
22.46 
23.16 
13:10 
25.91 
27.10 
22.53 
23.22 
13:11 
25.98 
27.18 
22.60 
23.29 
14:0 
26.05 
27.26 
22.66 
23.35 
14:1 
26.12 
27.33 
22.73 
23.41 
14:2 
26.18 
27.41 
22.80 
23.47 
14:3 
26.25 
27.48 
22.86 
23.53 
14:4 
26.32 
27.55 
22.93 
23.59 
14:5 
26.38 
27.63 
22.99 
23.65 
14:6 
26.45 
27.70 
23.06 
23.71 
14:7 
26.52 
27.77 
23.13 
23.76 
14:8 
26.58 
27.84 
23.19 
23.82 
14:9 
26.65 
27.91 
23.26 
23.88 
14:10 
26.71 
27.99 
23.32 
23.93 
14:11 
26.77 
28.05 
23.39 
23.99 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
107
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
108 of 118 
 
Age 
(Year: Month) 
Obesity (95th percentile) 
Overweight (85th percentile) 
BMI for Males 
BMI for Females 
BMI for Males 
BMI for Females 
15:0 
26.84 
28.12 
23.45 
24.05 
15:1 
26.90 
28.19 
23.52 
24.10 
15:2 
26.96 
28.26 
23.58 
24.15 
15:3 
27.02 
28.33 
23.64 
24.21 
15:4 
27.09 
28.39 
23.71 
24.26 
15:5 
27.15 
28.46 
23.77 
24.31 
15:6 
27.21 
28.53 
23.83 
24.36 
15:7 
27.27 
28.59 
23.90 
24.42 
15:8 
27.33 
28.66 
23.96 
24.47 
15:9 
27.39 
28.72 
24.02 
24.52 
15:10 
27.45 
28.78 
24.09 
24.57 
15:11 
27.51 
28.85 
24.15 
24.62 
16:0 
27.56 
28.91 
24.21 
24.66 
16:1 
27.62 
28.97 
24.27 
24.71 
16:2 
27.68 
29.03 
24.33 
24.76 
16:3 
27.74 
29.10 
24.40 
24.81 
16:4 
27.80 
29.16 
24.46 
24.85 
16:5 
27.85 
29.22 
24.52 
24.90 
16:6 
27.91 
29.28 
24.58 
24.94 
16:7 
27.97 
29.34 
24.64 
24.99 
16:8 
28.03 
29.40 
24.70 
25.03 
16:9 
28.08 
29.46 
24.76 
25.08 
16:10 
28.14 
29.52 
24.82 
25.12 
16:11 
28.20 
29.57 
24.88 
25.16 
17:0 
28.26 
29.63 
24.94 
25.20 
17:1 
28.31 
29.69 
25.00 
25.25 
17:2 
28.37 
29.75 
25.06 
25.29 
17:3 
28.43 
29.81 
25.12 
25.33 
17:4 
28.49 
29.87 
25.18 
25.37 
17:5 
28.55 
29.92 
25.24 
25.41 
17:6 
28.60 
29.98 
25.30 
25.45 
17:7 
28.66 
30.04 
25.36 
25.49 
17:8 
28.72 
30.10 
25.42 
25.53 
17:9 
28.78 
30.15 
25.48 
25.57 
17:10 
28.84 
30.21 
25.54 
25.60 
17:11 
28.90 
30.27 
25.60 
25.64 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
108
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
109 of 118
Monitoring of calcitonin
Background
Treatment with GLP-1 RAs has been shown to be associated with thyroid C-cell changes in rodents 
but not in non-human primates. The human relevance of this finding is unknown. However, based 
on the findings in rodents, monitoring of serum calcitonin (a sensitive biomarker for C-cell 
activation) is currently being performed in clinical trials with semaglutide.
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (> 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values between 
upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is less clear 
with regards to indication of disease.
There is little information available on normal calcitonin levels in children. The available 
information suggests that children in the age range included in this clinical trial (10 to less than 18 
years) will have calcitonin levels indistinguishable from adults69. 
There are several known confounding factors affecting calcitonin levels, e.g.:
•
renal dysfunction
•
tobacco use
•
autoimmune thyroiditis
•
several drug classes (e.g. proton pump inhibitors, beta-blockers, H2-blockers and 
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various comorbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.
Calcitonin monitoring
Subjects with a personal or family (family is defined as a first degree relative) history of MTC or 
multiple endocrine neoplasia syndrome type 2 (MEN 2) or with a screening calcitonin ≥50 ng/L at 
visit 1 must be excluded from the trial. 
In case a subject has a calcitonin value ≥ 10 ng/L, the algorithm outlined in Figure 11-2 and 
described below should be followed. The algorithm applies for all calcitonin values in the trial.
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
109
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
110 of 118
Evaluation of 
calcitonin results
Calcitonin < 10 ng/L
 ! "   	 
  
 ( 10 ng/L and < 50 ng/L
 ! "   	 
  
 ( 50 ng/L and < 100 ng/L
 ! "   	 
  
 ( 100 ng/L 
 ! "   	 
  
 ( 10 ng/L and last 
measurement in the trial
No action
• 
Investigate potential confounding 
factors
• 
Continue sampling of calcitonin 
according to protocol
• 
Discontinue trial product
• 
Refer to thyroid specialist
• 
Discontinue trial product
• 
Refer to thyroid specialist
• 
Refer to thyroid specialist
Figure 11-2
Flowchart of calcitonin monitoring
Calcitonin ≥ 100 ng/L
Action: The subject (even if a screen failure) must immediately be referred to a paediatric 
endocrinologist or thyroid specialist for further evaluation and the trial product must be 
discontinued (Section 8.1.1). The subject should remain in the trial; however, all medications 
suspected to relate to this condition must be discontinued until diagnosis has been established.
Background: These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease70. All of these patients were diagnosed with MTC, resulting in a positive predictive 
value of 100%.
Diagnostic evaluation should include:
•
thyroid ultrasound examination
•
fine needle aspiration of any nodules > 1 cm 
•
potentially, surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 and perform a genetic test for RET proto-oncogene mutation.
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
110
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
111 of 118 
 
Calcitonin ≥ 50 and < 100 ng/L 
Action: The subject (even if a screen failure) should be referred to a paediatric endocrinologist or 
thyroid specialist for further evaluation. The subject should remain in the trial but must discontinue 
from trial product. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease70. Two of these subjects were diagnosed with MTC and two were diagnosed with C 
cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%. 
Diagnostic evaluation should include:  
• thyroid ultrasound examination  
• if available, and if there are no contraindications, a pentagastrin stimulation test should be done. 
For subjects with positive pentagastrin stimulation test, surgery should be considered  
• if pentagastrin stimulation test is not available, thyroid ultrasound and fine needle aspiration 
biopsy may add important clinical information about the need for surgery 
Calcitonin ≥ 10 and < 50 ng/L 
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol. 
If the subject is a screen failure, or if the value is from the last sample taken in the trial, the subject 
should be referred to a paediatric endocrinologist or thyroid specialist for further evaluation. 
Background: Calcitonin values from 20-50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease70. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm 
with calcitonin in this range is extremely low. 
For calcitonin values between 10-20 ng/L, Costante et al.70 identified 216 (3.7%) patients. One 
patient out of the 216 had a subsequent basal (unstimulated) calcitonin value of 33 ng/L, and had C-
cell hyperplasia at surgery. Two other studies used a cut-off of calcitonin > 10 ng/L to screen for C-
cell disease, but they do not provide sufficient information on patients with basal CT > 10 and < 20 
ng/L to allow conclusions71, 72. 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
111
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol
CONFIDENTIAL
Date:
06 January 2021
Novo Nordisk
Trial ID: NN9536-4451
Version:
2.0
Status:
Final
Page:
112 of 118
Country-specific requirements 
For Austria: 
Section 2 and Appendix 5 Pregnancy testing
A monthly pregnancy test is mandatory for female subjects of childbearing potential. , i.e. at P19, 
P21, P23, P25, P27 and P29 the subject must perform a pregnancy urine test at home and results 
must be recorded in the medical record.
Appendix 3 section 14 Indemnity statement
Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with BGBl. I Nr. 40/2017.
For Belgium:
Appendix 3 section 14 Indemnity statement
Law concerning experiments on the human person of 07 May 2004 - Article 29:
§1. Even if without fault, the sponsor is liable for the damage which the subject and/or his rightful 
claimants sustain and which shows either a direct or an indirect connection with the trial.
For Ireland:
Section 6.1 inclusion criterion no. 5 
In line with the SPC in Ireland, metformin is contraindicated in patients with severe renal failure 
(creatinine clearance below 30 ml/min) and therefore creatinine clearance needs to be established 
(glomerular filtration rate below 30 ml/min, calculated by the Cockroft & Gault formula).
For Mexico:
Section 8.2  Withdrawal from the trial
Should the subject, his/her family members, parents or legal representative decide to withdraw the 
consent for participation in the trial, the subject will be entitled to receive appropriate, free of 
charge medical care and/or trial drug during the follow up period of the protocol when it will be 
established with certainty that no untoward medical consequences of the subject´s participation in 
the research occurred.
Appendix 3 section 1 Regulatory and ethical considerations
In the case of Mexico, the following responsibilities for the head of the Institution/Health Care 
Establishment, Ethics, Research and, when applicable, Biosafety Committees and sponsor within 
their scope of responsibility: 
a) Investigation follow-up
b) Damages to health arising from the investigation development; as well as those arising from 
interruption or advanced suspension of treatment due to non-attributable reasons to the Subject;
c) Timely compliance of the terms in which the authorization of a research for health in human 
beings had been issued;
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
112
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
 
Status: 
Final 
 
Page: 
113 of 118 
 
d) To present in a timely manner the information required by the Health Authority. 
 
Appendix 3 section 14 Indemnity statement 
a) Novo Nordisk carries product liability for its products assumed under the special laws, 
acts/and/or guidelines for conducting trials in any country, including those applicable provisions on 
the Mexican United States.   If the subject feels that something goes wrong during the course of this 
trial, the subject should contact the trial staff in the first instance. 
b) If during their participation in the trial the subject experiences a disease or injury that, according 
to the trial doctor and the sponsor, is directly caused by the study medication and/or a study 
procedure that otherwise would not have been part of his/her regular medical care, the subject will 
receive from the institution or medical care establishment and free of charge, the appropriate 
medical treatment as required. In this case, the costs resulting from such treatment  as well as the 
costs of any indemnification established by law will be covered by the trial sponsor in accordance 
with the terms provided by all applicable regulations; even if the  subject discontinues his/her 
participation in the study by his own will or by a decision from the investigator. 
c)  By signing the informed consent, the subject will not renounce to any compensation or 
indemnification he/she may be entitled to by law, nor will he/she will incur any additional expense 
as a result of his/her participation in the trial; any additional expense resulting from the subject’s 
participation in the trial will be covered by the trial sponsor. 
For Russia: 
Appendix 3 section 1 Regulatory and ethical considerations 
The trial should be conducted in compliance with the protocol and Ministry of Healthcare of 
Russian Federation’ order #200н from April, 01, 2016 ”Approval of rules of good clinical practice”. 
For UK: 
Contraceptive measures considered adequate include highly effective contraceptive methods as 
listed in Table 11-4 ‘Highly effective contraceptive methods’ in Appendix 5. This means that the 
use of double barrier methods is not applicable for UK. 
Appendix 3 section 5 Data protection 
In the UK the IRB/IEC do not have access to the patients’ medical records. 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
113
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
114 of 118 
 
 
12 References 
1. 
The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the member states relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use. 2001. 
2. 
Smith KB, Smith MS. Obesity Statistics. Prim Care. 2016;43(1):121-35, ix. 
3. 
Kolsgaard ML, Joner G, Brunborg C, Anderssen SA, Tonstad S, Andersen LF. Reduction in 
BMI z-score and improvement in cardiometabolic risk factors in obese children and 
adolescents. The Oslo Adiposity Intervention Study - a hospital/public health nurse 
combined treatment. BMC Pediatr. 2011;11:47. 
4. 
Ford AL, Hunt LP, Cooper A, Shield JP. What reduction in BMI SDS is required in obese 
adolescents to improve body composition and cardiometabolic health? Arch Dis Child. 
2010;95(4):256-61. 
5. 
Reinehr T, Kleber M, Toschke AM. Lifestyle intervention in obese children is associated 
with a decrease of the metabolic syndrome prevalence. Atherosclerosis. 2009;207(1):174-
80. 
6. 
Whitlock EP, O'Connor EA, Williams SB, Beil TL, Lutz KW. Effectiveness of Weight 
Management Interventions in Children: A Targeted Systematic Review for the USPSTF. 
Pediatrics. 2010;125(2):E396-E418. 
7. 
Chao AM, Wadden TA, Berkowitz RI. The safety of pharmacologic treatment for pediatric 
obesity. Expert Opin Drug Saf. 2018;17(4):379-85. 
8. 
The American Society for Metabolic and Bariatric Surgery, The Obesity Society, The 
American Society of Bariatric Physicians and the American Association of Clinical 
Endocrinologists. Obesity is a Disease: Leading Obesity Groups Agree (Joint Press 
Release). 19 June 2013. 
9. 
Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical 
Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 
2012;18(5):642-8. 
10. 
Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JC, Frühbeck G. 2014 EASO 
Position Statement on the Use of Anti-Obesity Drugs. Obes Facts. 2015;8(3):166-74. 
11. 
Fruhbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM, et al. Obesity: the 
gateway to ill health - an EASO position statement on a rising public health, clinical and 
scientific challenge in Europe. Obes Facts. 2013;6(2):117-20. 
12. 
Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. 
Pharmacological management of obesity: an endocrine Society clinical practice guideline. J 
Clin Endocrinol Metab. 2015;100(2):342-62. 
13. 
Ferguson C, David S, Divine L, Kahan S, Gallagher C, Gooding M, et al. Obesity Drug 
Outcome Measures. A Consensus Report of Considerations Regarding Pharmacologic 
Intervention. Avaliable from: https://publichealth.gwu.edu/pdf/obesitydrugmeasures.pdf. 
2012. 
14. 
Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-
term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-
604. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
114
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
115 of 118 
 
 
15. 
Schwartz A, Doucet E. Relative changes in resting energy expenditure during weight loss: a 
systematic review. Obes Rev. 2010;11(7):531-47. 
16. 
Pasman WJ, Saris WH, Westerterp-Plantenga MS. Predictors of weight maintenance. Obes 
Res. 1999;7(1):43-50. 
17. 
Dombrowski SU, Knittle K, Avenell A, Araujo-Soares V, Sniehotta FF. Long term 
maintenance of weight loss with non-surgical interventions in obese adults: systematic 
review and meta-analyses of randomised controlled trials. BMJ. 2014;348:g2646. 
18. 
Barlow SE. Expert committee recommendations regarding the prevention, assessment, and 
treatment of child and adolescent overweight and obesity: Summary report. Pediatrics. 
2007;120:S164-S92. 
19. 
Kumar S, Kelly AS. Review of Childhood Obesity: From Epidemiology, Etiology, and 
Comorbidities to Clinical Assessment and Treatment. Mayo Clin Proc. 2017;92(2):251-65. 
20. 
Durkin N, Desai AP. What Is the Evidence for Paediatric/Adolescent Bariatric Surgery? 
Curr Obes Rep. 2017;6(3):278-85. 
21. 
Brethauer SA, Chand B, Schauer PR. Risks and benefits of bariatric surgery: current 
evidence. Cleve Clin J Med. 2006;73(11):993-1007. 
22. 
Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after 
laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232(4):515-29. 
23. 
Miller JL, Silverstein JH. Management approaches for pediatric obesity. Nat Clin Pract 
Endocrinol Metab. 2007;3(12):810-8. 
24. 
Viner RM, Hsia Y, Tomsic T, Wong IC. Efficacy and safety of anti-obesity drugs in 
children and adolescents: systematic review and meta-analysis. Obes Rev. 2010;11(8):593-
602. 
25. 
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 
Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 
Kidney Int Suppl. 2013;3(1):1-150. 
26. 
Kelly AS, Fox CK, Rudser KD, Gross AC, Ryder JR. Pediatric obesity pharmacotherapy: 
current state of the field, review of the literature and clinical trial considerations. Int J Obes 
(Lond). 2016;40(7):1043-50. 
27. 
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and 
safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 
diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, 
multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-60. 
28. 
Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like 
peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. 
Am J Physiol. 1999;276(5 Pt 2):R1541-4. 
29. 
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, et al. Efficacy and safety of 
once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or 
without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a 
randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet 
Diabetes Endocrinol. 2017;5(5):355-66. 
30. 
Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and 
safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, 
thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, 
double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341-54. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
115
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
116 of 118 
 
 
31. 
Ahmann A, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and 
safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 
diabetes (SUSTAIN 3).  European Association for the Study of Diabetes, 52nd meeting 
2016, Oral Presentation #1472016. 
32. 
Rodbard H, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Efficacy and safety 
of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination 
with metformin in subjects with type 2 diabetes (SUSTAIN 5) [abstract]. Diabetologia. 
2016;59(Suppl 1):364-5. 
33. 
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-
weekly semaglutide on appetite, energy intake, control of eating, food preference and body 
weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-51. 
34. 
Lu TT, Secher A JJ, Alanentalo T, Juel Paulsen S, Hecksher-Sørensen J, Larsen JN, 
Baquero A, Knudsen LB. Semaglutide interacts with hypothalamic neurons and lowers body 
weight in mice.  Poster discussion 1072-P. American Diabetes Association, 77th Scientific 
Sessions, San Diego, CA, USA.9–13 June 2017. 
35. 
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. 
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in 
patients with obesity: a randomised, double-blind, placebo and active controlled, dose-
ranging, phase 2 trial. Lancet. 2018;392(10148):637-49. 
36. 
Novo Nordisk A/S. Investigator's Brochure, Semaglutide subcutaneous administration, 
Project NN9536 (edition 6). 03 Dec 2020. 
37. 
Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. Body-Mass Index in 
2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med. 
2016;374(25):2430-40. 
38. 
European Medicines Agency. EMA/CHMP/311805/2014; Guideline on clinical evaluation 
of medicinal products used in weight management. 01 Jan 2017. 
39. 
Food and Drug Administration. FDA Guidance for Industry: Developing products for 
weight management. 2007. 
40. 
Novo Nordisk A/S. Investigator's Brochure, Semaglutide subcutaneous administration, 
Project NN9536 and NN9931, (edition 3). 
41. 
World Health Organisation. Growth reference 5-19 years, BMI-for-age. 2011. 
42. 
Carlsson Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Semaglutide s.c. Once-
Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. Diabetes Ther. 
2018;9(4):1533-47. 
43. 
World Health Organization, Global Strategy on Diet, Physical Activity and Health 2015. 
44. 
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis-2012: revision of the Atlanta classification and definitions by 
international consensus. Gut. 2013;62(1):102-11. 
45. 
The European Commission. Ethical considerations for clinical trials on medicinal products 
conducted with the paediatric population - Recommendations of the adhoc group for the 
development of implementing guidelines for Directive 2001/20/EC relating to good clinical 
practice in the conduct of clinical trials on medicinal products for human use. 2008. 
46. 
American Diabetes Association. Standards of medical care in diabetes - 2017. Diabetes 
Care. 2017;40(Suppl 1):S1-135. 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
116
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
117 of 118 
 
 
47. 
de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a 
WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 
2007;85(9):660-7. 
48. 
Organization WH. Growth reference data for 5-19 years 2016 [cited 2016 03 June]. 
49. 
Kolotkin RL, Zeller M, Modi AC, Samsa GP, Quinlan NP, Yanovski JA, et al. Assessing 
weight-related quality of life in adolescents. Obesity (Silver Spring). 2006;14(3):448-57. 
50. 
Kroenke K, Spitzer RL, Williams JB. The PHQ-9 - Validity of a brief depression severity 
measure. J Gen Intern Med. 2001;16(9):606-13. 
51. 
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification 
Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's 
pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-43. 
52. 
Tanner JM. Normal growth and techniques of growth assessment. Clin Endocrinol Metab. 
1986;15(3):411-51. 
53. 
McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 
2016;26(1):30-6. 
54. 
Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol 
deviation: a framework for relevant, accessible assumptions, and inference via multiple 
imputation. J Biopharm Stat. 2013;23(6):1352-71. 
55. 
World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. Last amended by the 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013. 
56. 
ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2), Step 4 
version. 09 Nov 2016. 
57. 
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org. 
58. 
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):1250-1. 
59. 
U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007 as amended by the Final Rule "Clinical 
Trials Registration and Results Information Submission". 21 September 2016. 
60. 
The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal 
products for human use, article 11. Official Journal of the European Communities. 01 May 
2001. 
61. 
The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004. 
62. 
The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
117
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol 
CONFIDENTIAL 
Date: 
06 January 2021 
Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
2.0 
      
Status: 
Final 
      
Page: 
118 of 118 
 
 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. 
Official Journal of the European Communities. 27 Dec 2006. 
63. 
Association AD. 12. Children and Adolescents:. Diabetes Care. 2018;41(Suppl 1):S126-S36. 
64. 
International Diabetes Federation. Global IDF/ISPAD guideline for Diabetes in Childhood 
and Adolescence. 2011. 
65. 
Ly TT, Maahs DM, Rewers A, Dunger D, Oduwole A, Jones TW, et al. ISPAD Clinical 
Practice Consensus Guidelines 2014. Assessment and management of hypoglycemia in 
children and adolescents with diabetes. Pediatr Diabetes. 2014;15 Suppl 20:180-92. 
66. 
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384-95. 
67. 
U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. Avaliable from: 
http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. 2009. 
68. 
Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-
42. 
69. 
Basuyau JP, Mallet E, Leroy M, Brunelle P. Reference intervals for serum calcitonin in 
men, women, and children. Clin Chem. 2004;50(10):1828-30. 
70. 
Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive 
value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma 
in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 
2007;92(2):450-5. 
71. 
Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C, et al. Sporadic 
hypercalcitoninemia: clinical and therapeutic consequences. Endocr Relat Cancer. 
2009;16(1):243-53. 
72. 
Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M, et al. Histopathological 
and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic 
C-cell hyperplasia? Endocr Relat Cancer. 2007;14(2):393-403. 
 
 
 Protocol  V 2.0
4451
NN9536
0
 |
VV-TMF-4175483
118
 of
118
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


 
 
16.1.01 
Protocol Attachment 
 
Protocol Attachment I is located in the Trial Master File. 
If applicable, Protocol Attachment II is also located in the Trial Master File. 
Content: Global key staff and Country key staff. 
CONFIDENTIAL
Date:
Novo Nordisk
Version:
Status:
Semaglutide
Trial ID: NN9536-4451
Clinical Trial Report
Appendix 16.1.1
10 March 2022
1.0
Final
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol Amendment no 1
CONFIDENTIAL
Date:
09 October 2019
Novo Nordisk
Trial ID: NN9536-4451
Version:
1.0
Status:
Final
Page:
1 of 3
Protocol Amendment
no 1
to Protocol, version 1.0
dated 09 Apr 2019
Trial ID: NN9536-4451
Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents 
with overweight or obesity
Trial phase: IIIa
Applicable to Ireland
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
IE  Protocol Amendment  no 1
4451
NN9536
0
 |
VV-TMF-1047159
3
 of
1
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol Amendment no 1
CONFIDENTIAL
Date:
09 October 2019
Novo Nordisk
Trial ID: NN9536-4451
Version:
1.0
Status:
Final
Page:
2 of 3
Table of Contents   
1
Introduction including rationale for the protocol amendment...........................................................3
2
Changes ................................................................................................................................................3
IE  Protocol Amendment  no 1
4451
NN9536
0
 |
VV-TMF-1047159
3
 of
2
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol Amendment no 1
CONFIDENTIAL
Date:
09 October 2019
Novo Nordisk
Trial ID: NN9536-4451
Version:
1.0
Status:
Final
Page:
3 of 3
1
Introduction including rationale for the protocol amendment
This amendment was prepared to update protocol NN9536-4451 version 1.0 dated 09 Apr 2019 
with the following change:

To correct typographical error in appendix 11

To update contraceptive requirements for subjects in Ireland as per request from the 
Irish regulatory authority, the Health Products Regulatory Authority on 30 Sep 2019
In this protocol amendment:

Any new text is written in italics.

Any text deleted from the protocol is written using strike through.
2
Changes
Appendix 11 Country Specific Requirements
For Ireland:
Section 6.1 exclusion inclusion criteria no. 5
In line with the SPC in Ireland, metformin is contraindicated in patients with severe renal failure 
(creatinine clearance below 30 ml/min) and therefore creatinine clearance needs to be established 
(glomerular filtration rate below 30 ml/min, calculated by the Cockroft & Gault formula).
Appendix 5 Contraceptive guidance and collection of pregnancy information
Contraceptive measures considered adequate include highly effective contraceptive methods as 
listed in Table 11-4 ‘Highly effective contraceptive methods’ in Appendix 5. This means that the use 
of double barrier methods is not applicable for Ireland.
IE  Protocol Amendment  no 1
4451
NN9536
0
 |
VV-TMF-1047159
3
 of
3
 .
-
 |
1
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol Amendment no 1 IE 
CONFIDENTIAL 
Date: 
03 February 2021 Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
1.0 IE 
     
Status: 
Final 
     
Page: 
1 of 4 
 
Protocol Amendment 
no 1 IE 
to protocol, version 2 
dated 06 January 2021 
Trial ID: NN9536-4451 
Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents 
with overweight or obesity 
 
Trial phase: IIIa 
Applicable to Ireland 
 
 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties. 
IE  Protocol Amendment  Local Amendment
4451
NN9536
0
 |
VV-TMF-4238793
4
 of
1
 .
-
 |
2
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.


Protocol Amendment no 1 IE 
CONFIDENTIAL 
Date: 
03 February 2021 Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
1.0 IE 
     
Status: 
Final 
     
Page: 
2 of 4 
 
Table of contents 
 
Page 
Table of contents ............................................................................................................................................... 2 
1 Introduction including rationale for the protocol amendment ............................................................... 3 
2 Changes ........................................................................................................................................................ 4 
 
IE  Protocol Amendment  Local Amendment
4451
NN9536
0
 |
VV-TMF-4238793
4
 of
2
 .
-
 |
2
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol Amendment no 1 IE 
CONFIDENTIAL 
Date: 
03 February 2021 Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
1.0 IE 
     
Status: 
Final 
     
Page: 
3 of 4 
 
1 
Introduction including rationale for the protocol amendment 
This amendment was prepared to update protocol NN9536-4451 version 2.0 dated 06 January 2021 
with the following change: 
- 
To update contraceptive requirements for subjects in Ireland as per request from the Irish 
regulatory authority, the Health Products Regulatory Authority on 30 Sep 2019 
In this protocol amendment: 
• Any new text is written in italics 
• Any text deleted from the protocol is written using strike through 
IE  Protocol Amendment  Local Amendment
4451
NN9536
0
 |
VV-TMF-4238793
4
 of
3
 .
-
 |
2
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL


Protocol Amendment no 1 IE 
CONFIDENTIAL 
Date: 
03 February 2021 Novo Nordisk 
Trial ID: NN9536-4451 
Version: 
1.0 IE 
Status: 
Final 
Page: 
4 of 4 
2 
Changes 
Appendix 11 Country Specific Requirements 
For Ireland: 
Appendix 5 Contraceptive guidance and collection of pregnancy information 
Contraceptive measures considered adequate include highly effective contraceptive methods as 
listed in Table 11-4 ‘Highly effective contraceptive methods’ in Appendix 5. This means that the use 
of double barrier methods is not applicable for Ireland. 
IE  Protocol Amendment  Local Amendment
4451
NN9536
0
 |
VV-TMF-4238793
4
 of
4
 .
-
 |
2
 |
VV-CLIN-134191
1.0
.
CONFIDENTIAL

SAP_001.pdf: 
C o ver P a ge  f or S t atistic al A n al ysis Pl a n 
S p o ns or na me:  
N o v o N or dis k A/ S  
N C T n u m ber  
N C T 0 4 1 0 2 1 8 9  
S p o ns or t rial I D: 
N N 9 5 3 6 -4 4 5 1  
Official title of st u d y:  
Effect a n d safet y of se ma gl uti de 2. 4 m g o nce  wee kl y o n 
wei g ht ma na ge me nt i n a d olesce nts wit h o ver w ei g ht or  o besit y  
D oc u me nt date *  
1 6  Dece m b er  2 0 2 1  
* D oc u me nt  date refers to  th e date o n  whic h  the d oc u me nt  was most  rece ntl y up date d.  N ot e:  Th e  d at e  in t h e  h ea d er  of Pa ge  2  is the
date  of  co m pil ati o n of  th e  d o c u m e nts  a n d n ot  of an u p d at e  to c o nt e nt.


Li n k
List of c o nte nts
St atistic al a n al ysis pl a n ......................................................................................................................
C O N FI D E N TI A L
Date:
N o v o N or di s k
Versi o n:
Stat us:
Se ma gl uti de
Trial I D: N N 9 5 3 6- 4 4 5 1
Cli nical Trial Re p ort
A p pe n di x 1 6. 1. 9
1 0 Marc h 2 0 2 2
1. 0
Fi nal
1 6. 1. 9 D oc u me nt ati o n of st atistic al met h o ds
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L
Re d acte d st atistic al a n alysis pl a n  
I ncl u des re d acti o n of pers o n al i de ntifi a ble inf or m at i o n o nly. 
. 


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
Stat us:  
Fi n al  
P a ge:  
1  of 2 4  
St atistic al A n al ysis Pl a n  
Pr ot oc ol title : Effect a n d safet y of se ma gl uti de 2. 4 m g o nce 
wee kl y o n wei g ht ma na ge me nt i n a d olesce nts wit h o ver wei g ht or 
o besit y  
S u bst a nce: se m a gl uti de 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
2  of 2 4  
 
Ta ble of c o nte nts  
 
P a ge  
T a ble of c o nte nts  ............................................................................................................................................... 2  
List of a b bre vi ati o ns  ......................................................................................................................................... 3  
Versi o n hist or y  .................................................................................................................................................. 4  
1  I ntr o d ucti o n ................................................................................................................................................. 5  
1. 1  
Trial i nf or mati o n  ................................................................................................................................. 5  
1. 1. 1  
O bjecti ves  ............................................................................................................................ 5  
1. 1. 1. 1  
Pri mar y o bj ecti ve  ............................................................................................. 5  
1. 1. 1. 2  
Sec o n dar y o bj ecti ves  ........................................................................................ 5  
1. 1. 1. 3  
E x pl orat or y o bj ecti ves  ..................................................................................... 5  
1. 1. 2  
Esti ma n ds  ............................................................................................................................ 5  
1. 1. 2. 1  
Pri mar y esti ma n d  ............................................................................................. 5  
1. 1. 2. 2  
Sec o n dar y esti ma n d  ......................................................................................... 6  
1. 1. 3  
E n d p oi nts  ............................................................................................................................. 6  
1. 1. 3. 1  
Pri mar y e n d p oi nt  .............................................................................................. 6  
1. 1. 3. 2  
C o nfir mat or y sec o n dar y e n d p oi nts  .................................................................. 6  
1. 1. 3. 3  
S u p p orti ve sec o n dar y e n d p oi nts  ...................................................................... 6  
1. 1. 3. 4  
E x pl orat or y e n d p oi nts  ...................................................................................... 7  
1. 1. 4  
T y pe of trial  ......................................................................................................................... 8  
1. 2  
Sc o pe of t he statistical a nal ysis pla n  ................................................................................................... 8  
2  St atistic al c o nsi der ati o ns  ............................................................................................................................ 9  
2. 1  
St atistical h y p ot heses  .......................................................................................................................... 9  
2. 2  
Sa m ple size deter mi nati o n  .................................................................................................................. 9  
2. 3  
Defi niti o n of a nal ysis sets  ................................................................................................................. 1 0  
2. 4  
Statistical a nal yses  ............................................................................................................................ 1 0  
2. 4. 1  
Ge neral c o nsi derati o ns  ...................................................................................................... 1 0  
2. 4. 2  
Pri mar y e n d p oi nt  ............................................................................................................... 1 1  
2. 4. 3  
Sec o n dar y e n d p oi nts  .......................................................................................................... 1 5  
2. 4. 3. 1  
C o nfir mat or y sec o n dar y e n d p oi nt  .................................................................. 1 5  
2. 4. 3. 2  
S u p p orti ve sec o n dar y e n d p oi nts  .................................................................... 1 7  
2. 4. 4  
E x pl orat or y e n d p oi nts ........................................................................................................ 1 8  
2. 4. 5  
Ot her a nal yses  ................................................................................................................... 2 0  
2. 4. 5. 1  
S u b gr o u p a nal yses  .......................................................................................... 2 0  
2. 5  
E n d p oi nt deri vati o n met h o ds  ............................................................................................................ 2 1  
2. 5. 1  
B MI perce nta ge of t he 9 5 t h perce ntile ( C D C. g o v)  ............................................................. 2 1  
2. 5. 2  
B MI a n d hei g ht S D S ( W H O.i nt)  ....................................................................................... 2 1  
2. 5. 3  
I W Q O L-Ki ds  ..................................................................................................................... 2 2  
3  C h a n ges t o t he st atistic al a n al yses pl a n ne d i n t he pr ot oc ol  ................................................................... 2 3  
4  Ref ere nces  .................................................................................................................................................. 2 4  
 
 
 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
2
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
3  of 2 4  
 
 
List of a b bre vi ati o ns  
A D  
a vaila ble b ut disc o nti n ue d  
A D A  
A merica n Di a betes Ass o ciati o n  
A E  
a d verse e ve nt  
A L T  
ala ni ne a mi n otra nsf eras e  
A N C O V A  
a nal ysis of c o varia nce  
A T  
a vaila ble o n ra n d o mise d treat me nt  
B MI  
b o d y mass i n de x  
C D C  
Ce nters f or Disease C o ntr ol a n d Pre ve nti o n  
C O A  
cli nical o utc o me assess m e nt  
CI  
c o nfi de nce i nter val  
C -S S R S  
C ol u m bia S uici dalit y Se verit y Rati n g Scal e  
E C G  
electr ocar di o gra m  
E T D  
esti mate d treat me nt differe nce  
F A S  
f ull a nal ysis set 
F P G  
fasti n g plas ma gl u c ose 
H b A 1 c 
gl ycate d hae m o gl o bi n  
H D L  
hi g h de nsit y li p o pr otei n  
H O M A -B  
h o me ostasis m o del assess me nt of beta -cell f uncti o n  
H O M A -I R 
h o me ostasis m o del assess me nt of i ns uli n resista nce  
I S P A D 
I nter nati o nal S ociet y f or Pae diatric a n d A d ol esce nt Dia betes 
I W Q O L 
I m pa ct of Wei g ht o n Q ualit y of Life 
J 2 R-MI  
j u m p t o refere n ce m ulti ple i m p utati o n  
L A O -O T  
last a vaila ble o bser vati o n on -treat me nt 
L D L  
l o w-de nsit y li p o pr otei n  
L R  
l o gistic re gressi o n 
M D  
missi n g a n d disc o nti n ue d  
M M R M  
mi x e d m o del f or re peate d meas ure me nts  
M T  
missi n g o n ra n d o mise d tr eat me nt 
O R  
o d ds rati o  
P H Q -9  
Patie nt Healt h Q uesti o n naire 9  
P K  
p har mac o ki netic  
P Y E  
patie nt years of e x p os ure  
P Y O  
patie nt years of o bs er vati o n  
R D -MI  
m ulti ple i m p utati o n usi n g retrie ve d s u bjects  
S A E  
seri o us a d vers e e v e nt 
S A P  
statistical a nal ysis pla n 
S A S  
safet y a n al ysis set 
s.c. 
s u bc uta ne o us 
S D  
sta n dar d de viati o n 
T 2 D  
t y pe 2 dia b etes 
T E A E  
treat me nt-e mer ge nt a d verse e ve nt  
T P -MI  
ti p pi n g-p oi nt m ulti ple i m p utati o n  
V L D L  
ver y l o w -de nsit y li p o pr ot ei n  
W H O  
W orl d Healt h Or ga nisati o n  
 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
3
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
4  of 2 4  
 
 
Versi o n h ist or y 
T his statistical anal ysis p la n ( S A P) is base d o n t he u p date d pr ot oc ol f or trial N N 9 5 3 6 -4 4 5 1 “Effect 
a n d safet y of s e ma gl uti de 2. 4 m g o n ce wee kl y o n wei g ht ma n a ge me nt i n a d olesce nts wit h 
o ver wei g ht or o b esit y ”, v ersi o n 2. 0 (0 6 J a n uar y 2 0 2 1 ). 
S A P Versi o n  
D ate  
C h a n ge  
R ati o n ale  
1. 0  
 
N ot A p plica ble  
Ori gi nal versi o n  
 
 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
4
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
5  of 2 4  
 
 
1  I ntr o d ucti o n 
C ha n ges t o t he pr ot oc ol -pla n ne d a nal yses are d es cri be d i n secti o n  3 . 
1. 1  
Tri al i nf or m ati o n  
1. 1. 1  
O bjecti ves  
1. 1. 1. 1  
Pri m ar y o bjecti ve  
T o c o m pare t h e effect of se ma gl uti de s. c. o nce -wee kl y v ers us se ma gl uti de place b o as a n a dj u nct t o 
a re d uce d -cal orie diet a n d i ncreas e d p h ysical acti vit y o n wei g ht ma na ge m e nt i n a d olesce nts ( a ges 
1 2 t o < 1 8 years) wit h o ver wei g ht or o b esit y.  
1. 1. 1. 2  
Sec o n d ar y o bjecti ves  
T o c o m pare t h e effect of se ma gl uti de s. c. o nce wee kl y v ers us se ma gl uti de place b o as a n a dj u nct t o 
a re d uce d -cal orie diet a n d i ncreas e d p h ys ical acti vit y i n a d olesce nts (a ges 1 2 t o < 1 8 years) wit h 
o ver wei g ht or o b esit y o n:   
•  Car di o vasc ular ris k fact ors   
•  Gl uc ose meta b olis m  
T o c o m pare t h e safet y a n d t olera bilit y of se m a gl uti de s.c. o nce wee kl y vers us se ma gl uti de place b o  
as a n a dj u nct t o a re d uce d -cal orie di et a n d i ncreas e d p h ysic al acti vit y i n a d olesce nts wit h  
o ver wei g ht or o b esit y.  
1. 1. 1. 3  
E x pl or at or y o bjecti ves  
T o c o m pare t h e effect of se ma gl uti de s. c. o nce wee kl y v ers us se ma gl uti de place b o as a n a dj u nct t o  
a re d uce d -cal orie diet a n d i ncreas e d p h ysical acti vit y i n a d olesce nts (a ges 1 2 t o < 1 8 years) wit h  
o ver wei g ht or o b esit y o n:   
•  Cli nical O utc o me Assess me nts ( C O As)  
T o c o m pare a d diti o nal safet y a n d t olera bilit y of se ma gl uti de s.c. o n ce wee kl y vers us s e ma gl uti de  
place b o as a n a dj u nct t o a re d uce d -cal orie d iet a n d i ncreas e d p h ysical acti vit y i n a d olesce nts wit h 
o ver wei g ht or o b esit y.  
1. 1. 2  
Esti m a n ds  
1. 1. 2. 1  
Pri m ar y esti m a n d  
T he esti ma n d will q ua ntif y t he a vera ge tr eat me nt differe n ce of se ma gl uti de relati ve t o se ma gl uti de  
place b o after 6 8 wee ks, as a n a dj u nct t o a re d uce d -cal orie di et a n d i ncrease d p h ysical acti vit y, i n all  
ra n d o mise d s u bjects re gar dless of a d here nce t o treat me nt or i nitiati o n of resc ue i nter ve nti o ns 
( wei g ht ma na ge m e nt dr u gs or b ariatric s ur ger y) (“effecti ve ness”/ “treat me nt p olic y” esti ma n d). T he 
esti ma n d will c o ver all effect -relate d o bjecti ves. 
T he f oll o wi n g e x pa nsi o n of t he pri mar y esti ma n d will c o ver t he e x pl orat or y e n d p oi nt “ C ha n ge i n  
b o d y mass i n de x fr o m baseli ne ( wee k 0) t o wee k 5 2 ( %)”. T h e esti ma n d will q ua ntif y t he a v era ge  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
5
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
6  of 2 4  
 
 
treat me nt effect of s e magl uti de relati ve t o se ma gl uti de place b o after 5 2 wee ks, as a n a dj u nct t o a  
re d uce d-cal orie diet a n d i ncreas e d p h ysical acti vit y, i n all ra n d o mise d s u bj ects re gar dless of  
a d here n ce t o treat me nt or i nitiati o n of resc ue i nter ve nti o ns.   
T he f oll o wi n g e x pa nsi o n  of t he pri mar y esti ma n d will c o ver t he e x pl orat or y e n d p oi nt “ C ha n ge i n  
b o d y mass i n de x fr o m baseli ne ( wee k 0) t o wee k 7 5 ( %)”. T h e esti ma n d will q ua ntif y t he a v era ge  
treat me nt effect of s e ma gl uti de relati ve t o se ma gl uti de place b o after 7 5 wee ks, as a n a dju nct t o a  
re d uce d-cal orie diet a n d i ncreas e d p h ysical acti vit y, i n all ra n d o mise d s u bj ects re gar dless of  
a d here n ce t o treat me nt or i nitiati o n of resc ue i nter ve nti o ns.   
1. 1. 2. 2  
Sec o n d ar y esti m a n d  
T he esti ma n d will q ua ntif y t he a vera ge tr eat me nt differe n ce of se ma gl uti de relati ve t o se ma gl uti de  
place b o after 6 8 wee ks, as a n a dj u nct t o a re d uce d -cal orie di et a n d i ncrease d p h ysical acti vit y, i n all  
ra n d o mise d s u bjects ha d t he y re mai ne d o n t heir ra n d o mise d treat me nt f or t he e ntire pla n ne d 
d urati o n of t he trial a n d n ot s tarte d a n y res c ue i nter ve nti o n ( wei g ht ma na ge me nt dr u gs or bariatri c 
s ur ger y) (“efficac y”/” h y p ot hetical” esti ma n d). T h e esti ma n d will c o ver t he pri mar y o bjecti ve.  
1. 1. 3  
E n d p oi nt s 
1. 1. 3. 1  
Pri m ar y e n d p oi nt  
E n d p oi nt title  
Ti me fra me  
U nit  
C ha n ge i n B MI  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
%  
1. 1. 3. 2  
C o nfir m at or y s ec o n d ar y e n d p oi nts  
E n d p oi nt title  
Ti me fra me  
U nit  
A c hie vi n g ≥5 % re d ucti o n of b o d y wei g ht  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
 
1. 1. 3. 3  
S u p p orti ve sec o n d ar y e n d p oi nts  
Effect e n d p oi nts:  
E n d p oi nt title  
Ti me fra me  
U nit  
C ha n ge i n  b o d y wei g ht  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
k g  
C ha n ge i n b o d y wei g ht  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
%  
C ha n ge i n B MI perce nta ge of t he 9 5 t h perce ntile o n 
ge n der a n d a ge -s pecific gr o wt h c harts ( C D C. g o v) 1 
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
%  
C ha n ge i n B MI (sta n dar d de vi ati o n sc ore) ( W H O.i nt) 2 
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n waist circ u mfere nc e  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
c m 
C ha n ge i n  s yst olic bl o o d press ure 
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
m m H g  
C ha n ge i n  diast olic bl o o d press ure  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
m m H g  
C ha n ge i n  H b A 1c 
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
% p oi nt, m m ol/ m ol  
Ac hie vi n g ≥5 % re d ucti o n of B MI  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
6
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
7  of 2 4  
 
 
E n d p oi nt title  
Ti me fra me  
U nit  
C ha n ge i n fasti n g plas ma gl uc ose  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
m m ol/ L, m g/ d L  
C ha n ge i n fasti n g i ns uli n  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
p m ol/ L, m U/ L  
C ha n ge i n t otal c h olester ol  
Fr o m baseli ne ( wee k 0 ) t o we e k 6 8  
m m ol/ L, m g/ d L  
C ha n ge i n hi g h de nsit y li p o pr otei n ( H D L) c h olester ol  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
m m ol/ L, m g/ d L  
C ha n ge i n l o w de nsit y li p o pr otei n ( L D L) c h olester ol  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
m m ol/ L, m g/ d L  
C ha n ge i n ver y l o w de nsit y li p o pr otei n ( V L D L) 
c h olester ol  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
m m ol/ L, m g/ d L  
C ha n ge i n tri gl yceri des  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
m m ol/ L, m g/ d L  
S afety e n d p oi nts:  
E n d p oi nt title  
Ti me fra me  
U nit  
T reat me nt-e mer ge nt a d verse e ve nts ( T E A Es)  
Fr o m  baseli ne ( wee k 0) t o we e k 7 5   
C o u nt of s u bj ect  
T reat me nt-e mer ge nt seri o us a d verse e ve nts ( S A Es)  
Fr o m  baseli ne ( wee k 0) t o we e k 7 5  
C o u nt of s u bj ect  
C ha n ge i n p ulse  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
b p m  
C ha n ge i n a m ylase  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
U/ L  
C ha n ge i n li pase  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
U/ L  
C ha n ge i n calcit o ni n  
Fr o m  baseli ne ( wee k 0) t o we e k 6 8  
n g/ L  
C ha n ge i n A L T  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
U/ L  
1. 1. 3. 4  
E x pl or at or y e n d p oi nts  
Effect e n d p oi nts : 
E n d p oi nt title  
Ti me fra me  
U nit  
C ha n ge i n  B MI  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
k g/ m 2 
C ha n ge i n H O M A -B  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
%  
C ha n ge i n H O M A -I R 
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore  
C ha n ge i n I W Q O L -Ki ds p h ysical c o mf ort  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n I W Q O L -Ki ds b o d y estee m  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n I W Q O L -Ki ds s ocial life  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n I W Q O L -Ki ds fa mil y -relati o ns  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge  i n I W Q O L-Ki ds t otal  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
Ac hie vi n g ≥1 0 % re d ucti o n of b o d y wei g ht  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
C ha n ge i n B MI  
Fr o m baseli ne ( wee k 0) t o we e k 5 2  
%  
C ha n ge i n B MI  
Fr o m baseli ne ( wee k 0) t o we e k 7 5  
%  
S afety e n d p oi nts f or a d olesce nts wit h T 2 D:  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
7
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
8  of 2 4  
 
 
E n d p oi nt title  
Ti me fra me  
U nit  
Treat me nt -e mer ge nt se vere or bl o o d gl uc ose c o nfir me d 
s y m pt o matic h y p o gl ycae mia e pis o des 
Fr o m baseli ne ( wee k 0) t o we e k 7 5   
C o u nt of s u bj ect  
Treat me nt -e mer ge nt h y p o gl yc ae mic e pis o des acc or di n g  
t o A D A/I S P A D classificati o n ( b ot h t he 2 0 1 43 a n d t he  
2 0 1 8 4 defi niti o n)  
Fr o m baseli ne ( wee k 0) t o we e k 7 5  
C o u nt of s u bj ect  
Treat me nt -e mer ge nt h y p o gl yc ae mic e pis o des acc or di n g  
t o N o v o N or dis k classificati o n 
Fr o m baseli ne ( wee k 0) t o we e k 7 5  
C o u nt of  s u bj ect 
S afety a ssess me nts: 
E n d p oi nt title  
Ti me fra me  
U nit  
Occ urre nce of a nti -se ma gl uti d e a nti b o dies 
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
Occ urre nce of a nti -se ma gl uti d e a nti b o dies 
Fr o m baseli ne ( wee k 0) t o we e k 7 5  
C o u nt of s u bj ect  
C ha n ge i n b o ne a ge assess me nt, x -ra y 
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
years  
C ha n ge i n electr ocar di o gra m ( E C G) 
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
C ha n ge i n la b orat or y para met ers  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
 
C ha n ge i n p u bertal stat us ( T a n ner sta gi n g)  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
C ha n ge i n hei g ht (sta n dar d de viati o n sc ore) ( W H O.i nt) 
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n me ntal healt h assesse d b y C ol u m bia 
S uici dalit y  Se verit y Rati n g Sc ale ( C -S S R S)  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n P atie nt Re p orte d Healt h Q uesti o n naire 9 
( P H Q-9)  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
Sc ore p oi nts  
C ha n ge i n o p ht hal m ol o gical e val uati o n (f or s u bj ects 
wit h T 2 D)  
Fr o m baseli ne ( wee k 0) t o we e k 6 8  
C o u nt of s u bj ect  
P h ar m ac o ki netic  a n alysis  
T he p har mac o ki netic a n al ysis will be d o ne as me nti o ne d i n t he pr ot oc ol secti o n 1 0. 4.  
1. 1. 4  
T y pe of tri al  
T his is a 6 8 -wee k, ra n d o mise d, t w o -ar m, d o u ble-bli n de d, m ulti -ce ntre cli nical trial c o m pari n g 
se ma gl uti de s. c. 2. 4 m g o nce-w ee kl y wit h se ma gl uti de place b o i n a d oles ce nts wit h o ver wei g ht or 
o besit y .  
T he trial desi g n is pr o vi de d i n t he pr ot oc ol, secti o n 5. 
1. 2  
Sc o pe of t he st atistic al a n al ysis pl a n  
T his statistical a nal ysis pla n ( S A P) is base d o n t he u p date d pr ot oc ol f or trial N N 9 5 3 6 -4 4 5 1 “ Effect 
a n d safet y of s e ma gl uti de 2. 4 m g o n ce wee kl y o n wei g ht ma n a ge me nt i n a d olesce nts wit h 
o ver wei g ht or o b esit y”, v ersi o n  2. 0 ( 0 6 J a n uar y 2 0 2 1) a n d i ncl u des m ore d etaile d pr oce d ures f or  
e x ec uti n g t he statistical a nal yses.  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
8
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
9  of 2 4  
 
 
2  St atistic al c o nsi d er ati o ns  
2. 1  
St atistic al h y p ot heses  
T he tests of s u peri orit y of s.c. se ma gl uti de 2. 4 m g t o se ma gl uti de place b o f or t he pri mar y a n d 
c o nfir mat o r y sec o n dar y e n d p oi nts are perf or me d usi n g a fi x e d-se q u e nce statistical strate g y.  
T his strate g y t ests t he e n d p oi nts usi n g a pre d efi ne d hierarc hical or d er; first t he pri mar y e n d p oi nt  
c ha n ge i n B MI ( %) fr o m baseli ne ( wee k 0) t o wee k 6 8 is teste d at a si g nifi ca nce le vel of 5 %. If 
s u peri orit y of s.c. se ma gl uti de 2. 4 m g t o se ma gl uti de placeb o is n ot c o nfir me d, t he n t he testi n g will 
st o p. If s u p eri orit y is c o nfir me d (t w o-si de d p-val u e < 5 %) , t h e test of t he c o nfir mat or y sec o n d ar y 
e n d p oi nt s u bjects ac hie vi n g ≥5 % re d ucti o n of b o d y wei g ht will be perf or m e d.  
2. 2  
S a m ple size deter mi n ati o n  
T he trial is desi g n e d wit h a n effecti ve p o wer of 9 0 % a n d 7 2 % t o detect differe nces o n t he pri mar y 
e n d p oi nt a n d c o nfir mat or y sec o n dar y e n d p oi nt, res pecti vel y.  T he effecti ve p o wer was  calc ul ate d 
u n der t he ass u m pti o n of i n de pe n de n ce of e n d p oi nts b y m ulti pl yi n g t he res pecti ve  mar gi nal p o wers 
s uccessi vel y w hic h is a c o nser vati ve a p pr oac h.  
T he ass u m pti o ns  f or t hes e calc ul ati o ns are c o ns er vati vel y b ase d o n fi n di n gs fr o m t he s.c. 
se ma gl uti de 0. 1 m g a n d 0. 2 m g o nce dail y ar ms i n trial N N 9 5 3 6 -4 1 5 3  a n d  are prese nte d i n T a ble  1 . 
I n t he a nal ysis a p pr oac h a d dressi n g t he pri mar y esti ma n d, wee k 6 8 assess me nts fr o m retrie v e d 
s u bjects are i ncl u d e d. T h ese data are als o use d t o i m p ute missi n g meas ure m e nts at wee k 6 8 f or n o n -
retrie ve d s u bjects. T he i m p utati o n is d o ne se paratel y wit hi n eac h treat me nt ar m. H o we v er, f or t h e 
sa m ple siz e calc ulati o ns, missi n g val ues re gar dless of treat me nt ar m are ass u me d t o be si milar t o 
se ma gl uti de place b o s u bj ects. T hese ass u m pti o ns are li kel y c o ns er vati ve wit h res pect t o t he p o wer 
a n d c orres p o n d t o t he j u m p t o refere nce s e nsiti vit y a n al ysis d escri be d b el o w.  
T a ble  1  
Ass u m pti o ns, m ar gi n al p o wer a n d effecti ve p o wer f or e ac h e n d p oi nt i n t he 
hier arc hic al testi n g pr o ce d ure gi ve n a n a ntici p ate d n u m ber of 1 9 2  r a n d o mise d 
s u bjects 
Or der  E n d p oi nt  
Ass u me d me a n ( ± S D) or pr o p orti o n 
f or c o m pleters 
E x pecte d * 
me a n ( ±S D)  or 
pr o p orti o n  
E x pecte d *  
differe nce or 
pr o p orti o n  
r ati o 
M ar gi n al 
p o w er  
( %) 
Effecti ve 
p o w er  
( %) 
Se ma gl uti de  2. 4 
m g  
Se ma gl uti de 
place b o  
1  
C ha n ge i n 
B MI ( %)  
1 0. 5 ( ± 1 0 ) 
3 ( ± 1 0)  
8. 5 ( ± 1 1)  
5. 5 % -p oi nts  
9 0  
9 0  
2  
5 %  B W  
res p o n ders 
7 1 %  
4 2 %  
6 3 %  
1. 5  
8 0  
7 2  
* Acc o u nti n g f or re d uce d treat me nt effect a m o n g n o n -c o m pl eters 
All a b o ve o utli ne d sa m ple siz e a n d p o wer c o nsi derati o ns are f or t he pri mar y esti ma n d f or t he 
pri mar y e n d p oi nt or t he c o nfir mat or y sec o n d ar y e n d p oi nts (treat me nt p olic y  strat e g y). It is ass u me d 
that u p t o 3 5 % of s u bjects disc o nti n ue per ma ne ntl y a n d 5 0 % of t hes e are  retrie ve d at wee k 6 8. A n y  
s u peri orit y c o ncl usi o ns will be base d o n t he pri m ar y esti ma n d.  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
9
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 0  of 2 4  
 
 
F urt her ass u m pti o ns f or t he sa m ple siz e calc ulati o ns are  t hat t he si g nifica nce le vel is 5 %, a n d t hat 
s u bjects are ra n d o mise d i n a 2: 1 rati o t o se ma gl uti de or se ma gl uti de place b o . T he p o wer 
calc ulati o ns f or c o nti n u o us e n d p oi nts are bas e d o n a t -test o n t he mea n differe n ce ass u mi n g e q u al 
varia nces w hereas f or t he cate g orical e n d p oi nt it is base d o n  t he Pears o n c hi-s q uare test f or t w o 
i n de pe n de nt pr o p orti o ns. 
All s u bjects i n t he se ma gl uti de place b o ar m are ass u me d t o ha ve sa me effect as s u bjects w h o 
c o m plete t he trial o n se m a gl uti de pla ce b o . Retrie v e d s u bjects i n t he se ma gl uti de ar m are ass u me d t o 
ha ve a n effect c orres p o n di n g t o half t he treat me nt differe n ce (c o m pare d t o se ma gl uti de place b o) of 
s u bjects w h o c o m plete t h e trial o n se ma gl uti de. I n t he se ma gl uti de ar m, n o n -retrie v e d s u bjects a n d 
s u bjects wit h data missi n g o n ra n d o mise d treat me nt are ass u me d t o ha ve a n effect c orres p o n di n g t o 
t he se ma gl uti de place b o ar m . 
2. 3  
Defi niti o n of a n al ysis sets  
T w o a nal ysis sets are defi ne d:  
T he f ull a n alysis set ( F A S) i ncl u d es all ra n d o mise d s u bjects acc or di n g t o t h e i nte nti o n-t o-treat 
pri nci ple.  
T he s afety a n alysis set ( S A S) i n cl u des all ra n d o mise d s u bjects e x p ose d t o at least o ne d ose of 
ra n d o mise d treat me nt. 
A n y o bs er vati o n e x cl u de d fr o m t he a nal ysis data base will be d oc u me nte d b ef ore d ata bas e l oc k wit h 
t he reas o n f or e x cl usi o n pr o vi de d. 
T w o o bser vati o n peri o ds are d efi ne d f or eac h s u bject:  
•  I n-trial: T he i n-tri al peri o d is defi ne d as t he u ni nt err u pte d ti me i nter val fr o m date of 
ra n d o misati o n t o date of last c o ntact wit h trial site 
•  O n -treat me nt ( wit h trial pr o d uct): A ti me-p oi nt is c o nsi dere d as ‘ o n -tr eat m e nt’ if a n y dose of 
trial pr o d uct has bee n a d mi nistere d wit hi n t he pri or 2 wee ks ( 1 4 da ys). T he o n -tre at me nt peri o d 
is defi ne d as all ti mes w hic h are c o nsi dere d o n-treat me nt 
•  I n ge neral, t he o n-tr eat m e nt peri o d will t heref ore be fr o m t he dat e of first trial pr o d uct 
a d mi nistrati o n t o date of last trial pr o d uct a d mi nistrati o n e x cl u di n g p ote ntial off -tr eat me nt 
ti me i nter vals tri g gere d b y at least t w o c o nsec uti ve misse d d oses 
•  F or t he e val uati o n of A Es a n d h y p o gl ycae mic e pis o des t he la g ti me f or eac h o n -treat me nt 
ti me i nter val is 7 wee ks ( 4 9 da ys) 
T he i n -trial a n d o n-tr eat me nt peri o ds defi ne t he patie nt years of o bs er vati o n ( P Y O) a n d patie nt 
years of e x p os ure ( P Y E), res pecti vel y, as t he t otal ti me d urati o n i n t he peri o ds.  
2. 4  
St atistic al a n al yses  
2. 4. 1  
Ge ner al c o nsi der ati o ns  
T he last a v aila ble a n d eli gi ble o bser vati o n at or bef ore ra n d o misati o n is use d as t he baseli ne v al ue. 
If n o assess me nts are a v aila ble, t he mea n val ue at ra n d o misati o n acr oss all s u bjects is use d as t he 
baseli ne val ue.  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 0
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 1  of 2 4  
 
 
2. 4. 2  
Pri m ar y e n d p oi nt  
Defi niti o n of pri mar y e n d p oi nt %  c ha n ge i n B MI.  
C ha n ge fr o m bas eli ne t o wee k 6 8 i n B MI ( %) is defi ne d as:  
% c ha n ge i n B MI = ( B MI at wee k 6 8 –  B MI at baseli ne)
B MI at baseli ne
 × 1 0 0.  
A n al yses a d dressi n g t he pri m ar y esti m a n d  
T he f oll o wi n g statistical a nal ys es a n d i m p utati o n met h o ds are desi g ne d t o a d dress t he pri mar y 
esti ma n d, i.e. t o assess t he effecti ve n ess of se ma gl uti de 2. 4 m g.  
T he a nal ysis m o del f or % c ha n ge i n B MI is a li n ear re gressi o n ( A N C O V A) of % c ha n ge i n B MI o n 
ra n d o mise d treat me nt a n d stratificati o n gr o u p ( ge n der * Ta n n er stage gr o u p) as fact ors, a n d b aseli ne 
B MI ( k g/ m 2) as c o v ariate. T he esti mate d treat me nt differe n ce b et wee n s. c. s e ma gl uti de 2. 4 m g a n d 
se ma gl uti de place b o will be re p ort e d t o get her wit h t he ass ociate d t w o-si d e d 9 5 % CI a n d 
c orres p o n di n g p -v al ue.  
T he s u peri orit y tests of s e ma gl uti de 2. 4 m g vs. se ma gl uti de place b o will be carrie d o ut as f oll o ws.  
Let μ se ma gl uti de a n d μ se ma gl uti de place b o de n ote t he tr ue mea n of % c ha n ge i n B MI f or s.c. se m a gl uti de 2. 4 
m g a n d s e ma gl uti de place b o gr o u p, res p ecti vel y. T he n ull a n d al ter n ati ve h y p ot hes es teste d are 
𝐻: 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒≥𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒 𝑝𝑙𝑎𝑐𝑒𝑏𝑜 𝑣𝑠
𝐻𝐴:𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒< 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒 𝑝𝑙𝑎𝑐𝑒𝑏𝑜.  
T he h y p ot h esis will be rejecte d a n d s u peri orit y clai me d, if t he u p per li mit of t he esti mate d t w o -
si de d 9 5 % CI is b el o w 0. 
T a x o n o m y of w ee k 6 8 assess me nts bei n g a v ail a ble or missi n g  
F or eac h s u bject a gi ve n assess me nt at wee k 6 8 ma y b e a v aila ble or missi n g a n d T a ble  2  des cri bes 
t he ta x o n o m y f or t his. N ote, t his is d o ne per assess me nt n ot per s u bject; s u bjects ma y b e a differe nt 
t y pe f or differe nt ass ess me nts (a s u bject ma y ha v e “a v aila ble o n treat me nt ( A T)” f or wei g ht b ut 
“ missi n g o n treat me nt ( M T)” f or waist circ u mf ere nce).  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 1
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 2  of 2 4  
 
 
T a ble  2  
T a x o n o m y f or s u bjects b ase d o n wee k 6 8 assess me nts bei n g a v ail a ble or missi n g  
Assess me nt  
at wee k 6 8  
O n 
r a n d o mise d 
tre at me nt 
at wee k 6 8  
T y pe descri pti o n  
T y pe  
A b bre vi ati o n  
A vaila ble  
Yes  
A v ail a ble o n r a n d o mise d tre at me nt : 
S u bjects w h o c o m plete t he trial o n ra n d o mise d 
treat me nt wit h a n assess me nt at wee k 6 8: I n cl u des t h ose 
t hat st o p a n d restart trial pr o d uct. 
A T  
N o  
A v ail a ble b ut disc o nti n ue d   
S u bjects w h o disc o nti n ue d ra n d o mise d treat me nt 
pre mat urel y b ut r et ur ne d t o ha ve a n ass ess me nt at wee k 
6 8. T hese are als o c alle d retrie ve d s u bjects  
A D  
Missi n g  
Yes  
Missi n g o n r a n d o mise d tre at me nt : 
S u bjects w h o c o m plete t he trial o n ra n d o mise d 
treat me nt wit h o ut a n assess me nt at wee k 6 8: I ncl u des 
t h ose t hat st o p a n d restart trial pr o d uct. 
M T  
N o  
Missi n g a n d disc o nti n ue d : 
S u bjects w h o disc o nti n ue d ra n d o mise d treat me nt 
pre mat urel y a n d di d n ot ret ur n t o ha ve a n assess m e nt at 
wee k 6 8. T hes e are als o calle d n o n -retrie ve d s u bj ects 
M D  
H a n dli n g of missi n g week 6 8 v al ues f or t he pri m ary esti m a n d  
All a vaila ble data at wee k 6 8 ( A T a n d A D) are us e d a n d missi n g val u es ( M T a n d M D) at w ee k 6 8 
will be i m p ute d. Se veral a p pr oac h es f or i m p utati o n will be a p plie d. First, a descri pti o n of t he 
pri mar y i m p utati o n a p pr oac h t o a d dress t he pri mar y esti ma n d f or t he  pri mar y e n d p oi nts is gi ve n 
f oll o we d b y a des cri pti o n of t he se nsiti vit y a nal ys es use d t o assess t he r o b ust ness of t he pri mar y 
a nal ysis res ults. T he se nsiti vit y a n al ys es i n vesti gat e h o w ass u m pti o ns o n B MI d e vel o p me nt aft er 
disc o nti n uati o n of ra n d o mise d tre at me nt i m pact t he esti mate d treat me nt c o ntrasts bet wee n s. c. 
se ma gl uti de 2. 4 m g a n d s e ma gl uti de place b o. A n ill ustrati o n of all i m p utati o n a p pr oac h es f or t h e 
pri mar y  esti ma n d is gi v e n i n Fi g ure  1 . 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 2
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 3  of 2 4  
 
 
 
Fi g ure  1  
Ill ustr ati o n of i m p ut ati o n a p pr o ac hes f or t he effecti ve ness esti m a n d  
P ri m ary i m p ut ati o n a p pr o ac h f or t he pri m ary esti m a n d 
M ulti ple i m p ut ati o n a p pr o ac h usi n g retrieve d s u bj ects ( R D-MI):  T he pri mar y i m p utati o n a p pr o ac h 
f or t he pri mar y esti ma n d is a m ulti ple i m p utati o n si milar t o t he o ne descri be d b y Mc E v o y5. 
Missi n g B MI me as ure m e nts at wee k 6 8 f or n o n -retrie ve d s u bjects ( M D) are i m p ute d usi n g 
assess me nts fr o m retrie v e d s u bjects ( A D) i n eac h ra n d o mise d treat me nt ar m. T his will be d o ne 
acc or di n g t o t he ti mi n g of last a vaila ble o bser vati o n d uri n g t he o n -treat me nt peri o d ( L A O-O T) of 
B MI. Missi n g B MI me as ure me nts at wee k 6 8 f or s u bjects o n ra n d o mise d treat me nt ( M T) are 
i m p ute d b y sa m pli n g fr o m a vaila ble meas ure me nts at wee k 6 8 fr o m s u bjects o n ra n d o mise d 
treat me nt ( A T) i n t he rel e va nt ra n d o mise d tr eat m e nt ar m. T he m ulti ple i m p utati o n a p pr oac h is d o n e 
in t hree ste ps:  
1.  I m p ut ati o n: Defi nes a n i m p utati o n m o del usi n g retrie ve d s u bjects ( A D) fr o m F A S a n d d o ne 
wit hi n gr o u ps defi ne d b y ra n d o mi se d treat me nt . T he m o del will be a li near re gressi o n of B MI 
( k g/ m2) at wee k 6 8 o n stratificati o n gr o u p ( ge n d er * Ta n ner stage gr o u p) as a fact or a n d bas eli ne 
B MI ( k g/ m 2), ti mi n g of L A O-O T of B MI ( k g/ m 2) a n d L A O -O T of B MI ( k g/ m 2) as c o variates. 
N o i nteracti o ns will be i n cl u de d. If a n y s u bjects are M T, a n i m p utati o n m o del f or missi n g B MI 
meas ure me nts at w ee k 6 8 f or M T s u bjects w ill als o be defi ne d usi n g A T s u bjects i n a si milar 
wa y. T he esti mate d p osteri or distri b uti o n f or t he para meters (re gressi o n c o efficie nts a n d 
varia nces) i n t he i m p utati o n m o dels are t he n use d t o i m p ute missi n g wee k 6 8 B MI val u es f or 
eac h ra n d o mise d treat me n t ar m. T his will be d o ne 1 0 0 0 ti mes a n d res ult i n 1 0 0 0 c o m plete data 
sets 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 3
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 4  of 2 4  
 
 
2.  A n al ysis : A nal ysis of eac h of t he 1 0 0 0 c o m plete data sets, usi n g t he a nal ysis m o del 
( A N C O V A), res ulti n g i n 1 0 0 0 esti mati o ns 
3.  P o oli n g : I nt e grate t h e 1 0 0 0 esti mati o n res ults i nt o a fi nal res ult usi n g R u bi n’s f or m ula 
Base d o n N N 9 5 3 6 -4 1 5 3 p hase 2 res ults 1, 0 0 0 c o pies s h o ul d be s ufficie nt t o esta blis h sta ble res ults. 
If 1, 0 0 0 c o pies are i ns ufficie nt, 1 0, 0 0 0 c o pies will be use d. T he m ulti ple i m p utati o ns will be 
ge n erat e d usi n g N o v o N or di s k trial n u m ber 9 5 3 6 4 4 5 1 as see d n u m ber. 
Se nsitivity a n alyses  
J u m p t o refere n ce m ulti ple i m p ut ati o n a p pr o ac h (J 2 R -MI):  Missi n g v al ues of B MI at wee k 6 8 ( M T 
a n d M D) f or b ot h t he s e ma gl uti de 2. 4 m g a n d se ma gl uti de place b o gr o u p is b y sa m pli n g a m o n g all 
a vail a ble ass ess me nts at wee k 6 8 i n t he se ma gl uti de place b o gr o u p ( A T a n d A D). T his a p pr o ac h 
ma kes t he ass u m pti o n t hat s u bjects i nsta ntl y after disc o nti n uati o n l ose a n y effect of ra n d o mise d 
treat me nt be y o n d w h at c a n be e x pecte d fr o m se m a gl uti de place b o tr eat me nt as a dj u nct t o diet a n d 
p h ysical acti vit y 5. T he m ulti ple i m p utati o n a p pr oac h is d o ne as a b o v e wit h t he first ste p re place d 
b y:  
1.  I m p ut ati o n: Defi nes a n i m p utati o n m o del usi n g se ma gl uti de place b o s u bjects fr o m F A S wit h a 
wee k 6 8 me as ure me nt ( A T a n d A D). T he m o del will be a li near re gressi o n of B MI ( k g/ m 2) at 
wee k 6 8 o n stratificati o n gr o u p ( ge n der * Ta n n er st a ge gr o u p) as a fact or a n d baseli ne B MI 
( k g/ m2) as c o v ariate. N o i nteracti o ns will be i ncl u de d. T he esti mate d p osteri or distri b uti o n f or 
t he para met ers (regressi o n c oeffi cie nts a n d varia n ces) i n t he i m p utati o n m o dels are t he n us e d t o 
i m p ute missi n g wee k 6 8 B MI val u es f or eac h ra n d o mise d treat me nt ar ms. T his will be d o ne 
1 0 0 0 ti mes a n d res ult i n 1 0 0 0 c o m plete data sets.  
T he j u m p t o refere nce a p pr oac h is t he b asis f or t he sa m ple siz e calc ulati o ns.  
Ti p pi n g -p oi nt m ulti ple i m p ut ati o n a n alysis ( T P -MI):  T his a nal ysis will be perf or me d o nl y if 
s u peri orit y is c o n cl u de d wit h res pect t o t he pri mar y e n d p oi nt. First, missi n g dat a are i m p ute d 
acc or di n g t o t he pri mar y m ult i ple i m p utati o n a p pr oac h. T he n, a pe nalt y is a d de d t o t he i m p ute d 
val ues at wee k  6 8. T he a p pr oac h is t o e x pl ore a ra n ge of pe nalties f or b ot h treat me nt gr o u ps, a n d 
t he i m pact t hese w o ul d h a ve o n t he st u d y c o ncl usi o ns. T he 2 -di me nsi o nal s pace of pe nalties 
co veri n g t he ra n ge fr o m  -3 0 % t o 3 0 % will be e x pl ore d f or b ot h treat me nt gr o u ps. T his se nsiti vit y 
a nal ysis e val uates t he  r o b ust ness of t he s u peri orit y c o n cl usi o ns t o de part ures fr o m t he o bser ve d 
c ha n ge i n b o d y w ei g ht i n  b ot h treat me nt gr o u ps.  
Excl u di n g s u bje cts fr o m site 
: I n Bel gi u m site  
 w here si x s u bjects were ra n d o mise d it was 
disc o vere d after all si x s u bjects ha d bee n ra n d o mis e d t hat t he sta di o meter was n ot cali brate d. A 
se nsiti vit y a nal ysis of t he pri mar y e n d p oi nt will be perf or me d i n w hic h t hes e si x s u bjects are 
e x cl u de d. 
Mixe d m o del f or re p e ate d me as ure me nts ( M M R M): T his ‘ M M R M f or effecti ve ness’ will use all 
assess me nts re gar dless of a d here n ce t o r a n d o mise d treat me nt, i ncl u di n g assess me nts at wee k 6 8 f or 
retrie ve d dr o p-o uts ( A D). T he M M R M f or eff ecti ve ness will be fitte d usi n g t he sa m e fact or a n d 
c o variate as f or t h e pri mar y a nal yses all nest e d wit hi n visit. A n u nstr uct ure d c o varia n ce matri x f or 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 4
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 5  of 2 4  
 
 
meas ure me nts wit hi n t he sa me s u bject will be e m pl o ye d, ass u mi n g t hat meas ure me nts f or differe nt 
s u bjects are i n de p e n de nt. 
A N C O V A ass u mi n g u ne q u al v ari a nces:  A n alter nati ve a nal ysis m o del si milar t o t he pri mar y 
a nal ysis  m o del ( A N C O V A), f oll o wi n g t h e pri mar y i m p utati o n a p pr oac h ( R D -MI), b ut ass u mi n g 
u ne q ual  varia n ces i nstea d of e q ual varia nces. T he a nal ysis m o del f or % c h a n ge i n B MI is a li near 
re gressi o n ( A N C O V A) of % c ha n ge i n B MI o n ra n d o mise d treat me nt a n d stratificati o n gr o u p 
( ge n der * Ta n ner sta ge gr o u p) as fact ors, a n d b aseli ne B MI ( k g/ m2) as c o v ariate. T he esti mate d 
treat me nt differe nce bet wee n s.c. s ema gl uti de 2. 4 m g a n d s e ma gl uti de place b o will be re p orte d 
t o get her wit h t he ass ociat e d t w o-si de d 9 5 % CI a n d c orres p o n di n g p-v al ue.  
A n al ysis a d dressi n g t he sec o n d ar y esti m a n d  
T he sec o n d ar y esti ma n d f or % c h a n ge i n B MI a d dresses t he efficac y of se ma gl uti de 2 . 4 m g a n d 
will be assesse d usi n g a ‘ M M R M f or efficac y’. W ee k 6 8 assess me nts f or retrie ve d s u bjects ( A D) 
are n ot use d i n t his a nal ysis. T he M M R M f or efficac y will use assess me nts o nl y fr o m s u bjects w h o 
are ta ki n g t he ra n d o mise d treat me nt u ntil e n d of trial or at first disc o nti n uati o n of ra n d o mise d 
treat me nt. T he deri ve d d ate of t he sec o n d c o nsec uti ve misse d d ose will be use d as t he latest date f or 
assess me nts i ncl u de d i n t his M M R M. T he assess me nt cl osest i n ti me a n d bef ore t h e deri ve d d ate of 
t he sec o n d c o nsec uti ve misse d d ose will be use d as last assess me nt o n ra n d o mise d treat me nt. F or 
s u bjects w h o i nitiate resc ue i nter ve nti o ns ( wei g ht ma na ge me nt dr u gs or bariatric s ur ger y) bef ore 
c o m pleti o n or first disc o nti n uati o n of ra n d o mise d treat me nt, t he date of start i n g wei g ht 
ma na ge me nt dr u gs or u n der g oi n g bariatri c s ur ger y will be use d as last assess me nt o n ra n d o mise d 
treat me nt. T he M M R M f or effic ac y will be fitte d usi n g % c h a n ge i n B MI a n d t he sa me fact or a n d 
c o variate as f or t h e pri mar y a nal ysis all neste d wit hi n visit. A n u nstr uct ure d c o varia n ce matri x f or 
meas ure me nts wit hi n t he sa me s u bject will be e m pl o ye d, ass u mi n g t hat meas ure me nts f or differe nt 
s u bjects are i n de p e n de nt. 
2. 4. 3  
Sec o n d ar y e n d p oi nts  
2. 4. 3. 1  
C o nfir m at or y s ec o n d ar y e n d p oi nt  
T he c o nfir mat or y sec o n d ar y e n d p oi nt i s wei g ht l oss ≥5 % at wee k 6 8 ( Yes/ No ) ( ≥5 % b o d y wei g ht 
res p o n der e n d p oi nt), a n d is i ncl u de d i n t he fi x e d-se q ue nce statistical strate g y des cri be d a b o ve.  
A n al ysis a d dressi n g t he pri m ar y esti m a n d  
T he ≥5 % b o d y wei g ht r es p o n der e n d p oi nt will be a nal ys e d usi n g t he sa me i m p utati o n a p pr oac h as 
use d f or t he pri mar y e n d p oi nt a n d t o a d dress t he pri mar y esti ma n d. T he i m p utati o n m o del is t he 
sa me as f or t h e pri mar y e n d p oi nt, wit h B MI re place d b y b o d y wei g ht, a n d t he res ulti n g i m p ute d 
val ues will t he n be dic h ot o miz e d t o deri ve t he res p o n der e n d p oi nt. T he statistical m o del f or t he 
≥5 % b o d y w ei g ht res p o n der e n d p oi nt is a l o gistic re gressi o n usi n g ra n d o mise d treat me nt a n d 
stratificati o n gr o u p ( ge n d er * Ta n n er sta ge gr ou p) as fact ors, a n d bas eli ne b o d y wei g ht ( k g) as a 
c o variate. T he esti mate d o d ds rati o ( O R) bet w ee n se ma gl uti de 2. 4 m g a n d s e ma gl uti de place b o will 
be re p ort e d t o get her wit h t he ass ociate d t w o -si d e d 9 5 % CI a n d c orres p o n di n g p-v al ue.   
T he s u peri orit y tests of s e ma gl uti de 2. 4 m g vs. se ma gl uti de place b o will be carrie d o ut as f oll o ws 
f or t he t w o a n al ysis m o d els. 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 5
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 6  of 2 4  
 
 
Let O R s e ma gl uti de/ place b o de n ote t he tr ue o d ds rati o bet wee n se ma gl uti de 2. 4 m g a n d se ma gl uti de 
place b o. T he n ull a n d alter nati ve h y p ot hes es teste d ar e 
𝐻: 𝜇𝑠𝑒𝑚𝑎𝑔𝑙𝑢𝑡𝑖𝑑𝑒𝜇
𝑠𝑒𝑚𝑎𝑔𝑙𝑢
≤1  𝑡𝑖
𝑑𝑒:𝑝𝑙𝑎𝑐𝑒𝑏𝑜𝑣𝑠𝐻𝐴𝜇𝑠
𝑒𝑚𝑎𝑔𝑙𝑢𝑡
> 1 .  
T he h y p ot h esis will be rejecte d a n d s u peri orit y clai me d, if t he l o wer li mit of t he esti mate d t w o -
si de d 9 5 % CI is a b o ve 1. 
Se nsitivity a n alysis f or t he c o nfir m at ory sec o n d ar y e n d p oi nt : A se nsiti vit y a nal ysis c o nsi deri n g 
n o n -retrie v e d s u bjects as n o n-res p o n ders will be carrie d o ut. 
A n al yses a d dressi n g t he sec o n d ar y esti m a n d  
T he sec o n d ar y esti ma n d f or t he ≥5 % b o d y wei g ht res p o n der e n d p oi nt will be assesse d usi n g t he 
sa me M M R M as f or t he pri mar y e n d p oi nt. S u bjects w h o are missi n g wee k 6 8 b o d y wei g ht will be 
re place d b y pre di cte d val ues f or % w ei g ht c ha n ge at wee k 6 8 fr o m t he M M R M, a n d t hese pre dict e d 
val ues will t he n be dic h ot o miz e d t o deri ve t he res p o n der e n d p oi nt. A l o gistic re gressi o n m o del wit h 
ra n d o mise d treat me nt as a fact or a n d bas eli ne b o d y wei g ht ( k g) as a c o variate will t he n be use d t o 
a nal ys e t he 5 % res p o n der e n d p oi nt.  
F or all a n al ys es of res p o n der e n d p oi nt s (≥5 % b o d y wei g ht re d ucti o n, ≥1 0 % b o d y wei g ht re d u cti o n, 
a n d ≥5 % B MI  re d u cti o n), i n a d diti o n t o t he esti mate d O R, t he esti mate d treat me nt differe nces 
(E T D s) will be pr o vi de d b y calc ulati n g t he res p o n der pr o ba bilities a n d tr eat me nt differe n ces 
bet wee n res p o n der pr o ba bilities base d o n t he l o gistic re gressi o n m o del, wit h c o nfi de nce i nter vals 
f or treat me nt differe nces o btai ne d usi n g t he delta met h o d. 
A n o ver vie w of all a nal ysis a n d i m p utati o n met h o ds t o a d dress t he effecti ve ness a n d efficac y 
esti ma n ds f or t he pri mar y a n d c o nfir mat or y s ec o n dary e n d p oi nt is gi v e n i n  Ta ble  3 . 
T a ble  3  
A n al ysis a n d i m p ut ati o n met h o ds t o a d dress t he effecti ve ness a n d effic ac y 
esti m a n ds f or t he pri m ar y a n d c o nfir m at or y s ec o n d ar y e n d p oi nts i n t he 
st atistic al testi n g hier arc h y 
O bjecti ve  
E n d p oi nt  
Test 
or der  
E n d p oi nt 
t y pe 
Esti m a n d  
A n al ysis 
set 
St atistic al 
m o del  
I m p ut ati o n 
a p pr o ac h  
Se nsiti vit y 
a n al yses  
Pri m ar y e n d p oi nt  
Pri mar y  
% c ha n ge i n B MI  
1  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
J 2 R-MI  
T P -MI  
E xcl . 
 
M M R M  
U ne q ual 
varia nce  
Sec o n dar y  
F A S  
M M R M  
- 
- 
C o nfir m at or y sec o n d ar y e n d p oi nt  
Pri mar y  
≥5 % b o d y wei g ht 
res p o n ders 
2  
Bi n ar y  
Pri mar y  
F A S  
L R  
R D -MI  
N o n -
res p o n ders 
Sec o n dar y  
F A S  
L R  
M M R M  
- 
F A S = f ull a nal ysis set; A N C O V A = a nal ysis of c o varia nce; R D -MI = m ulti ple i m p utati o n usi n g retrie ve d s u bjects; J 2 R -MI = j u m p 
t o refere nce m ulti ple i m p utati o n; T P-MI = ti p pi n g p oi nt m ulti ple i m p utati o n; E xcl. 
 = se nsiti vit y a nal ysis e xcl u di n g site  
; 
M M R M = mi xe d m o del f or re peate d meas ure me nts; L R = l o gistic re gressi o n . 
Test or der refers t o t h e or der of t he e n d p oi nt i n t h e statistical test hierarc h y o utli n e d i n Ta ble  1 . 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 6
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 7  of 2 4  
 
 
2. 4. 3. 2  
S u p p orti ve sec o n d ar y e n d p oi nts  
S u p p orti ve sec o n dar y e n d p oi nts are liste d i n secti o n  1. 1. 3. 3 . 
A n al yses a d dressi n g t he pri m ar y esti m a n d  
T he effect -relate d s u p p orti ve sec o n dar y e n d p oi nts will be a nal ys e d usi n g t he sa me i m p utati o n 
a p pr oac h as use d f or t he pri mar y e n d p oi nt a n d t o a d dress t he pri mar y esti ma n d. T he i m p utati o n 
m o del is t he sa me as f or t he pri mar y e n d p oi nt wit h B MI re place d b y assess me nts of t he e n d p oi nt t o 
be a nal yse d. T h e statistical m o del f or c o nti n u o us e n d p oi nts will be A N C O V A wit h fact or a n d 
c o variate as f or t h e pri mar y e n d p oi nt % c ha n ge i n B MI wit h baseli ne B MI re place d b y t h e baseli ne 
assess me nt of t he e n d p oi nt t o be a nal ys e d.  
T he statistical m o del f or t he res p o n der e n d p oi nt relati n g t o B MI will be l o gistic re gressi o n wit h 
ra n d o mise d treat me nt as a fact or a n d t he baseli ne assess me nt of t he e n d p oi nt t o be a nal ys e d as 
c o variat e.  
F or fasti n g i ns uli n , li pi ds a n d A L T, a m ulti plicati ve m o del will be use d, i.e. t he rati o bet wee n p ost 
ra n d o misati o n meas ure m e nts a n d baseli ne will be calc ulate d i nstea d of differe nces, a n d b ot h t he 
de pe n de nt varia ble a n d c o variate will be l o g -tr a nsf or me d.  
A n al yses a d dressi n g t he sec o n d ar y esti m a n d  
T he s u p p orti ve sec o n d ar y e n d p oi nts w hic h relate t o t he pri mar y o bjecti ve will be a nal ys e d t o 
a d dress t he sec o n dar y esti ma n d usi n g t he sa me M M R M f or efficac y d escri be d f or t he pri mar y 
e n d p oi nt. 
A n al ysis of s af e t y e n d p oi nts 
T he safet y e n d p oi nt s p ulse a n d A L T will be a n al yse d usi n g a n M M R M f or efficac y as d escri be d i n 
secti o n 1. 1. 3. 2 . T hese a n al yses will be base d o n t he safet y a nal ysis set. F or a m yl ase, li pase a n d 
calcit o ni n descri pti ve statistics will be pr o vi de d. T he a nal ysis of calcit o ni n will be stratifie d b y 
ge n d er.  
A Es will be defi ne d as “treat me nt -e mer ge nt ” ( T E A E), if t he o nset of t he e ve nt occ urs i n t he o n -
treat me nt peri o d (s ee d efi niti o n i n secti o n 2. 3 ). T E A Es a n d S A Es will be s u m marise d b y d escri pti v e 
statistics, s uc h as fre q ue n cies a n d rates. N o f or mal statistical i nfere nce will be carrie d o ut base d o n 
t he n u m ber of T E A Es a n d S A Es. A Es i n t he r u n-i n peri o d ( pri or t o ra n d o misati o n) will be 
prese nte d i n listi n gs . 
A n o ver vie w of all a nal ysis a n d i m p utati o n met h o ds t o a d dress t he effecti ve ness a n d efficac y 
esti ma n ds f or s u p p orti ve sec o n dar y e n d p oi nts is gi ve n i n  Ta ble  4 . 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 7
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 8  of 2 4  
 
 
T a ble  4  
A n al ysis a n d i m p ut ati o n met h o ds t o a d dress t he effecti ve ness a n d effic ac y 
esti m a n ds f or s u p p orti ve sec o n d ar y e n d p oi nts  
O bjecti ve  
E n d p oi nt  
E n d p oi nt 
t y pe 
Esti m a n d  
A n al ysis 
set 
St atistic al 
m o del  
I m p ut ati o n 
a p pr o ac h  
S u p p orti ve sec o n d ar y e n d p oi nts (effect rel ate d)  
Pri mar y  
W ei g ht c ha n ge ( k g)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
F A S  
M M R M  
- 
Pri mar y  
W ei g ht c ha n ge ( %)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
F A S  
M M R M  
- 
Pri mar y  
B MI perce nta ge of t he 9 5 t h 
perce ntile o n ge n der a n d a ge -
s pecific gr o wt h c harts c ha n ge  
( C D C. g o v) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
F A S  
M M R M  
- 
Pri mar y  
B MI (sta n dar d de viati o n sc ore) 
( W H O.i nt) c ha n ge  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
F A S  
M M R M  
- 
Pri mar y  
W aist circ u mfere nce c ha n ge (c m)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
F A S  
M M R M  
- 
Pri mar y  
Ac hie vi n g ≥5 % re d ucti o n of  B MI  
Bi nar y  
Pri mar y  
F A S  
L R  
R D -MI  
Sec o n dar y  
F A S  
L R  
M M R M  
Sec o n dar y  
S yst olic bl o o d press ure  c ha n ge 
( m m H g) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
Diast olic bl o o d press ure  c ha n ge 
( m m H g) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
H b A 1c c ha n ge ( %, m m ol/ m ol)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
F P G c ha n ge ( m m ol/ L, m g/ d L)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
Fasti n g i ns uli n c ha n ge ( p m ol/ L, 
mI U/ L)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
T otal c h olester ol c ha n ge 
( m m ol/ L, m g/ d L) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
H D L c ha n ge ( m m ol/ L, m g/ d L)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
L D L c ha n ge ( m m ol/ L, m g/ d L)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
V L D L c ha n ge ( m m ol/ L, m g/ d L)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  
Tri gl yceri des c ha n ge ( m m ol/ L, 
m g/ d L)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
S u p p orti ve sec o n d ar y e n d p oi nts (s afet y rel ate d)  
Sec o n dar y  
N u m ber of T E A Es  
C o nti n u o us  
- 
S A S  
- 
- 
Sec o n dar y  
N u m ber of S A Es  
C o nti n u o us  
- 
S A S  
- 
- 
Sec o n dar y  
P ulse c ha n ge ( b p m)  
C o nti n u o us  
- 
S A S  
M M R M  
- 
Sec o n dar y  
A m ylase c ha n ge ( U/ L)  
C o nti n u o us  
- 
S A S  
Descri pti ve 
statistics 
- 
Sec o n dar y  
Li pase c ha n ge ( U/ L)  
C o nti n u o us  
- 
S A S  
Descri pti ve 
statistics 
- 
Sec o n dar y  
Calcit o ni n c ha n ge ( n g/ L)  
C o nti n u o us  
- 
S A S  
Descri pti ve 
statistics 
- 
Sec o n dar y  
A L T c ha n ge ( U/ L)  
C o nti n u o us  
 
S A S  
M M R M  
 
F A S = f ull a nal ysis set; A N C O V A = a nal ysis of c o varia nce; R D -MI = m ulti ple i m p utati o n usi n g retrie ve d s u bjects; M M R M = mi xe d 
m o del f or re peate d meas ure me nts; B MI = b o d y mass i n de x; H b A 1c = He m o gl o bi n A 1c; T E A Es = tre at me nt -e mer ge nt a d verse 
e ve nts; S A Es = seri o us a d verse e ve nts. 
2. 4. 4  
E x pl or at or y e n d p oi nts  
E x pl orat or y e n d p oi nts are liste d i n secti o n 1. 1. 3. 4 . 
A n al yses a d dressi n g t he pri m ar y esti m a n d  
T he effect -relate d e x pl orat or y e n d p oi nts will be a nal yse d usi n g t he s a me i m p utati o n a p pr oac h as 
use d f or t he pri mar y e n d p oi nt a n d t o a d dress t he pri mar y esti ma n d. T he i m p utati o n m o del is t he 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 8
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
1 9  of 2 4  
 
 
sa me as f or t h e pri mar y e n d p oi nt wit h B MI re place d b y assess me nts of t he e n d p oi nt t o be a nal yse d. 
T he statistical m o del f or c o nti n u o us e n d p oi nts will be A N C O V A wit h fact or a n d c o variate as f or 
t he pri mar y e n d p oi nt % c ha n ge i n B MI wit h baseli ne B MI re place d b y t he baseli ne assess me nt of 
t he e n d p oi nt t o be a nal ys e d. 
T he statistical  m o del f or res p o n der e n d p oi nts relati n g t o b o d y wei g ht will be l o gistic re gressi o n 
wit h ra n d o mise d treat me nt as a fact or a n d t he bas eli ne assess me nt of t he e n d p oi nt t o be a nal ys e d as 
c o variate.  
F or H O M A -B a n d H O M A -I R, a m ulti plicati ve m o del will be use d, i.e. t he rati o bet wee n p ost 
ra n d o misati o n meas ure m e nts a n d baseli ne will be calc ulate d i nstea d of differe nces, a n d b ot h t he 
de pe n de nt varia ble a n d c o variate will be l o g -tr a nsf or me d. 
A n al yses a d dressi n g t he sec o n d ar y esti m a n d  
T he e x pl orat or y e n d p oi nts meas u re d at wee k 6 8 w hic h relate t o t he pri mar y o bjecti ve will be 
a nal ys e d t o a d dress t he s ec o n dar y esti ma n d usi n g t he sa me M M R M f or effi cac y d escri be d f or t he 
pri mar y e n d p oi nt.  
A n o ver vie w of all a nal ysis a n d i m p utati o n met h o ds t o a d dress t he effecti ve ness a n d  efficac y 
esti ma n ds f or effect -relat e d e x pl orat or y e n d p oi nts is gi ve n i n Ta ble  5 . 
A n al ysis of s af et y e n d p oi nts  
O bser ve d d ata f or e x pl orat or y s afet y e n d p oi nts a n d ot her safet y assess me nts will be s u m marise d b y 
descri pti ve statistics.  
H y p o gl ycae mic e pis o des will be s u m marise d b y d escri pti ve statistics, s uc h as fre q u e ncies a n d rates. 
N o f or mal statistical i nfere nce will be carrie d o ut base d o n t he n u m ber of h y p o gl ycae mic e pis o des.  
 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
1 9
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
2 0  of 2 4  
 
 
T a ble  5  
A n al ysis a n d i m p ut ati o n  met h o ds t o a d dress t he effecti ve ness a n d effic ac y 
esti m a n ds f or e x pl or at or y e n d p oi nts  
O bjecti ve  
E n d p oi nt  
E n d p oi nt 
t y pe 
Esti m a n d  
A n al ysis 
set 
St atistic al 
m o del  
I m p ut ati o n 
a p pr o ac h  
E x pl or at or y e n d p oi nts (effect rel ate d)  
Pri mar y  
B MI c ha n ge ( k g/ m 2) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  F A S  
M M R M  
- 
Pri mar y  
Ac hie vi n g ≥1 0 % re d ucti o n of 
b o d y wei g ht  
Bi nar y  
Pri mar y  
F A S  
L R  
R D -MI  
Sec o n dar y  F A S  
L R  
M M R M  
Pri mar y  
B MI c ha n ge t o wee k 5 2 ( %)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Pri mar y  
B MI c ha n ge t o wee k 7 5 ( %) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  H O M A -B c ha n ge ( %)  
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  H O M A -I R c ha n ge (sc ore) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  I W Q O L-Ki ds p h ysical c o mf ort  
c ha n ge  (sc ore) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  I W Q O L-Ki ds b o d y estee m  
c ha n ge  (sc ore) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  I W Q O L-Ki ds s ocial life  c ha n ge  
(sc ore) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  I W Q O L-Ki ds fa mil y -relati o ns 
c ha n ge (sc ore) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
Sec o n dar y  I W Q o L-Ki ds t otal c ha n ge 
(sc ore) 
C o nti n u o us  
Pri mar y  
F A S  
A N C O V A  
R D -MI  
F A S = f ull a nal ysis set; A N C O V A = a nal ysis of c o varia nce; R D -MI = m ulti ple i m p utati o n usi n g retrie ve d s u bjects; M M R M = mi xe d 
m o del f or re peate d meas ure me nts; B MI = b o d y mass i n de x; F P G = fasti n g plas ma gl u c ose; H D L = hi g h de nsit y li p o pr otei n; L D L = 
l o w de nsit y li p o pr otei n; V L D L = ver y l o w de nsit y li p o pr otei n; L R = l o gistic re gressi o n; I W Q o L-Ki ds = I m pact of Wei g ht o n Q ualit y 
of Life -Ki ds f or Cli nical Trials; P C D = p h ysical c o mf ort d o mai n; B E D = b o d y estee m d o mai n; S L D = s ocial life d o mai n; F R D = 
fa mil y relati o ns d o mai n. 
2. 4. 5  
Ot her a n al yses  
All c ollecte d data t hat w ere n ot defi ne d as e n d p oi nts will be s u m marise d b y descri pti ve statistics.  
2. 4. 5. 1  
S u b gr o u p a n al yses  
S u b gr o u p a n al ys es of t he pri mar y a n d t he c o nfir m at or y s ec o n d ar y e n d p oi nt will be carri e d o ut 
a d dressi n g b ot h t he pri m ar y a n d t he s ec o n dar y esti ma n d  usi n g t he sa me i m p utati o n a p pr oac h es a n d 
statistical m o dels as use d i n t he a nal ys es of t he pri mar y a n d c o nfir mat or y s ec o n dar y e n d p oi nts . T he 
s u b gr o u ps are d efi ne d i n Ta ble  6 . T he res ults of t he s u b gr o u p a nal ys es will be prese nt e d  wit h 
treat me nt c o ntrasts a n d tr eat me nt-b y -s u b gr o u p i nt eracti o n p-v al ues  i n ta ble f or m a n d f orest pl ots. 
If a treat me nt ar m has l ess t ha n 5 s u bjects wit hi n a s u b gr o u p, t he s u b gr o u p will be mer ge d wit h 
a n ot her, u ntil t he criteri a of at least 5 s u bjects per treat me nt ar m a n d s u b gr o u p is reac h e d. F or  
or dere d s u b gr o u ps (e. g. a ge, b aseli ne B MI ), t he m er gi n g will be d o ne acc or di n g t o t he or der. F or 
u n or dere d s u b gr o u ps (e. g. race, re gi o n), it will be d o n e b y m er gi n g t he s u b gr o u ps wit h  t he l o west 
n u m ber of s u bjects.  
T he res ults of t he s u b gr o u p a nal ys es will be s u b mitte d t o a u t h orities a n d will n ot be re p orte d i n t he 
cli nical trial re p ort.  
T a ble  6  
Defi niti o n of s u b gr o u ps  
S u b gr o u p  
Le v els  
A ge  
1 2 - < 1 5 years; 1 5 - < 1 8 years  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
2 0
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
2 1  of 2 4  
 
 
S u b gr o u p  
Le v els  
Se x  
Fe male; M ale  
Et h nicit y  
 His pa nic or Lati n o; N ot His pa nic or Lati n o  
Race  
W hite; Ot her  
T a n ner sta ge  
2 -3; 4 -5  
B MI  
< 3 5 k g/ m 2; 3 5 - < 4 0 k g/ m 2; ≥4 0 k g/ m2 
Re gi o n  
E ur o pe ( A ustria, B el gi u m, Cr oatia, Irela n d, R ussia n Fe derati o n, U nite d Ki n g d o m );  
N ort h A merica  ( U S A);  
S o ut h A merica  ( Me xic o) 
Re gi o n 2  
U S A; N o n -U S A  
 
2. 5  
E n d p oi nt deri v ati o n met h o ds  
2. 5. 1  
B MI perce nt a ge of t he 9 5 t h perce ntile ( C D C. g o v)  
T he gr o wt h c h arts fr o m t he C D C c o nsist of a series of perce ntile c ur ves t hat ill ustrate t he 
distri b uti o n of selecte d b o d y me as ure me nts i n c hil dre n  fr o m U nites States.  
T he  B MI -f or-a ge refere n ce data a p plies t o c hil dre n a n d a d olesce nts ( 2 -2 0 years).  
I n practice w he n usi n g t h e gr o wt h refere nce data, t he n t he a ge i n m o nt hs is used t o l o o k u p t he 9 5 t h 
perce ntile. E. g. if a s u bject is 1 8 0. 2 m o nt hs w he n bei n g meas ure d, t h e n t he 9 5 t h perce ntile t o be 
use d is o btai ne d fr o m t he 1 8 0. 5 m o nt h refere nce, si nce t his refere n ce c o v ers t he i nter val fr o m 1 8 0 
t o 1 8 0. 9 9 m o nt hs. Acc or di n g t o C D C 1 at a fi ner a ge ca n b e o btai ne d usi n g li near i nter p olati o n.  
He nce, i n  or der t o calc ul ate a n e x act perce nt a ge a b o ve t he 9 5 t h perce ntile  f or a gi ve n a ge i n m o nt hs, 
li near i nter p olati o n of t he 9 5 t h perce ntile  is a p plie d bet wee n t he l o wer 9 5 t h perce ntile  i n m o nt hs a n d 
t he u p per 9 5 t h perce ntile  i n m o nt hs.  
2. 5. 2  
B MI a n d hei g ht S D S ( W H O.i nt)  
T he B MI st a n dar d de viati o n sc ores ( S D S) a n d t he hei g ht S D S sc ore s will be calc ul ate d usi n g 
gr o wt h  refere n ce d ata f or c hil dre n a n d a d ol esce nts ( 5-1 9 years) fr o m W H O2. T he S D S sc ores are 
s o meti mes referre d t o as z-sc ores als o. 
T he z-sc ore f or a s u bject wit h a B MI y at a ge t is gi ve n as:  
𝐻=
( (
𝜇
𝑠(𝑒))
𝑚(𝑎)
−1 )
𝑔(𝑙)𝑢(𝑡)
             𝑖𝑑 |𝑒| ≤3  
w here L , M  a n d S  de pe n d o n se x a n d a ge i n m o nt hs a n d ca n be l o o k e d u p i n t he refere n ce dat a . If 
t he z-sc ore is b et wee n -3 a n d 3  t he n n o a dj ust me nt is nee de d. If t h e z-sc ore is > 3 t he n t he sc ore is 
a dj uste d as f oll o ws:  
𝜇= 3 + ( 𝑠−𝑒𝑚3 𝑎𝑔𝑙
𝑢𝑡2 3  𝑖𝑑𝑒)              𝑝𝑙 𝑎> 3  
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
2 1
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
2 2  of 2 4  
 
 
w here S D 3 p os  is t he c ut-off 3 S D calc ul ate d at t b y t he L M S met h o d 2: 
𝐻𝜇3 𝑠𝑒𝑚= 𝑎(𝑔) ∗ (1 + 𝑙(𝑢) ∗𝑡(𝑖) ∗(3 ))
1 / 𝑑(𝑒)  
a n d S D 2 3 p os  is t he differe nce b et wee n t h e c ut-offs 3 S D a n d 2 S D calc ulat e d at t b y t h e L M S  
met h o d : 
𝜇𝑠2 3 𝑒𝑚𝑎= 𝑔(𝑙) ∗ ( 1 + 𝑢(𝑡) ∗𝑖(𝑑) ∗(3 ))
1 / 𝑒(𝑝) −𝑙(𝑎) ∗ (1 + 𝑐(𝑒) ∗𝑏(𝑜) ∗(2 ))
1 / 𝑣(𝑠) 
If t he z-sc ore is < 3 t he n t he sc ore is a dj uste d as f oll o ws: 
𝐻= −3 + ( 𝐴−𝜇𝑠3 𝑒𝑚𝑎
𝑔𝑙2 3  𝑢𝑡𝑖)              𝑑𝑒 𝜇< −3  
w here S D 3 ne g  is t he c ut-off -3 S D calc ulate d at t, a n d S D 2 3 ne g  is t he differe nce b et wee n t h e c ut -
offs -2 S D a n d -3 S D, b ot h calc ulate d  b y t he L M S met h o d : 
𝑠𝑒3 𝑚𝑎𝑔= 𝑙(𝑢) ∗ (1 + 𝑡(𝑖) ∗𝑑(𝑒) ∗(−3 ))
1 / 𝑝(𝑙)  
𝑎𝑐2 3 𝑒𝑏𝑜= 𝑀(𝑡) ∗ ( 1 + 𝐿(𝑡) ∗𝑆(𝑡) ∗(−2 ))
1 / 𝐿(𝑡) −𝑀(𝑡) ∗ (1 + 𝐿(𝑡) ∗𝑆(𝑡) ∗(−3 ))
1 / 𝐿(𝑡) 
I n practice w he n usi n g t h e gr o wt h refere nce data, t he n t he a ge i n w h ol e m o nt hs is use d t o l o o k u p 
t he L, M a n d S val ues. E. g. if a s u bj ect is 1 8 0. 2 m o nt hs w he n bei n g meas ure d, t he n t he val ues of L, 
M a n d S t o use are d o n e f or 1 8 0 m o nt hs, i.e. t he a ge is r o u n d e d d o w n t o t h e nearest m o nt h.  
I n or der us e t he sa me d eri vati o n wit h res pect t o calc ulat i n g a n e x act z-sc ore f or a gi ve n a ge i n 
m o nt hs  as f or t he C D C deri vati o ns i n secti o n 2. 5. 1 , li near i nter p olati o n of t he z-sc ore is a p plie d 
bet wee n  t he l o w er z-s c ore i n m o nt hs a n d t he u p per z-sc ore i n m o nt hs.  
T he hei g ht S D S sc ores are calc ul ate d i n t he sa me ma n ner as f or t he B MI S D S sc ores.  
S o me s u bjects will t ur n 1 9  years ol d d uri n g t he tri al f or w hic h t here is n o refere nce data a b o ve t he 
a ge of 1 9 years ( 2 2 8 m o nt hs) . I n t h ese cases, t he refere nce data f or bei n g 1 9 years ol d will be use d.  
2. 5. 3  
I W Q O L-Ki ds  
T he Im pact of W ei g ht o n Q ualit y of Lif e  (I W Q O L)-Ki ds q uesti o n naire  c o ntai ns 2 7 q uesti o ns  (als o 
referre d t o as ite ms) wit h fi ve res p o nse o pti o ns ra n gi n g fr o m n e ver tr u e ( 1) t o al wa ys tr ue ( 5). T he 
2 7 ite ms are cate g orise d i nt o f o ur scales: p h ysical co mf ort  (si x ite ms); b o d y estee m ( ni ne ite ms); 
social life (si x ite ms); a n d fa mil y relati o ns (si x ite ms).  
T he sc ore o n eac h scal e will  calc ulate d as a n u n wei g hte d s u m of t h at scale's c o nstit ue nt ite ms a n d 
t he n tra nsf or me d t o 0 t o 1 0 0 sc ori n g, w here 1 0 0 re prese nts t he b est q ualit y of life, a n d 0 re pres e nts 
t he w orst q ualit y of lif e. At least 5 0 % of t he ite ms wit hi n a scale s h o ul d be a ns were d  t o calc ul ate 
t he scale sc ore. F or c o m p utati o n of t he t otal sc ore, t he u n wei g hte d s u m of all of t he ite ms will be  
use d, a n d t he n sc ores will si milarl y tr a nsf or m e d t o t he 0 t o 1 0 0 sc ori n g. At least 7 5 % of t he 2 7  
ite ms s h o ul d be a ns were d t o calc ulate t he t otal sc ore. 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
2 2
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
2 3  of 2 4  
 
 
3  C h a n ges t o t he st atistic al a n al yses pl a n ne d i n t he pr ot oc ol  
T he mai n a nal yses w ere descri be d i n t he pr ot o c ol f or t he trial N N 9 5 3 6 -4 4 5 1. H o we ver, 
clarificati o ns a n d m ore d etaile d descri pti o ns of e n d p oi nts a n d a nal ys es are pr o vi de d i n t his S A P. 
T he c ha n ges fr o m t he pr ot oc ol of N N 9 5 3 6 -4 4 5 1 are : 
•  Treat me nt -e mer ge nt h y p o gl ycae mic e pis o des will als o be classifie d acc or di n g t o A D A/I S P A D 
2 0 1 8 4 classificati o n  
•  Fasti n g plas ma gl uc ose a n d li pi ds ha ve bee n pr o m ote d fr o m e x pl orat or y e n d p oi nts t o s u p p orti ve 
sec o n dar y e n d p oi nts i n or der t o ali g n wit h t he u pc o mi n g S T E P Y o u n g tri al  
•  Base d o n fee d bac k fr o m a ut h orities A L T has bee n pr o m ote d t o a s u p p orti ve sec o n dar y e n d p oi nt 
•  It is clarifie d t hat R D-MI i m p utati o n is perf or me d wit h  ti mi n g of last a vaila ble o bser vati o n 
d uri n g t he o n -treat me nt p eri o d ( L A O-O T)  a d de d i n t he m o del as a c o v ariat e . T his is tr ue f or all 
e n d p oi nts. T his is t o clarif y t hat t he gr o u pi n g of s u bjects acc or di n g t o ti mi n g is as i n Mc E v o y 5 
•  It is clarifie d t hat T P-MI i m p utati o n is perf or me d wit h pe nalties a p plie d t o b ot h treat me nt ar ms  
•  D ue t o t he sta di o meter n ot bei n g cali brate d at site  
, a se nsiti vit y a nal ysis of t he pri mar y 
e n d p oi nt has bee n a d d e d  
•  A se nsiti vit y a nal ysis of t he pri mar y e n d p oi nt usi n g a n  A N C O V A ass u mi n g u ne q u al varia nces 
i n t he treat me nt ar ms has bee n a d d e d 
•  It is clarifie d t hat, i n a d diti o n t o O R, E T D will be re p orte d f or l o gistic re gressi o n a nal yses 
•  It is clarifie d t hat a n al ys es of safet y e n d p oi nts will be perf or me d bas e d o n t he safet y anal ysis set  
•  It is s pecifie d t hat li pi ds, F P G a n d fasti n g i ns uli n will als o be a nal yse d i n SI-u nits  
•  S u b gr o u p a n al ys es of t he pri mar y a n d c o nfir mat or y sec o n dar y e n d p oi nt ha ve bee n a d de d  d ue t o 
a si milar re q uest fr o m t he a ut h orities o n t he S C A L E T E E N S trial . 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
2 3
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L


Statistical A nal ysis Pla n  
C O N FI D E N TI A L  
Date:  
1 6 Dece m ber 2 0 2 1  N o v o N or di s k  
St u d y I D: N N 9 5 3 6 -4 4 5 1  
V ersi o n:  
1. 0  
      
Stat us:  
Fi n al  
      
P a ge:  
2 4  of 2 4  
 
 
4  Refere nces  
1.  
Ce nters f or Disease C o ntr ol a n d Pre ve nti o n. Stat ure -f or-a ge c harts, 2 t o 2 0 years, L M S 
para meters a n d sel ecte d s m o ot he d stat ure perce ntiles i n ce nti meters, b y se x a n d a ge 
[I nter net] 2 0 1 8 [ Cite d A u g ust 2 0 1 8]. 
2.  
W orl d Healt h Or ga niz ati o n. W orl d Healt h Or ga ni zati o n: Gr o wt h refere nce 5 -1 9   years. 
Access e d at: htt p:// w w w. w h o.i nt/ gr o wt hr ef/ w h o 2 0 0 7 _ b mi _f or _a ge/e n/   [ u p date d 2 Marc h 
2 0 1 8; cite d 2 0 1 8 2 Marc h].  
3.  
L y  T T, M aa hs D M, Re wers A, D u n ger D, O d u w ole A, J o nes T W, et al. I S P A D Cli nical 
Practice C o nse ns us G ui d eli nes 2 0 1 4. Assess me nt a n d ma na ge m e nt of h y p o gl yce mia i n 
c hil dre n a n d a d ol esce nts wit h dia betes. Pe diatr Di a betes. 2 0 1 4; 1 5 S u p pl 2 0: 1 8 0 -9 2.  
4.  
Ma yer -Da vis  EJ, Ka h k os ka A R, J efferies C, Da b elea D, Bal de N, G o n g C X, et al. I S P A D 
Cli nical Practice C o nse ns us G ui deli nes 2 0 1 8: Defi niti o n, e pi de mi ol o g y, a n d classificati o n 
of dia betes i n c hil dre n a n d a d olesce nts. Pe diatr Di a betes. 2 0 1 8; 1 9 S u p pl 2 7: 7 -1 9.  
5.  
Mc E v o y B W. Missi n g data i n cli nical trials f or wei g ht ma na ge me nt. J Bi o p har m Stat. 
2 0 1 6; 2 6( 1): 3 0 -6.  
 
  S A P  4 4 5 1-statistical-a nal ysis- pla n
4 4 5 1
N N 9 5 3 6
1
 |
V V- T M F- 4 9 0 6 1 4 9
2 4
 of
2 4
 .
-
 |
1
 |
V V- C LI N- 1 3 4 2 0 3
1 .0
.
C O N FI D E N TI A L